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Dnmt1 maintenance DNA methyltransferase 1
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eIF2C2 eukaryotic translation-initiation factor 2C, 2
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ES cell embryonic stem cell
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Fmr1-KO Fmr1-knockout
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GFP green fluorescent protein
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HDAC histone deacetylases
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IGF-1 insulin-like growth factor-1
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MAPK mitogen-activated protein kinase
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MEK mitogen-activated-protein-kinase kinase
mGluR metabotropic glutamate receptor
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NGF neurotrophic growth factor
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NPC neural progenitor cell
NRF1 nuclear respiratory factor 1
NSC neural stem cell
NT-3 neurotrophin-3
NUFIP nuclear FMRP interacting protein
OLP oligodendrocyte precursors
P10 postnatal day 10
p75NTR p75 neurotrophin receptor
PAK p21-activated kinase
PAR-4 prostate apoptosis response 4
PBS phosphate buffered saline
PCR polymerase chain reaction
PDGF platelet-derived growth factor
PFA paraformaldehyde
PI3K phosphatidylinositol-3-kinase
PKC protein kinase C
PLC phospholipase C
PNS peripheral nervous system
PSA-NCAM polysialylated neural cell adhesion molecule
PUR purine-rich single stranded DNA-binding
REST/NRSF RE1-silencing transcription factor
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RGS regulator for G-protein signaling
RISC RNA-induced silencing complex
RT room temperature
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SDF1-a stromal cell-derived factor 1 alpha
SGZ subgranular zone
SH2 Src-homology-2
11
Shh sonic hedgehog
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STAT3 signal transducer and activator of transcription-3
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TGF transforming growth factor
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ABSTRACT
Multipotent stem cells can self-renew and give rise to multiple cell types. One type of
mammalian multipotent stem cells are neural stem cells (NSC)s, which can generate
neurons, astrocytes and oligodendrocytes. NSCs are likely involved in learning and
memory, but their exact role in cognitive function in the developing and adult brain is
unclear.
We have studied properties of NSCs in fragile X syndrome (FXS), which is the most
common form of inherited mental retardation. FXS is caused by the lack of functional
fragile X mental retardation protein (FMRP). FMRP is involved in the regulation of
postsynaptic protein synthesis in a group I metabotropic glutamate receptor 5 (mGluR5)-
dependent manner. In the absence of functional FMRP, the formation of functional
synapses is impaired in the forebrain which results in alterations in synaptic plasticity. In
our studies, we found that FMRP-deficient NSCs generated more neurons and less glia
than control NSCs. The newborn neurons derived from FMRP-deficient NSCs showed an
abnormally immature morphology. Furthermore, FMRP-deficient NSCs exhibited aberrant
oscillatory Ca2+ responses to glutamate, which were specifically abolished by an
antagonist of the mGluR5 receptor. The data suggested alterations in glutamatergic
differentiation of FMRP-deficient NSCs and were further supported by an accumulation of
cells committed to glutamatergic lineage in the subventricular zone of the embryonic
Fmr1-knockout (Fmr1-KO) neocortex. Postnatally, the aberrant cells likely contributed to
abnormal formation of the neocortex. The findings suggested a defect in the differentiation
of distinct glutamatergic mGluR5 responsive cells in the absence of functional FMRP.
Furthermore, we found that in the early postnatal Fmr1-KO mouse brain, the expression of
mRNA for regulator of G-protein signalling-4 (RGS4) was decreased which was in line
with disturbed G-protein signalling in NSCs lacking FMRP.
Brain derived neurotrophic factor (BDNF) promotes neuronal differentiation of
NSCs  as  the  absence  of  FMRP  was  shown  to  do.  This  led  us  to  study  the  effect  of
impaired BDNF/TrkB receptor signaling on NSCs by overexpression of TrkB.T1 receptor
isoform. We showed that changes in the relative expression levels of the full-length and
truncated TrkB isoforms influenced the replication capacity of NSCs. After the
differentiation, the overexpression of TrkB.T1 increased neuronal turnover.
To summarize, FMRP and TrkB signaling are involved in normal differentiation of
NSCs in the developing brain. Since NSCs might have potential for therapeutic
interventions in a variety of neurological disorders, our findings may be useful in the
design of pharmacological interventions in neurological disorders of learning and
memory.
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REVIEW OF THE LITERATURE
1. Definition of stem cells
Characteristics of stem cells are their ability to self-renew and give rise to one or usually
many different cell types (reviewed in Lovell-Badge, 2001). In adult animal, stem cells
participate in the maintenance of tissue homeostasis and the repair of damaged tissue. The
potential of stem cells can be defined based on the amount of cell types they can produce.
Totipotent stem cells, which only include in mammals the fertilized egg, are the most
potent and they can give rise to every cell type in the animal. Pluripotent stem cells differ
from totipotent stem cells only by their inability to give rise to embryonic trophectoderm
cells.  Multipotent  stem  cells  are  tissue  specific  stem  cells,  which  can  give  rise  to  more
than one cell type. Finally, unipotent stem cells, which include spermatogonial stem cells
in the testis, can give rise to only one cell type.
1.1. Adult stem cells in their niches
The term stem cell “niche” was already introduced long time ago (Schofield, 1978) but
only after studies in invertebrate Drosophila, microenvironment supporting adult stem
cells was accepted as stem cell niche (Xie and Spradling, 2000; Moore et al., 2004;
Guasch and Fuchs, 2005; Li and Xie, 2005). The niche is comprised of an environment of
surrounding cells that support adult stem cells and mediate signals of self-renewal,
survival and differentiation. To maintain the adult stem cell pool, the niche must prevent
excessive apoptosis or proliferation which could lead to the depletion of stem cells or the
development of cancer, respectively. The main function of multipotent adult stem cells is
to preserve tissue homeostasis in case of naturally occurring apoptosis of terminally
differentiated cells, injury and disease.
Well-characterized niches for multipotent adult stem cells include hematopoietic
stem cells in the bone marrow (Spangrude et al., 1988), intestinal stem cells in the villus of
the small intestine (Booth and Potten, 2000), hair follicle stem cells in the skin (Cotsarelis
et al., 1990), germ line stem cells in the testis (Brinster, 2002), and neural stem cells
(NSC)s in the subventricular zone (SVZ) and hippocampus (Gage, 2000). In addition to
these established niches, other niches for multipotent adult stem cells have also been
proposed (Seale et al., 2001; Beltrami et al., 2003; Laugwitz et al., 2005; Buchstaller et al.,
2004; Kim et al., 2005).
2. NSCs and their niches
Cells that are undifferentiated, self-renewing multipotent progenitors for neurons and glia
in the developing and adult brain are termed as NSCs (Gage, 2000; Temple, 2001; Merkle
and Alvarez-Buylla, 2006). NSCs were first isolated from the embryonic mammalian
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central nervous system (CNS) (Temple, 1989; Cattaneo and McKay, 1990; Kilpatrick and
Bartlett, 1993) and the peripheral nervous system (PNS) (Stemple and Anderson, 1992).
Adult NSCs were found subsequently (Reynolds and Weiss, 1992; Lois and Alvarez-
Buylla, 1993) and are located in two established niches, which are the SVZ and
subgranular zone (SGZ) (Lois and Alvarez-Buylla, 1993; Palmer et al., 1997; Doetsch et
al., 1999). In addition, adult NSCs have been isolated and cultured from brain regions
including caudal portions of the SVZ, cortex, striatum, septum, corpus callosum,
hypothalamus, spinal cord, optic nerve, retina, and olfactory bulbs (Palmer et al., 1995;
Weiss et al., 1996; Shihabuddin et al., 1997; Palmer et al., 1999; Pagano et al., 2000;
Tropepe et al., 2000; Lie et al., 2002). However, in the adult human neocortex,
neorogenesis does not likely occur (Spalding et al, 2005; Bhardwaj et al, 2006). NSCs in
the early embryonic brain are neuroepithelial cells (Haubensak et al., 2004), which are
suggested to turn into radial glia at the onset of neurogenesis (Malatesta et al., 2003;
Anthony et al., 2004; Götz and Huttner, 2005). Adult NSCs in the prominent brain niches
are radial glial derived astrocyte-like cells (Doetsch et al., 1999; Imura et al., 2003; Garcia
et al., 2004) thus suggesting the same lineage for embryonic radial glia and NSCs in the
adult brain (Tramontin et al., 2003; Merkle et al., 2004)
How to discriminate between NSCs, progenitor cells and precursor cells? Progenitor
cells and precursor cells (both termed as NPCs from here on) are multipotent daughter
cells of NSCs with limited capacity to self-renew. These cells are dividing symmetrically
at the SVZ to enlarge their population (Gage et al., 1995; Weiss et al., 1996; McKay,
1997; Haubensak et al., 2004; Noctor et al., 2004; Martinez-Cerdeno et al., 2006). This
review will mainly focus on the properties of NSCs, since they are largely overlapping
with properties of NPCs and there is only very thin and partially undefined line between
these multipotent cell types. This issue will be discussed more closely when reviewing the
development of neocortex.
NSCs, as other stem cells with a potential to create different types of cells, need to
be controlled during brain development to make correct structures at a certain time. This
requires patterning of signals from the environment and intrinsic expression of genes. In
embryonic mammalian forebrain development, this means that neurogenesis and
gliogenesis follow neural tube closure. Initially during brain development, NSCs are
required to generate proper cell numbers in the brain and subsequently to produce the right
types of differentiated cells in the correct place. NSC self-renewal and proliferation must
be constantly controlled to prevent the depletion of stem cell pool or cancer. This is
especially important in the adult brain. The relevance of NSCs in the adult brain is perhaps
not as obvious as, for example, the relevance of hematopoietic stem cells in the bone
marrow. Nevertheless, in the adult brain NSCs are associated with the creation of new
olfactory neurons, hippocampal granule neurons and oligodendrocytes (Gage, 2000;
Kempermann et al., 2004; Merkle and Alvarez-Buylla, 2006). The renewal of granule
neurons may be important for learning, memory and emotion (Emsley et al., 2005;
Paizanis et al., 2007). To some extent, NSCs can also be recruited to repair damaged brain
tissue (Singec et al., 2007). As is true for other types of stem cells, NSCs can be
manipulated in vitro to exhibit features that are absent in vivo.
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2.1. Self-renewal/proliferation of NSCs
Self-renewal and maintenance of NSCs in the SVZ and SGZ niches are mediated by
attachment and various signals emanating from endothelial cells of blood vessels and the
specialized basal lamina (Doetsch, 2003; Shen et al., 2004). b-catenin and cadherins form
adherens junctions, which play a role in the maintenance of NSCs, and Wingless type
(WNT) signaling overexpression of b-catenin leads to exaggerated proliferation of NSCs
(Chenn and Walsh, 2002, 2003). By contrast, deletion of b-catenin  leads  to  a  loss  of
cortical NPCs (Zechner et al., 2003; Backman et al., 2005). Cortical WNT signaling
mediates NPC proliferation through Emx2 (Muzio et al., 2005). At later stages of cortical
development the role of WNT signaling is shifted to promote differentiation and inhibitors
including Axin and Dkk1 can act to retain the undifferentiated state of NPCs at this point
(Hirabayashi et al., 2004). Primarily genes that interfere with differentiation programs
regulate NSC maintenance in the undifferentiated state. The polycomb family
transcriptional repressor Bmi-1 is important for NSC self-renewal but not for their
survival or differentiation (Molofsky et al, 2003). Hes proteins, which are downstream of
Notch, promote the undifferentiated state as repressors of proneural transcription and
inhibitors of neurogenesis (Kageyama and Ohtsuka, 1999). An RE1-silencing transcription
factor (REST/NRSF) is a transcriptional repressor of neuronal gene expression in NSCs
and neurons. Activation of neural differentiation from NSCs requires repression and
degradation of RE1-silencing transcription factor (REST/NRSF) (Ballas et al., 2005). A
binding site for REST/NRSF in promoter region of proneural Mash1, further suggests a
role for REST/NRSF in retaining multipotency (Ballas et al., 2005).
Another approach to maintain NSC in an undifferentiated state is to prevent
proneural proteins from acting normally. The inhibitor of differentiation (Id) proteins
sequester E proteins, which are their dimerizing partners and this leads to inhibition of
neurogenesis (Yokota, 2001). The cell cycle regulator and cell fate determinator Geminin
inhibits the interaction of proneural basic helix-loop-helix (bHLH) proteins with Brahma-
related gene 1 (Brg1) thus blocking their action and leading to inhibition of neurogenesis
(Seo et al., 2005; Spella et al., 2007). The SRY-related high-mobility group (HMG)-box
protein-1 (SOX1), SOX2, and SOX3 of B1 group proteins of the SOX family participate
in maintaining the NSC pool (Bylund et al., 2003; Graham et al., 2003). These SOX
proteins block proneural bHLH protein activity without affecting proneural gene
expression and inhibit neurogenesis (Bylund et al., 2003). Furthermore, it seems that
proneural genes inhibit SOXs expression (Bylund et al., 2003). In addition, proneural gene
regulated expression of SOX21 is blocking the action of SOX1-3 possibly by interfering
with their targets (Sandberg et al., 2005).
Extracellular signals mediated by basic fibroblast growth factor (FGF2) and Notch1
are  also  important  for  maintaining  the  NSC  pool  and  promoting  self-renewal  within  the
SVZ niche (Hitoshi et al., 2004; Zheng et al., 2004). In fact, Notch pathways are well
established in promoting an undifferentiated state in NSCs during developmental
neurogenesis (Artavanis-Tsakonas et al., 1999; Mizutani and Saito, 2005). For example,
endothelial cells secrete factors that stimulate NSC proliferation promoting Notch
activation in neurogenic niches involving consolidation of cell-cell contacts required for
Notch signaling (Shen et al., 2004). In vitro self-renewal and proliferation can be mediated
by high concentration of mitogens, epidermal growth factor (EGF) and FGF, in the culture
medium (Reynolds and Weiss, 1992; Palmer et al., 1995; Craig et al., 1996; Tropepe et al.,
1999). In addition, ciliary neurotrophic factor (CNTF) augments self-renewal of neural
precursors by promoting the expression of Notch1 in vitro (Chojnacki et al., 2003). Early
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embryonic NSCs require FGF to proliferate, and later NSCs require FGF or EGF for
proliferation (Kalyani et al., 1997; Gritti et al., 1999; Tropepe et al., 1999; Vaccarino et
al., 1999; Raballo et al., 2000). More committed NPCs are responsive to sonic hedgehog
(Shh), FGF, and neurotrophin-3 (NT-3). Shh, the soluble form of amyloid precursor
protein (APP) and EGF signalling, act in concert to promote proliferation of NSCs/NPCs
(Machold et al., 2003; Caille et al., 2004; Palma and Ruiz i Altaba, 2004). The
transforming growth factor (TGF)a, another ligand for EGF receptor, may also have a role
in regulating proliferation of NSCs/NPCs (Enwere et al., 2004).
Extracellular signaling molecules such as FGF2, TGFa, and CNTF are secreted by
astrocytes and the relative amount of astrocytes in neurogenic SVZ and SGZ is high
suggesting a possible explanation for the maintenance of multipotent NSCs in those
regions (Emsley and Hagg, 2003). There are other regions in the CNS in which astrocytes
are abundant but no neurogenic proliferation is occurring, which suggest that the amount
of astrocytes is not the rate limiting factor. Actually, the important thing would be to
distinguish neurogenic proliferating adult NSCs, which have been shown to be of glia
lineage from differentiated glia (Götz and Huttner, 2005). The actual mechanisms of
maintaining proliferative regions in the adult brain may involve desintegrin and
metalloproteases (ADAM)s which can activate TGFa, Notch1, and APP by cleaving their
extracellular domains (Huovila et al., 2005; Yang et al., 2005). Since astrocytes and
ADAMs co-localize in non-neurogenic regions, there must be another way of defining the
neurogenic niche.
Neurotransmitters as well as their receptors and transporters are already expressed in
the embryonic cortex (Dammerman and Kriegstein, 2000; Haydar et al., 2000; Olivier et
al., 2000). GABA and glutamate directly regulate NSC/NPC proliferation by changes in
DNA synthesis (LoTurco et al., 1995; Haydar et al., 2000), and alterations in intracellular
calcium concentrations (LoTurco et al., 1995; Owens et al., 2000; Weissman et al., 2004).
These effects may be area specific since the NPC response to glutamate and GABA is
opposite in the VZ compared to the SVZ (Haydar et al., 2000). Interaction between
neurotransmitters and growth factors may underlie this difference (Antonopoulos et al.,
1997). D2/3-dopamine receptor activation plays a role in regulation of proliferation of
NSCs in the SVZ presumably in a diverse cell type specific manner (Baker et al., 2004;
Höglinger et al., 2004; Baker et al., 2005; Kippin et al., 2005). Dopamine can have a direct
effect  on  proliferation,  since  its  receptor,  D2,  is  expressed  in  both  NSCs  and  NPCs
(Höglinger et al., 2004; Kippin et al., 2005). Another neurotransmitter, 5-
hydroxytryptamine (serotonin or 5-HT), can also promote NPC proliferation (Banasr et
al., 2004). Interestingly, dopaminergic and serotonin releasing projections converge in the
SVZ suggesting some kind of coordinated action of these neurotransmitters (Simpson et
al., 1998). Supporting this idea, a similar overlap between serotonergic and noradergic
projections occurs in the SGZ (Goldman-Rakic et al., 1990).
Hormones regulate NSC/NPC proliferation, since thyroid hormone increases NSC
proliferation through its a-receptor and by regulating c-MYC expression (Lemkine et al.,
2005). Prolactin together with TGFa seems to promote proliferation in the SVZ (Shingo et
al., 2003). Estrogen receptor activity promotes the proliferation of NSCs in the embryonic
brain (Brännvall et al., 2002). Furthermore, evidence indicates that IGF-1 increases
proliferation presumably in an estrogen dependent manner (Perez-Martin et al., 2003). On
the other hand, testosterone analogue, 19-nortestosterone, was shown to reduce the
proliferation of NSCs in the adult rat brain (Brännvall et al., 2005), and glucocorticoid
hormones seem to reduce the proliferation of NSCs by inhibiting the cell cycle (Sundberg
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et al., 2006). Again, SVZ and SGZ NSCs/NPCs respond differentially to proliferative
signals, which this time are mediated by hormones (Shingo et al., 2003; Abrous et al.,
2005).
Cell cycle regulation is of course essential for maintaining a proliferative state.
Activation of RAS/RAF/MEK/ERK protein kinase pathway shortens cell cycle length, and
thus alters proliferation rate (Edgar, 1995). This pathway operates through p53,
retinoblastoma tumor suppressor (Rb), and E2F families of proteins (Yoshikawa, 2000).
Of these, the E2F family of proteins may be essential for promoting self-renewal in NSCs.
Rb and p53 have another role in promoting proliferation by mediating telomerase
signaling in a cell type specific manner (van Steensel and de Lange, 1997).
FGF2 has a major role in cerebral cortex development by promoting proliferation of
NPCs (Ghosh and Greenberg, 1995; Raballo et al., 2000). EGF and its receptor are also
expressed in the neocortex during development and act to increase NPC proliferation
(Burrows et al., 1997; Morrow et al., 2001). Interestingly, the EGF receptor is
asymmetrically inherited by its progeny when the cortical NPC divides, which probably
contributes to a cell fate determination by EGF receptor distribution in NPC populations
(Sun et al., 2005). Heparan sulfate proteoglycans, components of the extracellular matrix,
can participate in growth factor actions (Dutton and Bartlett, 2000). Furthermore, FGF and
EGF are differently regulated by these components of extracellular matrix (Ford et al.,
1994; Ferri et al., 1996) and, on the other hand, growth factors modulate the production of
extracellular matrix components by NPCs (Drago et al., 1991). The extracellular matrix
seems to be important in regulating NSC/NPC proliferation by directly affecting cell
numbers and indirectly regulating the actions of growth factors. Integrins expressed by
NPCs are activated by binding to the extracellular matrix proteins or cell surface integrins
in other cells, which results in the activation of intracellular pathways. In this manner,
a5b1 integrins promote proliferation by activating intracellular phosphatidylinositol-3-
kinase (PI3K) and AKT (Jacques et al., 1998).
2.2. Survival of NSCs
During neurogenesis and gliogenesis in the developing mammalian brain, NSCs
proliferate and differentiate into neurons and glia to give rise to a stratified cell diversity
of the mature brain. This proliferation is exaggerated since only 15-40% of post-migratory
cells survive implicating some kind of selection system to decide which cells are required
(Finlay and Slattery, 1983; Oppenheim, 1991; Ferrer et al., 1992). A substantial amount of
programmed cell death or apoptosis occurs in mitotically active NSCs and progenitor cells
in various regions during brain development (Kuan et al., 2000). The principle of NSC
apoptosis is to regulate the number of proliferating cells, which will eventually affect brain
size. This has been demonstrated by abnormal brain size and morphology caused by
disrupting the function of genes in the apoptotic pathway (Frade and Barde, 1999; Haydar
et al., 1999; Kuan et al., 2000; Depaepe et al., 2005; Putz et al., 2005).
Apoptosis is regulated by caspases (Raff, 1998) of which the telencephalic
transcripts are especially linked with NSCs survival (Kuan et al., 2000; Ceccatelli et al.,
2004). Staurosporine activation or caspase inhibitor-mediated blocking of caspase-3 leads
to apoptosis or excess survival of NSCs, respectively, thus suggesting a caspase dependent
death pathway in NSCs (D'Sa-Eipper and Roth, 2000). Inactivation of brain caspases
results in hyperplasias in a similar manner as inactivation of another proapoptotic gene,
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Apaf-1 (Cecconi et al., 1998; Yoshida et al., 1998). Caspase-3 and caspase-9 as promoters
of apoptosis seem to be essential for early forebrain development in a region or cell
population specific manner (Kuida et al., 1996; Kuida et al., 1998; Levison et al., 2000).
Apoptosis in NSCs via caspase activation can be blocked by activation of anti-apoptotic
Bcl-2 (Cheng a et al., 2001; Esdar et al., 2001). Another pathway that activates caspase-3
via Fas does not seem to cause apoptosis in NSCs (Tamm et al., 2004). Antiapoptotic gene
Bcl-X which regulates neuron survival is not involved with NSC apoptosis revealed by
normal  VZ  after  genetic  manipulation  of  this  gene  (Motoyama  et  al.,  1995;  Roth  et  al.,
2000). However, proapoptotic gene Bax which is important for developmentally occurring
neuronal death seems to be also important for naturally occurring apoptosis of adult NSCs
through caspase and inositol 1,4,5-trisphosphate (IP3) activation (White et al., 1998; Shi et
al., 2005).
Extrinsic factors are important in preventing apoptosis since neuroepithelial NSCs
survival is mediated by FGF, EGF, insulin/IGF, and antidepressant mediated activation of
antiapoptotic Bcl-2 in vitro (Kalyani et al., 1997; Diaz et al., 1999; de la Rosa and de
Pablo, 2000; Chen et al., 2007; Huang et al., 2007). Moreover, the importance of insulin
for neuroretinal NSCs survival has been demonstrated in vivo with a blocking antibody,
which increases apoptosis in intrinsic areas (Diaz et al., 2000). Some factors like c-Jun N-
terminal kinases (Jnk)s seem to affect NSC survival in a regional and temporal manner,
since Jnks decrease apoptosis in neuroepithelial NSCs and promote it in the forebrain VZ
(Kuan et al., 1999). Neurotrophic factors play a role in cortical NSC/NPC survival as
shown by increases in apoptosis when endogenous TrkB and TrkC mediated signaling are
blocked by antibodies (Barnabe-Heider and Miller, 2003). This kind of action involves
downstream signaling target of Trks, PI3K and its adapter protein ShcA, suggesting an
autocrine/paracrine action of neurotrophins in NSC/NPC survival (Barnabe-Heider and
Miller, 2003; McFarland et al., 2006). Platelet-derived growth factor (PDGF) also acts
through the PI3K pathway to promote survival of NSCs (Guillemot, 2007). The well-
characterized tumor suppressor p53 is expressed in NSCs/NPCs and it decreases the
survival of these cells (Akhtar et al., 2006; Meletis et al., 2006). Ephrin signaling appears
to be one factor controlling brain size by negatively regulating the survival of NPCs
(Depaepe et al., 2005). Amyloid-beta peptide induces Fas-independent apoptosis in NPCs
(Millet et al., 2005) and prostate apoptosis response 4 (PAR-4) prevents apoptosis in
NSCs (Wang et al., 2006). The neurotransmitter glutamate promotes the survival of SVZ-
derived NPCs (Brazel et al., 2005), and on the contrary, hydrogen peroxide and rotenone
induce apoptosis in NSCs/NPCs (Lin et al., 2004; Li et al., 2005).
2.3. Epigenetic control of NSC fate
Epigenetic modifications occur without affecting DNA sequence and expose certain genes
to be available for expression. Histone acetylation, methylation, phosphorylation,
ubiquitination, sumoylation and ADP-ribosylation, DNA methylation, noncoding RNAs,
and chromatin remodeling are known mechanisms of epigenetic control of gene
expression (Strahl and Allis, 2000; Hsieh and Gage, 2004; Lund and van Lohuizen, 2004;
Kondo, 2006). Cellular diversity in the CNS has especially provoked interest in epigenetic
mechanisms as controllers of cell fate (Branchi et al., 2004).
  Chromatin remodeling through covalent changes in histones has emerged as one of
the epigenetic mechanisms regulating gene expression (Strahl and Allis, 2000). Chromatin
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structure can be modified through histone acetylation, and particularly by lysine
acetylation, which is a well characterized type of histone modification (Strahl and Allis,
2000). Histone acetyltransferases (HAT)s mediate the acetylation, and histone
deacetylases (HDAC)s counteract this by removing acetylation. Non-acetylated DNA is
packed into tight nucleosomes, which blocks the attachment of transcription activators to
the promoter sites of certain genes leading to gene silencing. Action by HATs facilitates
nucleosomal relaxation and access to gene promoter elements.  In NSCs, class II  HDAC,
which are one human transcript of HDACs expressed also in brain, seem to be increased
upon differentiation (Ajamian et al., 2003) and particularly affect oligodendrocyte
differentiation (Marin-Husstege et al., 2002; Shen et al., 2005). To control cell fate
HDACs are pivotal for repressing neuronal genes in non-neuronal cell types (Chong et al.,
1995; Schoenherr and Anderson, 1995). These genes share a common NRSE element,
which is a binding site for REST/NRSF. This factor interacts with mSin3A/B complex
(Naruse et al., 1999), the nuclear receptor co-repressor (N-CoR) (Jepsen et al., 2000),
CoREST/HDAC2 (Ballas et al., 2001), and the H3K9 histone methyltransferases G9a and
SUV39 (Lunyak et al., 2004; Ballas et al., 2005). CoREST recruits methyl DNA binding
protein MeCP2, heterochromatin protein 1 and the histone lysine methyltransferase,
suppressor of variegation 39H1 to silence REST/NRSF target genes (Lunyak et al., 2002).
Valproic acid inhibition of HDACs promotes neuronal differentiation and suppresses glial
differentiation  from adult  NPCs (Hsieh  et  al.,  2004).  Inhibitors  of  HDACs are  generally
promoting specifically neuronal differentiation from NPCs (Hao et al., 2004; Hsieh et al.,
2004; Acharya et al., 2005).
Histone methylation of lysine residues in histones H3 and H4 are thought to be
involved with molecular imprinting of gene expression in eukaryotes (Sims et al., 2003).
In embryonic neuroepithelial NSCs, acetylation and methylation of histone H3 in the
promoter of SOX2 regulates the NSC proliferation and maintenance (Kondo and Raff,
2004). Histone methylation has emerged as a transcriptional regulator in the CNS, since
dimethylated and trimethylated histone H3 show brain region and developmental stage
dependent changes in human glutamate receptor promoters (Stadler et al., 2005).
DNA cytosine methylation is another epigenetic modification implicated in genomic
imprinting and X-chromosome inactivation (Jaenisch and Bird, 2003). The mechanism of
DNA methylation includes repressing transcription factor binding by methylation of CpG
sites or reversing methylation by methyl-CpGs binding proteins (MBD)s and HDAC
repressor complexes. The absence of an enzyme that establishes and maintains DNA-
methylation, maintenance DNA methyltransferase 1 (Dnmt1), results in impaired neuronal
function and premature death in mice (Fan et al., 2001). On the other hand, mice deficient
in methyl-CpGs binding protein 1 (MBD1) exhibit impaired neurogenesis in the dentate
gyrus, decreased neuronal differentiation of NSCs, increased aneuploidy in NSCs, and
resemblance with the genomic instability found in cancer cells (Zhao et al., 2003).
Inappropriate and early expression of glial specific genes can be blocked in NSCs and
non-glial cells by, for example, by CpG methylation of the binding site of signal
transducer and activator of transcription-3 (STAT3) (Takizawa et al., 2001; Namihira et
al., 2004).
Noncoding RNAs, such as repressor microRNAs, are beginning to reveal their
importance as epigenetic regulators of gene expression in the CNS (Grewal and Moazed,
2003; Bartel, 2004; Smirnova et al., 2005). Remarkably, a novel noncoding dsRNA was
shown to be able to interact with REST/NRSF and convert it to activator of neuronal gene
expression in a manner opposite to its proposed function (Kuwabara et al., 2004).
Chromatin remodeling protein complex family, switching (SWI/SNF), which uses ATP
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hydrolysis to disrupt the connection between histones and DNA, interact with HATs or
HDACs and/or specific transcription factors to upregulate or downregulate target genes
(Knoepfler and Eisenman, 1999; Cho et al., 2004). Loss of function in members of this
family of proteins Brahma, Breast-ovarian cancer susceptibility gene 1 (Brca1), Brg1, and
Bmi-1 leads to promotion of NSC self-renewal and maintenance (Molofsky et al., 2003;
Kondo and Raff, 2004; Seo et al., 2005). Another chromatin remodeling system, imitation
switch (ISWI), which is expressed in the embryonic and postnatal brain, is sure to play a
role in NSCs/NPCs, since it induces bone morphogenetic protein 4 (BMP4) expression
and inhibits Shh expression (Dirscherl et al., 2005).
2.4. Regulation of NSC differentiation
NSCs normally differentiate in multiple steps to produce the final cellular diversity found
in the mammalian CNS. Beginning from NSCs, through NPCs to maturing terminally
differentiated cell types including a vast variety of neurons, as well as glial cells including
astrocytes and oligodendrocytes. During brain development, the generation of neurons and
glia is temporally organized. Neocortical layer formation especially occurs in a highly
orchestrated manner. The secrets behind the generation of neuron subtypes are only now
beginning to be elucidated (Muotri and Gage, 2006). Finally, the onset of shaping of
neuronal networks is occurring during postnatal development and lasting to some extent
throughout mammalian life.
2.4.1. Neuronal differentiation
WNT signaling pathways play an important role in the NSC differentiation process after
the switch to support neuronal differentiation of NSCs/NPCs instead of proliferation.
Consequently, WNT7A or stabilized b-catenin promote cell cycle arrest and neuronal
differentiation of cortical NPCs both in vivo and in vitro (Hirabayashi et al., 2004;
Hirabayashi and Gotoh, 2005). WNT signaling is suggested to promote neurogenesis by
directly activating the expression of proneural genes, Neurogenin1 and Neurogenin2
(Ngn1 and Ngn2) in clonal NPC culture (Machon et al., 2003; Hirabayashi et al., 2004;
Israsena et al., 2004). Furthermore, WNT signaling is also required for adult hippocampal
neurogenesis (Zhou et al., 2004; Lie et al., 2005). WNT signaling in NPCs may be
regulated by the presence of FGF2 signaling to switch to support neuronal differentiation
instead of proliferation (Hirabayashi et al., 2004; Israsena et al., 2004).
PDGF is suggested to promote neuronal fate in NPC cultures by binding to a
tyrosine kinase receptor which, in turn, activates the intracellular SHP2-mitogen-
activated-protein-kinase kinase (MEK)-ERK pathway that mediates neurogenic signals of
a variety of growth factors (Johe et al., 1996; Williams et al., 1997; Menard et al., 2002;
Barnabe-Heider and Miller, 2003; Gauthier et al., 2007). SHP2-MEK-ERK further
phosphorylates transcription factors of the CAAT/enhancer-binding protein (C/EBP)
family to activate neuronal genes including Ta1 a-tubulin (Menard et al., 2002) and
Math2 (Uittenbogaard et al., 2007). Perturbations in C/EBP activity direct NPCs towards
glial fate, which suggests that growth factor mediated SHP2-MEK-ERK-C/EBP signaling
pathway is contributing to neurogenesis by promoting neuronal fate determination (Paquin
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et al., 2005). In addition, SHP2 directly represses the nonreceptor tyrosine kinase Janus
(JAK)-STAT signaling to promote neuronal fate over glial fate (Gauthier et al., 2007).
Adult neurogenesis is in part promoted by neuronal activity received by
hippocampal NPCs, which increases intracellular calcium dependent expression of
differentiation factors such as NeuroD and repressing inhibitors of neurogenesis including
Hes1 and Id2 (Deisseroth et al., 2004; Overstreet Wadiche et al., 2005; Tozuka et al.,
2005). GABAergic signaling promotes neuronal network integration related properties of
newly born neurons in the CNS, which include neurite outgrowth and synaptogenesis
(Represa and Ben-Ari, 2005). Noggin inhibits BMP4 signaling to favor neuronal
differentiation of NPCs in the adult SVZ and SGZ (Chmielnicki et al., 2004).
The transcription factor Pax6, which has been implicated in neurogenesis in the
neocortex and the adult SVZ, is a direct activator of Ngn2 in neocortical NPCs suggesting
a mechanism for regulating neurogenesis through proneural genes (Heins et al., 2002;
Scardigli et al., 2003; Hack et al., 2005). Perturbations in Pax6 action result in loss of
cortical neurons (Heins et al., 2002; Hack et al., 2005). However, Pax6 also acts through
distinct pathways independent of proneural proteins, because Pax6 promotes neurogenesis
in postnatal astrocytes, and loss of Pax6 does not result in gliogenesis (Heins et al., 2002).
Neuronal differentiation of NSCs/NPCs seems to be regulated by dual action of Pax6 with
or without proneural proteins.
Proneural genes encode bHLH transcription factors, which have fundamental role in
neurogenesis (Bertrand et al., 2002; Ross et al., 2003). These genes expressed in the
mammalian telencephalon include Mash1, Ngn1, and Ngn2. Mash1 is expressed in basal
ganglia NPCs as well as in neocortical NPCs, whereas Ngn1 and Ngn2 are expressed only
in neocortical NPCs (Britz et al., 2006). The most important function for proneural genes
is to direct NSCs/NPCs towards neuronal fate instead of astroglial fate (Tomita et al.,
2000; Nieto et al., 2001; Sun et al., 2001). Other functions of these genes include
converting NSCs into mature neurons (Bertrand et al., 2002; Helms and Johnson, 2003;
Schuurmans et al., 2004; Hand et al., 2005). When proneural gene expression is absent in
vivo, loss of neurons and NPCs occurs and astroglial fate determination is promoted
(Tomita et al., 2000; Nieto et al., 2001). In vitro,  proneural  genes  have  been  shown  to
promote neuronal lineage of NPCs by direct transcriptional activation of downstream
genes such as NeuroD (Nieto et al., 2001; Sun et al., 2001; Parras et al., 2004). In contrast,
glial fate inhibition by proneural genes occurs through inhibiting the signaling pathways
JAK-STAT and BMP-mothers against decapentaplegic homologue (SMAD) (Nieto et al.,
2001; Sun et al., 2001; Parras et al., 2004; He et al., 2005). Proneural bHLH genes require
other  transcription  factors  to  act  in  concert  to  regulate  NSCs/NPCs  differentiation.  The
evidence suggests that Ngn proteins interact with histone acetylase CBP/P300 to activate
target genes (Sun et al., 2001; Ge et al., 2006) and with a component of chromatin
remodeling complex, Brg1, to promote neurogenesis in mammalian embryonic carcinoma
cells (Seo et al., 2005). However, absence of Brg1 expression in embryonic neocortex
results in neuronal differentiation and the inhibition of astroglial fate (Matsumoto et al.,
2006). Surprisingly, one of the proastrocytic bHLH genes, stem cell leukemia (scl),
appears to promote neuronal differentiation and maturation in addition to promoting
astrogenesis (Bradley et al., 2006).
Ngn1 and Ngn2 are able to initiate neural differentiation (Farah et al., 2000;
Mizuguchi et al., 2001; Nakada et al., 2004) and their sequential downstream targets
include bHLH transcription factors NeuroD1, NeuroD2, Math2, Math3, Nscl1 and T-box
proteins Tbr1 and Tbr2 (Schuurmans et al., 2004; Englund et al., 2005; Hevner et al.,
2006). Tbr1 is essential to neural differentiation of some cortical NPCs and Tbr2 is useful
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as a marker for intermediate cortical NPCs committed to glutamatergic fate (Englund et
al., 2005; Hevner et al., 2006). The actual function of Tbr2 is yet unknown. Ngn1 and
Ngn2-mediated expression of Tbr1 and Tbr2 is restricted to cortical NPCs and neurons,
and it is absent in subcortical regions or basal ganglia (Schuurmans et al., 2004). NeuroD
and its related partner Math2/Nex may be involved in the differentiation of neurons
located in the dentate gyrus (Miyata et al., 1999; Liu et al., 2000; Schwab et al., 2000).
These two genes also have a role in promoting adult hippocampal neurogenesis
(Deisseroth et al., 2004; Tozuka et al., 2005). Ngn1 and Ngn2 have been specifically
implicated in inducing neurogenesis and neural differentiation in the NSCs/NPCs of the
developing dorsal telencephalon in contrast to Mash1, which is implicated in the basal
ganglia development (Fode et al., 2000; Schuurmans et al., 2004). This was elucidated in
knockout studies, which showed that Ngn1 and Ngn2 were controlling differentiation of
cortical NPCs into a glutamatergic phenotype through activation of their target
transcription factors, while on the other hand; Mash1 seems to promote neural
differentiation into a GABAergic phenotype through activation of Dlx homedomain genes
(Schuurmans et al., 2004). Furthermore, Ngn1 and Ngn2 appear to repress Mash1
activation and action in cortical NPCs and Ngn2 appears to be able to initiate a neocortical
glutamatergic program independent of Mash1 repression.
Other factors that specify certain neuronal subtypes are Gsh2, which induces
differentiation of striatal projection neurons through production of retinoic acid (Waclaw
et al., 2004); GDNF, which is involved in neocortical interneuron maturation (Pozas and
Ibanez, 2005); and Dlx1, which participates in the morphological development of a certain
population of neocortical interneurons (Cobos et al., 2005).
2.4.2. Astroglial differentiation
Notch signaling has been associated with converting neuroepithelial NPCs into radial glia
and radial glia into mature astrocytes. Neuroepithelial NPCs and radial glia share the
common apical to basal polarity and interkinetic nuclear motility (Götz and Huttner,
2005). The change from neuroepithelial NPCs to radial glia requires increased expression
of several astroglial-specific genes including astrocyte-specific glutamate transporter
(GLAST), S100b, glutamine synthase (GS), vimentin and tenascin-C (TN-C) and this is
where  Notch  signaling  plays  a  key  regulative  role  (Gaiano  et  al.,  2000;  Anthony  et  al.,
2005; Götz and Huttner, 2005). Direct targets for Notch in radial glia are brain lipid
binding protein (BLBP) through activation of CSL/CBF-1 and the Neuregulin receptor
ErbB2 through activation of Deltex (Schmid et al., 2003; Anthony et al., 2005; Patten et
al., 2006). Astrocytes are differentiated from radial glia when Neuregulin-ErbB2 signaling
is suppressed (Schmid et al., 2003). Overexpression of Notch receptor promotes
astrogenesis in the adult brain and the differentiation of astrocytes from NPCs in culture
(Gaiano et al., 2000; Tanigaki et al., 2001). The Notch pathway has been shown to be
active in radial glia and immature astrocytes and to promote astrogenesis directly through
activation  of  GFAP expression  (Ge et  al.,  2002;  Tokunaga  et  al.,  2004;  Kohyama et  al.,
2005). Notch signaling plays a role in maintaining NPCs in undifferentiated state during
neurogenesis through the members of the Hes family of transcription repressors, Hes1 and
Hes5 (Nakamura et al., 2000; Ohtsuka et al., 2001; Hatakeyama et al., 2004). Moreover,
Hes proteins repress target proneural genes Ngn1, Ngn2 and Mash1 to promote
astrogenesis. In addition, Hes proteins activate JAK-STAT signaling to induce astrocyte
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differentiation (Kamakura et al., 2004). In summary, Notch promotes astrogenesis both
directly and indirectly by inducing GFAP expression and through Hes protein activation,
respectively. The absence of Numb and Numb-like, which are intracellular inhibitors of
Notch signaling, lead to perturbations in neocortex development in mice (Li et al., 2003;
Petersen et al., 2004). The effect of Numb in cultured cortical NSCs/NPCs appears to be
stage dependent and results in premature neuronal differentiation or increased
proliferation. Furthermore, around midneurogenesis Numb unequally segregates with the
daughter cell to promote neuronal fate (Shen et al., 2002).
JAK-STAT signaling is the major promoter for astroglial fate and differentiation in
the neocortex. CNTF, LIF and cardiotrophin-1 are cytokines expressed by newborn
neurons, which mediate activation of JAK-STAT signaling upon binding with the
glycoprotein-130-LIFR receptor complex on NSCs/NPCs (Johe et al., 1996; Bonni et al.,
1997; Rajan and McKay, 1998; Barnabe-Heider et al., 2005). Activated STATSs bind to
the promoter of GFAP causing transcriptional activation of the target (Bonni et al., 1997;
Nakashima et al., 1999a). In addition, cytokines such as CNTF can phosphorylate and
inactivate co-repressor N-CoR on the GFAP promoter to induce astrocyte differentiation
(Hermanson et al., 2002). In early NPCs, BMP cytokines promote neurogenesis but later
they will switch to promote astrocyte differentiation and inhibit other cell fates (Gross et
al., 1996; Li et al., 1998a; Nakashima et al., 2001). BMPs recruit downstream
transcription factor SMADs to bind the promoter region of GFAP and induce astrogenesis
(Nakashima et al., 1999b). However, astrogenesis promoting BMP signaling involves
interaction with the JAK-STAT pathway and complex interaction with Notch and its
downstream partner Hes5 (Takizawa et al., 2003). BMP2 can inhibit neurogenesis and
olidendrogenesis through activation of repressing Id proteins and Hes5 (Nakashima et al.,
2001; Samanta and Kessler, 2004; Vinals et al., 2004). BMP signaling is present in the
adult SVZ, where it acts coordinately with the inhibitor Noggin to produce astrocytes or
neurons (Lim et al., 2000).
Growth factors, such as FGF2 interacting with other extrinsic signals, induce
astrocyte differentiation (Qian et al., 1997). Furthermore, NPCs expressing high quantities
of EGF receptor can have increased expression and activation of STAT3 by cytokine
action and promote astrocyte fate (Burrows et al., 1997; Viti et al., 2003; Lillien and
Gulacsi, 2006).
The most important proastrocytic transcription factors seem to be nuclear factor-1
(NFI) family of proteins, which are expressed ubiquitously but with partially differential
patterns  (Gronostajski,  2000).  In  the  absence  of  certain  NFIs,  corpus  callosum
development is perturbed along with a reduction of GFAP mRNA. Most importantly, the
timing and extent of astrogenesis are affected (Cebolla and Vallejo, 2006; Gopalan et al.,
2006). Proastrocytic bHLH proteins, scl and Ngn3, are essential for the differentiation of
astrocytes and oligodendrocytes in specific regions of the embryonic spinal cord (Lee et
al., 2003; Muroyama et al., 2005).
2.4.3. Oligodendroglial differentiation
Oligodendrocyte precursors (OLP)s are generated from embryonic ventro-medial
telenchephalon, late embryonic ventro-lateral telencephalon and postnatal dorsal
telencephalon (Kessaris et al., 2006). There are a few extrinsic signaling pathways
promoting oligodendroglial fate. For example, generation of embryonic OLPs from
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NSCs/NPCs can be induced by Shh signaling through activation of two important
oligodendrocyte fate determinants, bHLH genes Olig1 and Olig2 (Lu et al., 2000; Yung et
al., 2002). In addition, FGF2 has been shown to promote OLP generation from NPCs
independently in vitro (Chandran et al., 2003; Kessaris et al., 2004). PDGF signaling
appears to play a role in the oligodenrocyte differentiation in the adult SVZ by favoring
oligodendrocyte fate over neuronal fate (Jackson et al., 2006). Furthermore, in the adult
SVZ, GFAP-positive NSCs can generate OLPs and mature oligodendrocytes expressing
Olig2, PDGF receptor a, and polysialylated neural cell adhesion molecule (PSA-NCAM)
(Menn et al., 2006).
The function of Olig genes appears to be promoting both oligodendrogenesis and
neurogenesis and inhibiting astrogenesis (Zhou and Anderson, 2002). Olig1 and Olig 2 are
expressed in OLPs and mature oligodendrocytes but ectopic expression of these genes can
induce oligodenrocyte fate in the NSCs/NPCs of embryonic and postnatal brain (Lu et al.,
2000; Zhou and Anderson, 2002; Marshall et al., 2005). Simultanous or separate deletion
of Olig1 and Olig2 leads to depletion of OLPs and oligodendrocytes in the brain (Zhou
and Anderson, 2002). Olig2 seems to act during earlier developmental stages generating
OLPs and oligodendrocytes and Olig1 is required by more mature oligodendrocytes and
myelination (Arnett et al., 2004). One specific adult OLP population expressing
chondroitin sulfate proteoglycan NG2 appears to be Olig2 dependent (Ligon et al., 2006).
Interestingly, Olig2 is expressed in common NPCs for oligodendrocytes and neurons in
the spinal cord and also in the embryonic telencephalon and is required for fate
determination of both lineages (Tekki-Kessaris et al., 2001; Yung et al., 2002; Zhou and
Anderson, 2002; Furusho et al., 2006). Olig2 represses neurogenesis by competing with
Ngn proteins for same promoter place and Olig2 expression must be downregulated before
neuronal differentiation can occur (Lee et al., 2005; Furusho et al., 2006). Repression of
astrogenesis by Olig2 occurs through inhibition of STAT3 and co-activator P300 activity
(Fukuda et al., 2004). In NPCs, BMP signaling inhibits Olig protein function by causing
dimer formation with downstream Id proteins (Yung et al., 2002; Samanta and Kessler,
2004). Inhibition of Oligs can also occur through nuclear export initiated by AKT, which
is downstream of cytokine signaling (Setoguchi and Kondo, 2004). In mature astrocytes,
Olig2 expression is low or absent but some astrocytes can begin to express it again upon
brain injury (Buffo et al., 2005). In the early postnatal SVZ, Olig2 is expressed in
astrocytes and oligodendrocytes but not in neurons (Marshall et al., 2005). Olig2 may
have a temporally regulated role in astrocyte differentiation during embryonic and
postnatal brain development. The homeobox gene Nkx2.2 interacts with Olig2 to produce
OLPs and differentiated oligodendrocytes in the developing CNS but the role of this
interaction  is  not  entirely  clear  (Fu  et  al.,  2002).  One  of  the  proneural  bHLH  genes,
Mash1, is co-expressed in the closely-related and overlapping regions with Olig2 and is
involved with specification of certain populations of oligodendrocytes differentiated from
NPCs in the developing and postnatal brain (Kondo and Raff, 2000; Parras et al., 2004).
Recently, it was shown that Mash1 cooperates with Olig2 during the early embryonic
neurogenic period to produce a distinct population of oligodendrocytes from OLPs by
controlling PDGF receptor a expression in the dorsal telencephalon (Parras et al., 2007).
SOX E transcription factors including SOX8, SOX9 and SOX10, play a role in glial
development in the CNS (Kordes et al., 2005). They have largely overlapping expression
patterns in developing oligodendrocytes, which are temporally sequential. SOX9 is
expressed in OLPs and in immature myelinating oligodendrocytes in the embryonic VZ.
SOX8 expression appears later and it is present only in the ventral VZ. SOX10 is
expressed in specified OLPs emerging after the onset of SOX8 and SOX9 expression.
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Furthermore, SOX8 and SOX10 expression persists in mature oligodendrocytes after
SOX9 expression has been switched off. SOX9 may participate in NSC fate
determination, since in the absence of SOX9 expression, neural lineage is promoted at the
expense of glia (Stolt et al., 2003; Stolt et al., 2005).
Unexpectedly, proastrocytic genes such as NFIs have been shown to be required for
normal oligodendrocytic lineage choice and parallel inhibition of neurogenesis (Deneen et
al., 2006). Oligodendrocytes have been thought to be of ventral forebrain origin but recent
evidence suggests that a distinct population of oligodendrocytes is generated from
neocortical NPCs instead (Kessaris et al., 2006).
3. Neocortex development
The CNS is made from cells that divide to form neuroepithelium, which folds into the
fluid-filled neural tube. During the onset of neurogenesis, neuroepithelial cells divide
asymmetrically in the VZ and SVZ of the anterior and dorsal neural tube to give rise to
radial glia, which produces radially migrating newly born neurons of the neocortex. These
neurons find their place in the six neocortical layers in an inside out fashion and mature to
exhibit various neuronal phenotypes. GABAergic interneurons are generated mainly in
subcortical regions and they migrate tangentially to the neocortex. The last steps of
neocortical development are synaptogenesis and neuronal network formation, which
include making new connections and removing unnecessary ones in activity dependent
manner (McConnell, 1988; Marin and Rubenstein, 2003; Guillemot et al., 2006) (Fig. 1).
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Figure 1 Neocortex development in mouse. The formation of layers in the embryonic
mouse neocortex from embryonic day 11 (E11) to E17 and the structure of adult mouse
neocortex. CP, cortical plate; FL, filament layer; IZ, intermediate zone; MZ, marginal
zone; PP, preplate; SP, subplate; SVZ, subventricular zone; VZ, ventricular zone; I-VI,
cortical layers. Adapted from Molnar et al., 2006 and reprinted by permission from
Federation of European Neuroscience Societies and Blackwell Publishers Ltd.
3.1. Corticogenesis
Dividing  NSCs  in  the  mammalian  neocortical  VZ  and  SVZ,  also  known  as  apical  and
basal NSCs, first give rise to the subplate and cortical layer I. After this, cortical layers are
formed in order VI, V, IV, and last II/III. Layer I is the most superficial and the layer VI is
the deepest. The mouse is widely used as a model for mammalian neocortex development
so only the events during mouse neocortical development will be discussed (Fig. 1 and 2).
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Figure 2 The neocortex contains apical and basal progenitor cells, which generate neurons
and glia. a In neuroepithelial cells, nucleus migrates from the apical end to basal end of
the cell and these cells divide at the apical surface. b In radial glial cells, basal side of the
interkinetic nuclear migration is limited to a boundary between ventricular and
subventricular zones. These cells divide at the apical surface. c In basal progenitors,
nucleus migrates to basal boundary and the cells divide in that position at the basal end of
the ventricular zone or at the subventricular zone. G1, S, G2 and M are phases of the cell
cycle. Adapted and reprinted by permission from Macmillan Publishers Ltd: Nature
Reviews Molecular Cell Biology, Götz and Huttner, copyright 2005.
At the onset of cortical neurogenesis, NSCs located at the VZ divide symmetrically first
and then change to produce more restricted NPCs by asymmetric divisions and give rise to
mainly projection neurons and also astrocytes (Davis and Temple, 1994; Williams and
Price, 1995; Nieto et al., 2001). A rather complex inhibition of astrocyte differentiation
plays a major role in the sequential generation of neurons before the generation of
astrocytes in the neocortex (Qian et al., 2000; Morrow et al., 2001; Sun et al., 2001; Fan et
al., 2005; He et al., 2005). As afromentioned, proneural genes, which include Ngn1, Ngn2
and Mash1 are crucial for the neuronal differentiation program and mediating neuronal
commitment during neocortical neurogenesis (see 2.4.1. Neuronal differentiation) (Fode
et al., 2000; Nieto et al., 2001).
The regulation of cell cycle progression, cell cycle length and cell cycle exit affects
the number of neurons produced during neurogenesis and the neocortical lamination
(Polleux et al., 1997; Caviness et al., 2003; Lukaszewicz et al., 2005). Proneural bHLH
genes promote cell cycle exit in some areas of the CNS but this has not been shown in the
neocortex (Mizuguchi et al., 2001; Lo et al., 2002). Differentiated neocortical neurons are
originally  generated  from  either  radial  glial  apical  VZ  NPCs  or  basal  SVZ  NPCs
(Haubensak et al., 2004; Miyata et al., 2004; Noctor et al., 2004). Basal NPCs originate
from apical NPCs and this process may be mediated by Ngn2 action on the properties of
mitotic cells (Miyata et al., 2004). Neocortical neuronal differentiation may involve
sequential expression of certain transcription factors including Pax6, Tbr2, NeuroD and
Tbr1  in  a  temporal  order  although  this  has  not  been  shown  conclusively  (Hevner  et  al.,
2001; Englund et al., 2005; Hevner et al., 2006). Neural subtype identity is regulated by
proneural bHLH genes, Ngn1 and Ngn2, and homeodomain genes, such as Pax6, in the
developing neocortex (Bertrand et al., 2002; Shirasaki and Pfaff, 2002; Lee and Pfaff,
33
2003). Pax6 directly regulates the transcription of Ngn2 in cortical NPCs (Scardigli et al.,
2003). Pax6 and Emx2 are required to promote corticogenesis (Muzio et al., 2002). On the
other hand, interactions between Pax6 and homeobox gene Gsh2 contribute to the
formation of the pallial-subpallial border (cortical-subcortical) (Toresson et al., 2000).
Pax6 is also required to generate appropriate functional phenotype in the neocortical
neurons (Schuurmans et al., 2004; Kroll and O'Leary, 2005). The highest expression levels
of Pax6 are found in the NPCs of the ventral neocortex accompanied by region specific
expression of sFrp2 and Dbx1 genes (Kim et al., 2001; Yun et al., 2001; Assimacopoulos
et al., 2003). Furthermore, Pax6 or nuclear orphan receptor Tlx are essential for inducing
expression of sFrp2 in NPCs of ventral neocortex implicating a function for these genes in
the patterning of the lateral telencephalon (Stenman et al., 2003). Pax6 expression in the
NPCs of the ventral neocortex is required for the development of the claustrum,
endopiriform nucleus, piriform cortex, amygdalar lateral nucleus, amygdalar basolateral
nucleus, amydalar basomedial nucleus and the nucleus of the lateral olfactory tract
(Stoykova et al., 2000; Tole et al., 2005). The radial glia functions contributing to
neurogenesis are supported by Pax6 (Heins et al., 2002; Haubst et al., 2004). Cortical layer
formation involves a series of complex events (Mallamaci and Stoykova, 2006) and Pax6
participates in these events by mainly specifying later born neurons of upper neocortical
identity (Götz et al., 1998; Fukuda et al., 2000). Supporting studies report abnormalities
affecting upper but not lower layers of the neocortex in the absence of Pax6 expression
(Tarabykin et al., 2001; Noctor et al., 2004; Schuurmans et al., 2004; Zimmer et al., 2004).
SVZ is possibly the origin of upper layer neurons in the primate neocortex (Lukaszewicz
et al., 2005) and in mice (Tarabykin et al., 2001). Subventricular tag (Svet1), a marker for
both SVZ NPCs and upper cortical layers at perinatal stages, seems to be abolished from
these areas in the absence of Pax6, which further supports a role for Pax6 in upper
neocortical layer specification (Tarabykin et al., 2001). Other genes expressed in the VZ
and in proliferating SVZ cells that migrate to form upper neocortical layers are Cux1 and
Cux2, which also seem to specify upper layers in a Pax6 dependent manner (Nieto et al.,
2004; Zimmer et al., 2004). It is not known whether Svet1 and Cux genes are expressed
intrinsically or extrinsically in these defined populations of neocortex cells. Tlx is also
involved in the generation of upper cortical layers and may cooperate with Pax6 (Stenman
et al., 2003; Schuurmans et al., 2004).
So far a number of layer specific genes in the neocortex have been identified (Gray
et al., 2004; Guillemot et al., 2006). Some of them such as SOX5, Klf6, Zfp312 and
NR4A3 are clearly markers for deeper layers and others such as FoxO1, NR4A2 (Nurr1),
bHLHb5 and Lmo4 are markers for upper layers. Some of them also exhibit
anteroposteriorly and mediolaterally specific or dynamic expression patterns in addition to
dorsoventral layer specific patterns. Such genes include Cadherin-6 and ephrin-45, which
are expressed in the parietal cortex. On the other hand, Lmo4 is expressed in the frontal
cortex and Clim1a is expressed in the occipital cortex. Decreasing mediolateral gradient
expression of NR4A3 has been reported in the deeper layers of neocortex. Some layer-
specific  genes  are  also  essential  for  the  formation  of  a  given  layer  or  layers.  In
experiments, where layer-specific genes were rendered inactive or functionally blocked,
genes such as Brn1, Brn2, were shown to perturb layer II-IV formation, whereas
homeobox transcription factor Otx1 affected layer V and Tbr1 caused abnormalities in
layers I and VI and the subplate.
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3.2. Radial glia
At the onset of neocortical neurogenesis, radial glia forms from neuroepithelial cells upon
downregulation of tight junction genes (Aaku-Saraste et al., 1996) and apical to basal
separation of certain proteins (Aaku-Saraste et al., 1997). The radial glial cells exhibit a
partially neuroepithelial as well as an astroglial phenotype (Campbell and Götz, 2002;
Kriegstein and Götz, 2003). The radial glia as direct followers for neuroephelial cells
represents a more restricted form of neocortical NPCs and most of the neocortical neurons
and astrocytes are originated from radial glia (Malatesta et al., 2003; Anthony et al.,
2004). Radial glia emerges around embryonic day 10 (E10) in the mouse neocortex and is
marked by expression of RC1/RC2 and little later by BLBP (Götz and Barde, 2005).
Radial glia retain features from neuroepithelial cells including expression of intermediate-
filament  protein  nestin  (Hartfuss  et  al.,  2001),  an  apical  localization  of  centrosomes  and
prominin-1 (Weigmann et al., 1997; Chenn et al., 1998), adherence junctions and
associated proteins at the apical end of the lateral plasma membrane (Aaku-Saraste et al.,
1997; Wodarz and Huttner, 2003), and basal lamina contact (Halfter et al., 2002). In
addition, radial glial cells exhibit apical-basal interkinetic nuclear migration, although this
is more restricted compared to neuroepithelial cells (Fig. 2). Several astrocytic markers are
expressed in radial glia after the onset of neurogenesis including GLAST, BLBP, S100b,
GS, TN-C and vimentin (Götz and Barde, 2005; Götz and Huttner, 2005). The radial glia
astrocytic structural phetype includes the emergence of the glycogen granules that are
storage sites for glycogen in these cells (Gadisseux and Evrard, 1985). Notch signaling
through Hes proteins seems to be essential for maintaining radial glia during neurogenesis
(Hatakeyama et al., 2004). Radial glia have limited ability to give rise to only a single type
of progeny either astrocytes or oligodendrocytes, or neurons (Malatesta et al., 2003;
Anthony et al., 2004). The traditional role for radial glial fibers, reaching from ventricle
lumen to pial surface, is to provide a surface on which the newly born neurons can migrate
to their destined neocortical layers (Rakic, 1978; Kriegstein et al., 2006). The radial glia
seem to be the progeny of neuroepithelial cells with a more restricted potential to generate
different kinds of cell types in the neocortex (Götz and Huttner, 2005).
3.3. Gliogenesis
The  onset  of  gliogenesis  occurs  at  time  when  neocortical  NPCs  become  responsive  to
BMP, EGF or the cytokines CNTF, LIF and cardiotrophin-1, and glial specific genes such
as GFAP and S100b begin to be expressed (Guillemot, 2007). The competence of
neocortical NPCs to respond to cytokine signals is achieved by the action of FGF2 and
EGF (Lillien and Gulacsi, 2006). Newly born cortical neurons secrete cytokines to
promote  gliogenesis,  which  act  through the  JAK-STAT pathway (Barnabe-Heider  et  al.,
2005). An essential cytokine may be cardiotrophin-1, since other cytokines of the IL-6
family, CNTF and LIF, are only expressed postnatally (Barnabe-Heider et al., 2005; Miller
and Gauthier, 2007). In culture, cytokine TGFb1  signaling  through  the  activation  of
SMADs appears to be one of the factors that promote gliogenesis by inducing radial glia
to produce astrocytes instead of neurons (Stipursky and Gomes, 2007). BMP and Notch
signaling favor gliogenesis primarily by blocking the action of proneural genes
(Nakashima et al., 2001; Louvi and Artavanis-Tsakonas, 2006). As Notch signaling is
required to maintain radial glia, it seems to be equally important in gliogenesis (Taylor et
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al., 2007). Notch signaling through DNA binding protein RBP/J seems to be a key element
in glial differentiation and it involves the regulation of glial specification gene Sox9
expression (Taylor et al., 2007).
A proportion of the neocortical oligodendrocytes are generated in subcortical regions
from which they migrate tangentially into the neocortex in the same manner as
GABAergic interneurons and other proportion are generated from cortical NSCs/NPCs
(Thomas et al., 2000; He et al., 2001; Tekki-Kessaris et al., 2001; Ross et al., 2003) (Fig.
3).
Figure 3 Induction of neurogenesis and gliogenesis in the embryonic neocortex. Multiple
extracellular signals and transcription factors determine whether progenitors adopt
neuronal or astroglial fate. Thick black arrows show transcriptional activation and thin
grey arrows show non-transcriptional positive interactions. Thick grey lines represent
transcriptional repression and thin grey lines represent non-transcriptional negative
interactions. BMP, bone morphogenetic protein; C/EBP, CAAT/enhancer-binding protein;
CNTF, ciliary neurotrophic factor; CSL, DNA-bound transcription factor; CT-1,
cardiotrophin-1; EGF, epidermal growth factor; E10, embryonic day 10; FGF2, fibroblast
growth factor 2; Hes1/5, bHLH transcription factors; ICD, intracellular domain; Id1/3,
inhibitors of differentiation 1/3; LIF, leukemia inhibitor factor; N-COR, nuclear receptor
co-repressor; PDGF, platelet-derived growth factor; SMAD, mothers against
decapentaplegic homologue; STAT, signal transducer and activator of transcription; Wnt,
wingless. Reprinted from Progress in Neurobiology, Vol 83, Guillemot, Cell fate
specification in the mammalian telencephalon, Pages 37-52, Copyright 2007, with
permission from Elsevier.
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3.4. Modes of neural migration in the developing telencephalon
In the developing brain, the migration of newborn cells is directed away from the
proliferative zones the VZ and the SVZ. Radial migration is the main mechanism that
creates the layered structure of excitatory neurons in the neocortex. The migration of
interneurons occurs in a largely tangential manner from subpallium to pallium. In the
olfactory bulb, new neurons migrate from the SVZ along the rostral migratory stream
(RMS).
The migration of pallial neocortical neurons, which occurs in a ventral to dorsal
direction from the embryonic VZ towards the pial surface, is termed radial migration
(Rakic, 1971; Marin and Rubenstein, 2003). An important scaffold for migrating neurons
is provided by radial glial cells, which are also the progenitors for a subset of neocortical
neurons (Miyata et al., 2001; Noctor et al., 2001; Noctor et al., 2002). Radial migration of
a newborn neocortical neuron involves four stages including initiation of movement,
attachment to radial glial fiber, and locomotion with nucleokinesis, detachment, and
laminar positioning (Marin and Rubenstein, 2003). During their radial migration newborn
neocortical neurons also make retrograde and tangential moves and acquire a transient
multipolar phenotype (Tabata and Nakajima, 2003; Noctor et al., 2004).
Tangential migration is a mode of neuronal migration that is not associated with
radial glial guidance or direction in the CNS (O'Rourke et al., 1992; Walsh and Cepko,
1992), but cell motility includes the same steps as radial migration (Kriegstein and Noctor,
2004; Marin et al., 2006). Tangentially migrating cells can acquire diverse morphological
appearance with short compact processes, long elongated processes, or branched processes
(Marin et al., 2006). Tangential migration includes cell motility along the neuronal
scaffold, along axons, or dispersed migration from the subpallium to the pallium. First two
modes are involved in the migration of olfactory bulb interneurons along the rostral
migratory stream and the migration of Gonadotrophin-releasing hormone neurons (Lois
and Alvarez-Buylla, 1994; Wray, 2001). The third mode involves migration of
interneurons and oligodendrocytes to the neocortical and hippocampal regions during
forebrain development (Wichterle et al., 1999; Corbin et al., 2001; Letinic et al., 2002;
Marin and Rubenstein, 2003).
After creating the neuronal variety in the layered neocortex, synaptic connections are
established and strenghtened mainly in an activity-dependent fashion. This operation is
very complex and new information is altering the overall picture frequently (Muotri and
Gage, 2006; Price et al., 2006; Merkle et al., 2007; Toni et al., 2007) and so will not be
discussed further.
4. NSCs in disease
Altered adult hippocampal neurogenesis has been suggested to occur in several
neurological disorders. Epileptic seizures are known to induce proliferation of NSCs and
increase neurogenesis, which may contribute to the dentate granule cell abnormalities
found in many cases of temporal lobe epilepsy (Bengzon et al., 1997; Parent et al., 1997;
Scharfman et al., 2000). Increased neurogenesis occurs in Alzheimer’s disease and
Huntington’s disease (Curtis et al., 2003; Jin et al., 2004a). On the other hand, in a
Parkinson’s disease model, NSC proliferation and neurogenesis are reduced in the SVZ
and in the dentate gyrus (Höglinger et al., 2004), although, it seems unlikely that
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neurogenesis of dopaminergic neurons of the adult substantia nigra would be affected
(Zhao et al, 2003; Frielingsdorf et al, 2004). Interestingly, major depression has been
proposed to be accompanied by a defect in hippocampal neurogenesis, although this kind
of depression is not primarily a hippocampal disorder (Jacobs et al., 2000; Kempermann
and Kronenberg, 2003).
Some of the brain tumors are lethal with resistance to conventional treatments. Only
a few cells in the brain tumor may be responsile for generating cancer cell mass as well as
for the recurrence of cancer. This cell type has the properties of a somatic stem cell with
the capability to initiate malignant cell proliferation and has been termed a brain tumor
stem cell (Vescovi et al., 2006). The most typical types of brain tumors are glioblastomas,
medulloblastomas, and ependymomas in which the brain tumor stem cell type has been
already identified. Brain tumor stem cells exhibit the ability to self-renew and they have
the potential to differentiate into neurons, astrocytes, and oligodenrocytes in vitro
(Ignatova et al., 2002; Hemmati et al., 2003; Singh et al., 2003; Galli et al., 2004; Tunici et
al., 2004; Taylor et al., 2005; Vescovi et al., 2006; Nicolis,2007).
NSCs may be exploited to establish well-standardized cell assays for drug screening
and toxicology to replace assays which do not properly represent the actual human system
(Singec et al., 2007). For disease modeling, NSCs carrying known pathological defects
derived from different developmental stages of the CNS may be useful when seeking an
understanding of the mechanisms causing these defects (Martinat et al., 2004; Singec et
al., 2007).
Based on current knowledge, pathological neuron loss in the adult CNS may in some
extent recruit quinscent endogenous NSCs in neuronal repair and rescue, which can be
benefical in NSC-based therapeutic interventions.
5. NSC-based cell therapy
The potential of NSCs or NPCs to populate the brain and restore function has been shown
during the last decade (Snyder et al., 1992; Flax et al., 1998; Ourednik et al., 2002). In
vitro, NSCs have been propageted successfully in the presence of EGF and/or FGF2 in
cell clusters termed neurospheres for relatively long time, but still a standardized method
for NSC culture is lacking (Snyder et al., 1992; Singec et al., 2006). Fundamental to NSC
therapy is the fact that new neurons are generated in the olfactory bulb and hippocampal
dentate gyrus in the adult brain (Lledo et al., 2006). Another important observation has
been that radial glial cells and a yet undefined subtype of astrocytes are actually NSCs in
the developing and in the adult brain, respectively (Noctor et al., 2001; Anthony et al.,
2004; Ihrie and Alvarez-Buylla, 2007). Therapeutic strategies for using NSCs in
neurological diseases involves different types of approaches and possibilities including
cell replacement, chaperon effects, NSC-based gene therapy, standardized cell assays,
disease modeling, and somatic cell nuclear transfer (SCNT) (Singec et al., 2007). The
potential of NSCs in cell replacement was shown in the adult mammalian neocortex by an
experimental model of induced pyramidal neuron death, in which NSCs were able to
replace lost neurons with the same type of neurons (Snyder et al., 1997). The potential of
NSCs has to be carefully validated according to the individual circumstances since
transplants  can  die  during  cell  preparations,  after  the  implantation,  or  due  to  a  cell  craft
size (Bakshi et al., 2005; Karlsson et al., 2005). Improved transplantation techniques, anti-
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apoptotic drugs, and immunosuppression after transplantation are required for utilizing
NSCs in clinical cell replacement therapy (Takagi et al., 2005; Singec et al., 2007).
The ablity to secrete neurotrophic factors brain derived neurotrophic factor (BDNF),
GDNF, nerve growth factor (NGF), and NT-3, and cytoprotective molecules to rescue
diseased neurons manifest the inherited chaperone effect of crafted NSCs (Ourednik et al.,
2002). These crafted cells also deliver other factors that decrease scarring, promote
angiogenesis, and prevent inflammatory action. This type of NSC action can be considered
to promote the homeostatic recovery of the diseased tissue (Singec et al., 2007).
Endogenous and crafted NSCs can be used as vehicles for transgene delivery into the
diseased brain, since these cells exhibit the ability to target pathology with incredible
integration capabilities and stably express a foreign gene. Furthermore, the migration
tendency of NSCs is guided by chemoattractants released from inflammation and during
acute or chronic tissue damage. One of the molecules secreted during the inflammatory
response, stromal cell-derived factor 1 alpha (SDF1-a),  is  a  strong  attractant  for  human
NSCs migrating even from long distances (Imitola et al., 2004). Thus, transgenic NSCs
may present a powerful tool in long-range delivery of drugs and therapeutic molecules
into an injured CNS.
Endogenous NSCs may be induced to produce new neurons upon injury. Some
regions of the adult brain are suggested to contain NSCs but they are quiscent under
normal homeostatic inhibitory conditions in contrast to the hippocampal dentate gyrus and
olfactory bulb, which constantly generate new neurons (Bernier et al., 2002; Lie et al.,
2004). Non-neurogenic NSCs can be induced to proliferate and generate neurons in vitro
or when transplanted to neurogenic regions in vivo or upon CNS injury (Snyder et al.,
1997; Shihabuddin et al., 2000). However, it is unclear whether these endogenous NSCs
can be recruited without causing exhaustion or tissue malformations and whether NSC-
derived new neurons can establish correct synaptic contacts. Furthermore, activating
endogenous NSCs may be useless when considering therapeutic treatment of diseases with
inherited genetic mutations.
SCNT or therapeutic cloning may be one possibility to generate NSCs specificly for
individual patients by deriving the nucleus from a fully differentiated cell and transfering
it into an egg which will be allowed to develop into a blastocyst. In theory, cells from the
blastocyst could be manipulated to differentiate into a neuronal lineage and transplanted
into the CNS, although this method has not been successfully employed in the CNS or in
humans in general (Rideout et al., 2002; Singec et al., 2007).
Various brain disorders can potentially benefit from NSC therapy, including
Parkinson’s disease, Huntington’s disease, lysosomal storage diseases, and brain cancer.
Parkinson’s disease is caused by the degenerative death of nigro-striatal dopaminergic
neurons that results in the clinical symtoms including tremor, rigidity, and bradykinesis
(Clarke, 2007). Transplantation of fetal mesencephalic tissue into diseased striatum which
is lacking dopamine, and is innervated by axons from the substantia nigra, has proven to
be a successful method in improving Parkinson’s disease (Lindvall and Björklund, 2004).
Due to difficulties of getting human fetal tissue for transplantation, immortalized animal
NSC lines and human embryonic stem (ES) cell lines producing unlimited numbers of
specific type of midbrain dopaminergic neurons have been established (Kim et al., 2002;
Singec et al., 2007). In animal models of Parkinson’s disease, transplantation of these stem
cell-derived differentiated cells have improved the functional phenotype (Björklund et al.,
2002), but this needs to be shown in human CNS in vivo.
Inherited trinucleotide CAG-repeat expansion mutation on chromosome 4, which
results in nuclear and cytoplasmic accumulation of huntingtin fragments and the death of
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medium spiny striatal GABAergic neurons, causes Huntington’s disease (Ramaswamy et
al., 2007; Singec et al., 2007). This devastating disease, which exhibits motor, cognitive,
and psychiatric symptoms, leads to the eventual death of patients 15 to 20 years after
disease  onset.  Transplantation  of  NSCs  may  provide  therapy  for  improving  the  odds  of
Huntington’s disease patients, since animal models have shown that crafted fetal neural
tissue can survive, grow, and establish functional contact with the host brain (Peschanski
et al., 2004). Clinical trials on neural transplantation in Huntington’s disease patients have
provided positive evidence on improving the condition of these patients and shown that
fetal striatal tissue crafted into patient’s brain can survive, produce synaptic contacts, and
resist the process of the disease (Bachoud-Levi et al., 2006; Singec et al., 2007).
Lysosomal storage diseases (LSD)s such as human MPS VII has been studied via
mouse models in experiments were the potential of crafted migratory NSCs to deliver
important molecules has been demonstrated. MPS VII is caused by a deficiency in a b-
glucuronidase (GUSB) enzyme, which is involved in the degradation of
glycosaminoglycans. The symptoms of this disease include neurodegeneration throughtout
the brain, and mental retardation in humans (Singec et al., 2007). NSCs crafted into the
ventricles of the newborn mouse disseminated throughout the neural axis, corrected
lysosomal  function  and  increased  the  levels  of  GUSB  (Snyder  et  al.,  1995).  Similar
progress has been observed in transplantation experiments in other types of LSDs, but
despite promising results in animal models clinical trials have not yet been initiated
(Lacorazza et al., 1996; Shihabuddin et al., 2004).
Other neuropathological conditions presenting NSC trophism in which NSC-based
therapy may be useful include amyotrophic lateral sclerosis (Muller et al., 2006), stroke
(Kelly et al., 2004), traumatic brain injury (Wennersten et al., 2004), multiple sclerosis
(Totoiu et al., 2004), Alzheimer’s disease (Tuszynski et al., 2005), acute spinal cord injury
(Cummings et al., 2005), and epilepsy (Chu et al., 2004).
NSCs may be used as novel therapies to treat malignant brain cancers, since NSCs
and brain tumor stem cells have very similar properties (Yip et al., 2006). In fact, NSCs
can migrate long distances and home tumor cells (Aboody et al., 2000). Transgenic NSCs
can deliver drugs into tumors and significantly reduce tumor cell mass (Aboody et al.,
2000). Cells related to brain tumors may express various factors such as chemokine
receptor CXCR4, stem cell factor (SCF), monocyte chemoattractant protein-1 (MCP1),
and vascular endothelial growth factor (VEGF) etc. that are involved in chemoattractions
of NSCs (Yip et al., 2006). Efforts are currently under way to exploit NSCs as vehicles in
brain cancer treatment (Yip et al., 2006).
In conclusion, NSC-therapy may prove valuable in treating CNS disorders involving
neoplastic, chronic/degenerative, metabolic, acute/traumatic, and inflammatory lesions
(Muller et al., 2006). However, the problems of NSC-therapy such as survival,
differentiation and correct network integration of transplanted cells remain as challenges
for the future stem cell research (Singec et al., 2007).
6. Neurotrophins and their receptors in the CNS
Neurotrophins are a family of structurally and fuctionally similar proteins that were first
characterised as survival factors for sensory and sympathetic neurons, and have since been
demonstrated to regulate many aspects of survival, development and function of neurons
in both the PNS and the CNS. The neurotrophin family in mammals contains four
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structurally and functionally related members: NGF, BDNF, NT-3, and NT-4. Shared
structural similarities between neurotrophins such as tertiary fold and cystein knot are also
features of other growth factors including TGF? and PDGF. The action of neurotrophins is
mediated through the Trk family of receptor tyrosine kinases (TrkA, TrkB, and TrkC) and
p75 neurotrophin receptor (p75NTR), all of which are transmembrane receptors (Huang
and Reichardt, 2001; Lu et al., 2005; Reichardt, 2006; Lei and Parada, 2007) (Fig. 4).
Figure 4 Neurotrophins and their receptors. Trk receptors and p75 receptor are membrane
spanning receptors that have extracellular domain which neurotrophins bind. Upon ligand
binding, Trk receptors can activate such intracellular patways as MAPK-pathway, PI3K-
pathway and PLC-?-pathway. Upon ligand binding, p75 activates such intracellular
pathways  as  NF-?B  and  JNK.  See  text  for  abbreviations.  Reprinted  by  permission  from
Macmillan Publishers Ltd: Nature Reviews Neuroscience, Chao, copyright 2003.
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6.1. BDNF and TrkB receptors
Of the neurotrophins, BDNF is most prominently involved in activity-dependent neuronal
organization during nervous system development (McAllister et al., 1999; Bibel and
Barde, 2000; Thoenen, 2000; Poo, 2001; Aid et al., 2007). In the adult brain, BDNF
modulates synaptic plasticity, and thus, is involved in processes including learning,
memory, and mood (Nestler et al., 2002; Lu, 003; Castrén, 2004; Castrén et al., 2007).
BDNF has been implicated in the modulation of pain, and in Alzheimer’s disease as well
as in other neurodegenerative disorders (Allen and Dawbarn, 2006; Chao et al., 2006). A
Val66Met polymorhism in the gene encoding BDNF disrupts hippocampal function,
episodic memory, and has been connected to schizophrenia and depression (Egan et al.,
2003; Hariri et al., 2003; Frey et al., 2007). In synaptic plasticity-related events, BDNF
promotes hippocampal LTP through TrkB activation, while proBDNF has been suggested
to enhance hippocampal LTD through p75NTR activation (Patterson et al., 1996;
Minichiello et al., 1999; Minichiello et al., 2002; Zakharenko et al., 2003; Pang et al.,
2004; Woo et al., 2005).
The effects of BDNF are mediated through binding to TrkB and p75NTR receptors
(Klein et al., 1989; Rodriguez-Tebar et al., 1990). The p75NTR has high affinity for
proBDNF whereas TrkB binds mature BNDF (Lu et al., 2005). In addition to the full-
length isoform bearing the catalytic domain, TrkB has three truncated isoforms TrkB.T1,
TrkB.T2, and TrkB.shc, which lack the tyrosine kinase domain in their intracellular part
(Klein et al., 1990; Middlemas et al., 1991; Stoilov et al., 2002). Full-length TrkB
receptors are highly expressed in neurons during development, while postnatally, TrkB
receptor expression is attenuated (Allendoerfer et al., 1994; Escandon et al., 1994). Like
BDNF expression, TrkB expression is upregulated in the hippocampus and neocortex in
an activity-dependent manner and lack of TrkB leads to the loss of specific neuron
populations in those areas (Xu et al., 2000; West et al., 2002; Kingsbury et al., 2003).
Depolarized cultured cortical neurons have increased expression of TrkB receptor
(Kingsbury et al., 2003). TrkB receptor expression is altered by stress, seizure, exercise,
antidepressant treatments, and antipsychotic agents in vivo (Lei and Parada, 2007).
Furthermore, TrkB receptors are activated upon antidepressant treatment (Saarelainen et
al., 2003). TrkB is required for the formation of hippocampal Schaffer collateral synapses
(Luikart et al., 2005) and cerebellar GABAergic synapses (Rico et al., 2002).
Truncated TrkB.T1 receptors are expressed in neurons as well as in non-neuronal
cells and their expression increases postnatally and predominates in the whole
telencephalon (Klein et al., 1990; Allendoerfer et al., 1994; Escandon et al., 1994; Fryer et
al., 1996). It was previously thought that these truncated receptors did not transmit any
intracellular signals but their function was to repress BDNF signaling through ligand
sequestering or forming dominant negative hetero dimers with full-length TrkB receptors
(Biffo et al., 1995; Eide et al., 1996; Ninkina et al., 1996; Li et al., 1998b; Haapasalo et
al., 2001). However, this has been challenged by the finding that TrkB.T1 receptors can
signal through distinct pathways of their own (Baxter et al., 1997; Rose et al., 2003; Ohira
et al., 2005; Cheng et al., 2007). TrkB.T1 may mediate BDNF-evoked G-protein and IP3-
dependent intracellular calcium release in astrocytes as well as control glial Rho GTPase
activity and thereby regulate glial cell morphology (Rose et al., 2003; Ohira et al., 2005).
Both full-length and truncated TrkB receptor expression is increased as a result of CREB
activation in cultured neurons (Deogracias et al., 2004). TrkB can be recruited into
cholesterol-rich rafts upon ligand binding and internalized through activity and Ca2+ influx
dependent potentiation of the tyrosine kinase domain (Du et al., 2003). TrkB expression is
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altered in several pathological and physiological conditions including brain trauma,
motoneuron axotomy, Parkinson’s disease, Alzheimer’s disease, schizopherenia, and
aging (Lei and Parada, 2007).
6.2. The role of BDNF action in NSCs and in the developing brain
BDNF signaling regulates the in vitro survival  and  differentiation  of  NSCs  and
NPCs derived from the developing embryonic and postnatal brain (Ahmed et al., 1995;
Lachyankar et al., 1997; Shetty and Turner, 1998; Takahashi et al., 1999; Benoit et al.,
2001; Caldwell et al., 2001; Barnabe-Heider and Miller, 2003). BDNF and nitric oxide
generate a paracrine positive feedback loop to inhibit NPC proliferation and promote
differentiation in the mammalian brain (Cheng et al., 2003). BDNF increases the
expression of bHLH proneural genes Mash1 and Math1 to facilitate differentiation of
NSCs (Ito et al., 2003). In the developing and adult brain, p75NTR expression defines
BDNF-responsive neurogenic NPCs in the SVZ (Young et al., 2007). BDNF signaling
through p75NTR is required for neuronal differentiation of fetal forebrain NPCs in vivo
and lack of p75NTR increases proliferation and nestin expression in these cells (Hosomi et
al., 2003). Furthermore, a sequencal activation of p75NTR and TrkB is involved in
dendritic development of SVZ derived differentiating NPCs (Gascon et al., 2005).
The expression of truncated TrkB.T1 directs neocortical NSCs towards a glial fate
through a new signaling mechanism (Cheng et al., 2007) and neuron-specific
overexpression of TrkB.T1 can promote proliferation of adult SGZ progenitors which is
accompanied by reduced survival of newborn granule neurons in vivo (Sairanen et al.,
2005).
During neocortex development, administering BDNF at E13 but not at E14 results in
the differentiation of deeper layer neurons instead of superficial neurons (Ohmiya et al.,
2002). Furthermore, BDNF alters the position, gene-expression properties and projection
of neurons of superficial layers to match those of the deeper layers, and in the absence of
BDNF migration of layer II/III neurons is affected (Fukumitsu et al., 2006). During
development, TrkB receptor expression regulates the temporal migration of neocortical
neurons and the differentiation of neurons and oligodendrocytes (Medina et al., 2004).
TrkB expression in thalamic axons is important for normal development of the barrel
cortex (Lush et al., 2005).
In the developing cerebellum, BDNF directly and acutely stimulates the migration of
newborn granule neurons in the cerebellum (Borghesani et al., 2002). These cells migrate
along a BDNF gradient, which involves vesicle trafficking as an important component for
responding to BDNF-mediated chemotactic stimulus (Zhou et al., 2007). Furthermore,
NPC migration from the SVZ along the rostral migratory stream is promoted by local
expression of both BNDF and TrkB receptors (Chiaramello et al., 2007). In migrating
cells, this neurotrophic effect causes the activation of CREB through PI3K and MAPK
pathways (Chiaramello et al., 2007).
TrkB signaling is important for the growth and stabilization of excitatory synapses
during development in a cell-autonomous manner both in pre- and postsynaptic cells
(Luikart and Parada, 2006). Overexpression of the full-length TrkB receptor leads to
increased expression of plasticity related genes in several brain regions (Koponen et al.,
2004). The expression of both full-length TrkB and TrkB.T1 receptors are suppressed by
thyroid hormone in the developing rat brain (Pombo et al., 2000).
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The expression of TrkB receptors has been associated with malignant
neuroblastomas (Brodeur et al., 1997; Schramm et al., 2005). TrkB receptor expression
can suppress anoikis, which is a form of apoptosis caused by the loss of cell-matrix
interactions, and induce metastasis in non-malignant epithelial cells (Douma et al., 2004).
Transiently overexpressed TrkB.T1 receptor competes with the full-length TrkB receptor,
and is able to increase process and filopodia formation in neuroblastoma cells thus
directing them toward differentiated morphology (Haapasalo et al., 1999). TrkB activation
can also promote the survival of human ES cells by counteracting apoptotic signals (Pyle
et al., 2006).
To summarize, BNDF signaling through TrkB and p75NTR signaling seems to play
a role in NSC/NPC survival, differentiation, and proper neocortical development.
6.3. TrkB.T1 overexpressing mouse
Overexpression of a truncated form of the TrkB receptor, TrkB.T1, may suppress the
normal function of BDNF (Eide et al., 1996). To test this hypothesis a transgenic mouse
model was generated, which harboured N-terminally flag-tagged TrkB.T1 cDNA under
the control of the Thy1 promoter (Caroni, 1997; Saarelainen et al., 2000a). Transgene
expression in these mice is neuron specific in mature brain, and the main regions for
expression are the hippocampus and neocortex. Initial characterization revealed that these
mice exhibit impaired long-term spatial memory and normal hippocampal LTP
(Saarelainen et al., 2000b). These mice have increased susceptibility for ischemia induced
neocortical injury, implicating impaired neurotrophin mediated rescue of neocortical
neurons upon ischemic insult (Saarelainen et al., 2000a). Adult hippocampal neurogenesis
is altered in these mice overexpressing TrkB.T1 receptor, since the survival of newborn
neurons in the dentate gyrus was reduced, and was accompanied by precursor proliferation
which was likely induced by a homeostatic feedback mechanism (Sairanen et al., 2005).
Based on these observations, the mouse model overexpressing the TrkB.T1 receptor can
be considered as a model for mildly impaired learning and memory.
7. Fragile X syndrome
Fragile X syndrome (FXS) is the most common form of inherited mental retardation with
a prevalence of 1 in 4000 males and 1 in 8000 females (Turner et al, 1996; O'Donnell and
Warren, 2002). The mental retardation linked to fragile X chromosome was first termed as
Martin-Bell syndrome in the early 80s (Richards et al., 1981), and it is now known as
FXS. FXS belongs to a large group of human X-linked mental retardation syndromes
(Chiurazzi et al., 2004). The fragile X site lies in locus Xq27.3 of the X-chromosome
between factor IX gene and marker st14 (Harrison et al., 1983; Oberle et al., 1986). FXS is
caused by a mutation in a single gene, fragile X mental retardation 1 (FMR1), which was
cloned in the early 90s (Heitz et al, 1991; Verkerk et al., 1991). The mutation leads to a
lack of fragile X mental retardation protein (FMRP) (Pieretti et al., 1991). Cloning of the
FMR1 gene accelerated research on the syndrome and the gene proved to be well
conserved between species. This allowed the generation of animal models to study the
syndrome.
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7.1. Phenotype of FXS
7.1.1. Behavioral phenotype in FXS
Characteristic of FXS is mental retardation, with IQ normally ranging from 20 to 70
(Fisch et al., 2002). The cognitive skills that are the most affected include speech, short-
term memory, and visuospatial abilities. Developmental delay in speech is the symptom
that is usually first noticed in FXS. A wide variety of non-cognitive symptoms of FXS
include hyperactivity, attention deficit, hypersensitivity to sensory stimuli, and autistic like
behavior (O’Donnell and Warren, 2002). Gaze avoidance, tactile defensiveness, and
repetitive behaviors, which are characteristic for autistic individuals, are also observed in
15% to 50% of FXS patients. In addition, FXS patients show a delayed return of
glucocorticoids to baseline levels following stress, which may be considered to be part of
autistic like features (Hessl et al., 2004).
7.1.2. Anatomical and neuroanatomical phenotype in FXS
In  FXS,  facial  morphology  is  usually  altered  in  a  manner  that  prominent  jaws,  forehead
and large ears accompany a long and narrow face (Chudley and Hagerman, 1987) (Fig. 5).
This is typical for macrocephalic facial morphology. A common and characteristic of FXS
is enlarged testicles or in other words macroorchidism (Turner et al., 1980). Other physical
features include a high arched palate, flat feet, hypotonia, mitral valve prolapse, and
increased joint laxity that are thought be a result from a connective tissue abnormality in
FXS (Hagerman et al., 1983; Loehr et al., 1986; Hjalgrim et al., 2000). Increased birth
weight, increased stature, and macrocephaly are part of the unusual growth patterns
associated with FXS. This is believed to be caused by neuroendocrine dysfunction, and in
particular, by hypothalamus dysfunction (Hessl et al., 2004).
FXS brains exhibit no major gross abnormalities (Rudelli et al., 1985; Hinton et al.,
1991; Wisniewski et al., 1991; Irwin et al., 2001). There are, however, observations about
ventricular enlargement and mild cortical atrophy (Wisniewski et al., 1991). MRI images
of  FXS  brains  have  revealed  other  abnormalities  such  as  decreased  size  of  posterior
vermis of cerebellum and increased size of caudate nucleus. The abnormalities seen in the
caudate nucleus, posterior vermis and ventricles correlate with the expression of the FMR1
gene and may result from the lack of FMRP (Reiss et al., 1991a; Reiss et al., 1991b; Reiss
et al., 1995; Mostofsky et al., 1998; Eliez et al., 2001). Interestingly, hippocampal volume
was observed to be enlarged in children and young adults with FXS (Reiss et al., 1994;
Kates et al., 1997) but not in older adults (Jäkälä et al., 1997) suggesting a developmental
defect in hippocampus of FXS patients. Recently, a tensor-based morphometry analysis
revealed minor neuroanatomical alterations in FXS brains including an increase in parietal
and temporal white matter (Lee et al., 2007). This analysis also confirmed the earlier
findings in FXS brains showing increases in lateral ventricle and caudate nucleus volumes.
Periventricular heterotopia has been found in two FXS patients, which suggests that
neuronal migration is impaired in FXS (Moro et al., 2006). Structural abnormalities in the
lateral geniculate nucleus of the visual pathway have been reported in FXS patients
(Kogan et al., 2004b). These abnormalities are shown to affect only magnocellular neuron
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layers of the lateral geniculate nucleus in which FMRP is normally expressed thus
suggesting a cell type specific function for FMRP in certain parts of the visual pathway.
Figure 5 A boy with fragile X syndrome. Reprinted, with permission, from Annual
Reviews of Genomics and Human Genetics, Volume 8 © 2007 by Annual Reviews,
www.annualreviews.org.
7.1.3. Neuronal ultrastructure: Dendritic spine phenotype in FXS
FMRP is expressed widely in the human CNS and highly in neurons (Abitbol et al., 1993;
Devys et al., 1993). Certain excitatory neurons show protrusions in their dendrites that are
important for synapse formation. These are called dendritic spines and they are
dysmorphed in FXS in such a manner that they generally exhibit an immature phenotype
with an increased density of longer, thinner and tortuous spines compared to healthy
controls (Rudelli et al., 1985; Hinton et al., 1991; Wisniewski et al., 1991; Irwin et al.,
2001) (Fig. 6). During normal development, dendritic spine maturation and pruning are
46
important steps in the formation of functional synaptic contacts and the elimination of
unnecessary ones. Dendritic spine abnormalities have also been observed in other
syndromes with mental retardation (Dierssen and Ramakers, 2006). Increased dendritic
spine density and the resulting increased excitatory activity are postulated to play a role in
epileptic seizure susceptibility in FXS patients (Incorpora et al., 2002). Spine
morphogenesis involves signaling pathways that eventually lead to rearrangement of actin
cytoskeleton. At the postsynaptic site, FMRP synthesis may affect related proteins and
signaling pathways involved in dendritic spine morphology including Rho GTPase Rac1,
microtubule-associated protein- 1B (MAP1B), calcium-calmodulin-dependent kinase II
(CaMKII), calbindin, alpha-glucocorticoid receptor, p21-activated kinase (PAK) and
cadherins (Grossman et al., 2006a; Hayashi et al., 2007).
Figure 6 Dendritic spines of fragile X neurons have an immature appearance. Adapted
from Irwin et al, 2001 and reprinted with permission from Wiley-Liss, Inc.
7.2. Causes of FXS
The 5’ untranslated region (UTR) of the FMR1 gene contains a CGG trinucleotide repeat
region, which is unusually expanded to over 200 repeats in FXS compared with 6 to 44
repeats in healthy controls and 55 to 200 repeats in premutation carriers (Verkerk et al.,
1991). The expansion to the full-mutation usually occurs when the premutation is
transmitted from a female, since male spermatogenesis is unable to preserve the long
repeat extension (Malter et al., 1997). The repeat extension, and the upstream CpG-island
are hypermethylated and the premutation-length extension increases in size when
transmitted to a pedigree (Heitz et al., 1991; Oberle et al., 1991; Eichler et al., 1993).
Microsatellite sequences, similar to the one causing FXS, are common in the human
genome and are usually relatively stable when transmitted to a pedigree whereas
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trinucleotide repeat sequences are much more unstable and can be lengthened upon
transmission (Richards and Sutherland, 1997). This type of dynamic mutation usually
results in a genetic disorder. FXS is one of the 16 disorders known so far to be caused by
this type of mutation mechanism (Cummings and Zoghbi, 2000). The trinucleotide repeat
extension mechanism is thought to involve slipped-strand mispairing during DNA
replication that occurs especially in Okazaki fragments (Kunkel, 1993; Richards and
Sutherland, 1997). Long trinucleotide repeat regions containing Okazaki fragments are
unstable and can suffer a slippage which results in the addition of new complementary
nucleotides to template strand by DNA repairing enzymes and thus generates an
expansion. This suggests defect in the mismatch repair system although an evidence of
this is lacking. Within the FMR1 gene, the full-mutation trinucleotide repeat and CpG-
island are hypermethylated together with the surrounding regions, which causes repression
or silencing of the FMR1 gene that leads to a lack of FMRP in FXS (Pieretti et al., 1991;
Sutcliffe et al., 1992; Hornstra et al., 1993). Methylation occurs very early in embryonic
development and the short time period when the full-mutation FMRP is expressed does
not seem to affect the severity of the FXS phenotype (Willemsen et al., 1996; Losekoot et
al., 1997). In FXS, methylation of the FMR1 gene prevents direct transcription factor-
binding and induces chromatin condensation which impairs the binding of transcriptional
machinery (Penagarikano et al., 2007). Four upstream footprints for transcription factor-
binding sites, which are inactivated after hypermethylation of the FMR1 gene in FXS,
include a GC rich palindrome, two GC boxes, and E-box-cAMP response element (CRE)
site (Drouin et al., 1997; Schwemmle et al., 1997).
Although  over  95%  of  FXS  cases  are  caused  by  the  CGG  trinucleotide  repeat
mutation (O’Donnell and Warren, 2002), it is not the only cause for FXS since other
mutations can also lead to a loss of functional FMRP. Several deletions (Hammond et al.,
1997) and some point mutations (De Boulle et al., 1993; Lugenbeel et al., 1995) affecting
the FMR1 gene have been found to cause FXS. A point mutation may lead to the
expression of non-functional protein and may offer an opportunity to characterize the
functional  domains  of  any  given  protein.  In  fact,  in  one  case  of  FXS  with  a  severe
phenotype, a missense point mutation in the nuclear ribonucleoprotein K Homology 2
(KH2) domain of FMRP at amino acid site 304 caused by substitution of isoleucine (I) to
asparagine (N) (I304N) was reported (De Boulle et al., 1993; Siomi et al., 1994). Since
then, this mutation has been studied and has provided valuable information of the
molecular binding partners of FMRP. In some patients, the FXS phenotype, which does
not  involve  a  trinucleotide  repeat  expansion  or  a  mutation  in  the  gene,  has  been  found
(Clarke et al., 2004). Overall, the bottom line is that the absence or loss-of-function
mutation of FMRP causes the phenotype in FXS. Recent research has shown that the
premutation size of the CGG trinucleotide repeat expansion results in a distinct phenotype
of its own referred to as fragile X-associated tremor/ataxia syndrome (Hagerman and
Hagerman, 2004) but will not be discussed further in this thesis.
7.3. The structure and expression of the FMR1 gene
The FMR1 gene spans 38 kb and encodes a 4.4 kb transcript consisting of 17 exons (Fig.
7). The gene encodes a protein, which has several splice variants and a maximum length
of 632 amino acids resulting in a molecular weight of 80 kDa (Ashley et al., 1993; Eichler
et al., 1993). The CGG trinucleotide repeat region is located within the first exon of the
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FMR1 gene and the translation initiation sequence is located 69 bp downstream (Ashley et
al., 1993).
Figure 7 The structure of the fragile X mental retardation 1 gene (FMR1). KH1/2, nuclear
ribonucleoprotein K Homology 1/2; NES, nuclear export signal; NLS, nuclear localization
signal; RGG, an Arginine-Glycine-Glycine box. Reprinted, with permission, from Annual
Reviews of Genomics and Human Genetics, Volume 8 © 2007 by Annual Reviews,
www.annualreviews.org.
Transcription factors that actively regulate FMR1 promoter activity include upstream
stimulatory factor 1 (USF1) and USF2, nuclear respiratory factor 1 (NRF1) and NRF2,
specificity protein 1 (Sp1) and Sp3, alpha-Pal/Nrf-1, and cAMP response element binding
protein (CREB) (Kumari and Usdin, 2001; Kumari et al., 2005; Smith et al., 2006). Of
these transcription factors, Sp1 is the strongest in regulating FMR1 transcription with
apparent resistance to DNA methylation, although the presence of MeCP2 and the
chromatin-remodeling protein Brahma may disrupt its association with the FMR1
promoter in FXS cells (Smith et al., 2004; Harikrishnan et al., 2005). Transcriptional
regulation of the Fmr1 gene in the embryonic but not adult mouse brain seems to involve
a transcription factor AP2 in a gene dosage dependent manner (Lim et al., 2005a).
Normally, the FMR1 gene is associated with acetylated histone proteins H3 and H4
at the 5’ region with acetylation of H3 being the most important for transcription, but in
FXS cells the acetylation of these proteins is  reduced (Coffee et  al.,  1999; Coffee et  al.,
2002). In addition, normal methylation patterns of the FMR1 gene show that histone 3 has
a methylated lysine 4 and unmethylated lysine 9 (Coffee et al., 2002). In FXS, opposing
methylation patterns occur (Coffee et al., 2002). The FMR1 CGG trinucleotide repeat
sequence is normally interrupted by an AGG trinucleotide sequence approximately every
9 to 10 repeat units, and if these interruption sequences are missing, as in some
premutation cases, the risk of full-mutation is greatly increased. Thus, the loss of these
interrupting trinucleotide sequences increases the instability of the trinucleotide repeat
region (Eichler et al., 1993; Kunst and Warren, 1994). Premutations, with at least 90
trinucleotide repeats, are converted to full-mutation when transmitted to a pedigree and
contain perhaps 2 AGG interruptions in all. This suggests that for full-mutation, 70 pure
trinucleotide repeats are required. This amount of repeats fits to a theory of Okazaki
fragment slipped-strand mispairing as a mechanism for trinucleotide repeat expansion.
The FMR1 gene has two autosomal homologs: fragile X related 1 (FXR1) and FXR2
(Siomi et al., 1995; Zhang et al., 1995) and highly conserved orthologs in mammals,
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chickens, fruit flies,  zebrafishes, and frogs (Ashley et al., 1993; Price et al., 1996; Wan et
al., 2000; Tucker et al., 2004; Lim et al., 2005b)
7.4. Fragile X mental retardation protein
The FRM1 gene product, FMRP, is most highly expressed in the brain and testis in which
the major phenotypic symptoms of FXS, mental retardation and macroorchidism, are
observed  (Devys  et  al.,  1993).  In  the  CNS,  the  majority  of FMR1 gene and FMRP
expression is localized to neurons. Recently, however, a developmentally transient
expression of FMRP was also observed in non-neuronal cells in the mouse brain (Abitbol
et al., 1993; Devys et al., 1993; Pacey and Doering, 2007). The protein is mainly localized
in the cytosol of neurons although it also has a nuclear localization signal (NLS)
suggesting a trafficking between the nucleus and the cytosol (Devys et al., 1993; Feng et
al., 1997b). Alternative splicing can generate at least 12 different FMRP isoforms (Devys
et al., 1993; Siomi et al., 1993), and they show the same expression pattern in different
tissues (Verkerk et al., 1993). The most common isoforms lack exon 12, and the isoforms
that are the least expressed lack exon 14 (Sittler et al., 1996). The isoforms with low
expression also locate to nucleus, since the nuclear export signal (NES) is located within
exon 14.
FMRP contains sequence motifs characteristic of RNA-binding proteins. Two
heterogeneous KH domains (KH1, KH2) and an Arginine-Glycine-Glycine (RGG) box are
found within exons 8, 10, and 15, of FMRP, respectively (Ashley et al., 1993). In addition,
the amino-terminal of FMRP contains an RNA-binding domain (Adinolfi et al., 2003;
Ramos et al., 2006). In vitro,  FMRP  associates  with  4%  of  fetal  human  brain  mRNAs
including its own message (Ashley et al., 1993). FMRP is associated with mRNP
complexes and translating polyribosomes and can regulate the localization, stabilization
and translation of a subset of mRNAs (Khandjian et al., 1996; Siomi et al., 1996; Feng et
al., 1997a,b; Brown et al., 2001; Zalfa et al., 2003; Khandjian et al., 2004; Stefani et al.,
2004; Zalfa et al., 2007).
Autosomal homologs for FMRP, FXR1P and FXR2P, also bind to 660 kDa mRNP
complex with FMRP and several other proteins (Zhang et al., 1995). These two homologs
possess the same structural organization as FMRP including the KH domains, the RGG
box, NLS, NES, and a homodimerization domain. They are also mainly localized to
cytosol,  although they  can  shuttle  between the  nucleus  and  the  cytosol.  FXR2P shows a
different nuclear localization than FMRP and FXR1P (Tamanini et al., 2000).
Nuclear shuttling of FMRP might be facilitated by interaction with Ran-binding
protein (RanBPM), which is involved in nuclear trafficking (Nakamura et al., 1998;
Menon et al., 2004). Furthermore, FMRP interacts with nuclear export factor NXF2 to
promote nuclear export (Lai et al., 2006). In the cytoplasm, MicroSpherule protein 58
(MSP58) interacts with FMRP in polyribosomal mRNPs of neurons and escorts it to the
somato-dendritic compartment (Davidovic et al., 2006). FMRPs action as an mRNA
transporter may occur through an interaction with neurospecific KIF3C kinesin and
dendritic RNA granules (Davidovic et al., 2007). Additional binding partners of FMRP in
the mRNP complex include nuclear FMRP interacting protein (NUFIP), cytoplasmic
FMRP interacting protein 1 (CYFP1) and CYFP2, an 82-kDa FMRP interacting protein
(82-FIP), nucleolin, and Y-Box factor 1/p50 (YB1/p50) (Bardoni et al., 1999; Ceman et
al., 1999; Ceman et al., 2000; Schenck et al., 2001; Bardoni et al., 2003). Of these,
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YB1/p50 has an interesting function, since it is involved in the transcription,
transportation, stabilization and translation of mRNAs (Stickeler et al., 2001; Nekrasov et
al., 2003). Although, the proteins present in the FMRP mRNP complex have been
identified, the content of the complex may vary spatiotemporally (Fig. 8).
Figure 8 FMRP  transports  mRNA  cargoes  from  the  nucleus  to  postsynaptic  sites  in
neurons. Adapted and reprinted by permission from Macmillan Publishers Ltd: Nature
Reviews Neuroscience, Bagni and Greenough, copyright 2005.
Post-translational modifications of FMRP have been shown to include methylation and
phosphorylation (Ceman et al., 2003; Dolzhanskaya et al., 2006). Methylation is directed
to arginine 544 within the RGG box and is postulated to regulate protein-protein and
protein-RNA interactions of FMRP (Dolzhanskaya et al., 2006; Stetler et al., 2006),
whereas the phosphorylation directed at the N-terminal end of FMRP, is thought to
negatively regulate the association of FMRP with actively translating polyribosomes
(Ceman et al., 2003).
7.5. The function of FMRP: Regulating the localization, stability and
translation of mRNAs
FMRPs RNA-binding properties are thought to be functionally important and many of the
mRNAs binding to FMRP have been identified (Ashley et al., 1993; Adinolfi et al., 1999;
Brown et al., 2001; Darnell et al., 2001; Chen et al., 2003; Miyashiro et al., 2003; Zalfa et
al., 2003) (Fig. 9). These messages encode proteins associated with the function and
maturation of neurons, and synaptic plasticity. FMRP-bound mRNAs are both up- and
downregulated suggesting a dual role for FMRP as a translation inducer and repressor
(Miyashiro et al., 2003). FMRP binds to its target mRNAs via different mechanisms. The
RGG box on FMRP binds to a RNA loop structure called G-quartet, which contains four
guanines that are stabilized by hydrogen bonds in a planar conformation (Darnell et al.,
2001; Zanotti et al., 2006). FXRP1 can modulate the FMRP affinity for the G-quartet
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RNA structure (Bechara et al., 2007). Another structural class of mRNAs binding to
FMRP has U-rich sequences that facilitate the interaction (Chen et al., 2003). The KH2
domain of FMRP binds to a distinct RNA structure named loop-loop pseudoknot or
kissing complex (Darnell et al., 2005; Valverde et al., 2007), which appears to compete
with binding of polyribosomes. Thus, it seems that the KH2 domain may be important in
translation regulation by FMRP. Furthermore, an I304N mutation in the KH2 domain of
FMRP has diverse consequences including altered RNA-binding activity (De Boulle et al.,
1993; Siomi et al., 1994; Feng et al., 1997a; Brown et al., 1998; Lewis et al., 2000),
impaired homodimerization (Feng et al., 1997a; Laggerbauer et al., 2001), inability to
inhibit mRNA translation in vitro and  assembly  of  80S  ribosomes  on  target  mRNAs
(Laggerbauer et al., 2001; Li et al., 2001). In addition, the mutated form of FMRP is faster
in shuttling between nucleus and cytosol (Tamanini et al., 1999). A mutation in KH
domains of the fruit fly ortholog of FMRP results in partial loss-of-function phenotypes
(Banerjee et al., 2007).
Figure 9 The  interaction  of  FMRP  with  mRNAs.  FMRP  interacts  with a G-quartet
structure, b Poly(U)  strecthes  and e kissing complex in the mRNA. Indirect interaction
between FMRP and mRNAs can occur through c the small non-coding RNA brain
cytoplasmic  RNA  1  (BC1)  or d microRNAs (miRNA). eIF2C2, eukaryotic translation
initiation factor 2C, 2. Adapted and reprinted by permission from Macmillan Publishers
Ltd: Nature Reviews Neuroscience, Bagni and Greenough, copyright 2005 and, with
permission, from Annual Reviews of Genomics and Human Genetics, Volume 8 © 2007
by Annual Reviews, www.annualreviews.org.
Another mechanism by which FMRP may regulate target mRNAs is through its
association with the microRNA pathway (Caudy et al., 2002; Jin et al., 2004b).
MicroRNAs  are  small  noncoding  RNAs  that  inhibit  the  translation  of  partially
homologous mRNAs by association with an RNA-induced silencing complex (RISC).
Before association with RISC, microRNAs are processed from longer RNAs by Dicer
enzyme. FMRP associates with microRNAs, RISC proteins as well as with components of
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the Dicer microRNA pathway and the mammalian ortholog of Argonite 1 (AGO1) [also
knowns as eukariotic translation-initiation factor 2C, 2 (eIF2C2)] (Jin et al., 2004b). This
suggests that FMRP participates in translation repression with microRNA pathway
components. FMRPs association with the microRNA pathway is further supported by the
reported regulation of translation of FMRP interacting CaMKII mRNA by a microRNA
mediated mechanism in neurons (Ashraf et al., 2006; Grossman et al., 2006a). There is
evidence that the microRNA pathway participates in inhibition of Lim-domain-containing
protein kinase 1 (LimK1), which is important for dendritic spine morphology (Schratt et
al., 2006). One function of FMRP and microRNA interaction may involve chromatin
remodeling in the nucleus since microRNAs regulate chromosome methylation (Jenuwein,
2002; Bao et al., 2004). The Small nonmessenger cytoplasmic RNA BC1 binds to FMRP
(Zalfa et al., 2003; Zalfa et al., 2005). BC1 is also associated with mRNAs that are
regulated by FMRP. BC1 participates in the formation of a translational inhibition
complex with polyA-binding protein and eIF4A (Wang et al., 2002). Although evidence
suggests that BC1 is an adapter between FMRP and target mRNAs, FMRP and BC1 are
unlikely to be directly associated since BC1 is present in lighter polysome fractions than
FMRP (Krichevsky and Kosik, 2001; Zalfa et al., 2005). A novel mechanism for FMRP
mediated translational regulation has emerged, since FMRP and AGO2, which are
microRNA pathway components, activate translation in a cell-growth-dependent manner
through interacting with AU-rich elements at 3’ UTR of target mRNAs (Vasudevan and
Steitz, 2007).
Regulation of translation is not the only role for FMRP, since it has also been shown
to participate in the transport and stabilization of neural mRNAs. The activation of
metabotropic glutamate receptors (mGluRs) increases transport of mRNA-containing
FMRP-granules to synaptic sites (Antar et al., 2004; Antar et al., 2005), and recently,
FMRP was shown to stabilize postsynaptic density-95 (PSD-95) mRNA in a mGluR-
mediated  manner  via  interaction  with  the  3’UTR  of  PSD  (Zalfa  et  al.,  2007).  In  the
absence of FMRP, transport granule diassembly is increased in response to mGluR
stimulation (Aschrafi et al., 2005). The status for FMRP as a transporter is supported by
the fact that some of the confirmed mRNA cargoes of FMRP are not located into the
dendritic region when the transporter is absent. Furthermore, ZBP1/insulin-like growth
factor II mRNA-binding protein1 (IMP1), which participates in mRNA transport in
neurons, can interact with FMRP in mRNP granules in vivo (Rackham and Brown, 2004).
Binding partners of FMRP, purine-rich single stranded DNA-binding (PUR) proteins and
Staufen, are probably participating in mRNA transport and the regulation of translation by
interacting with a kinesin motor (Kohrmann et al., 1999; Duchaine et al., 2002; Ohashi et
al., 2002; Kanai et al., 2004; Price et al., 2006).
mGluR-dependent protein synthesis in hippocampal slices of Fmr1-knockout (Fmr1-
KO) mice is required for epileptiform discharges and these can be blocked by ERK
inhibitors (Chuang et al., 2005). Interestingly, since phosphorylation represses the
association  of  FMRP  with  polyribosomes  and  the  stimulation  of  mGluR5  decreases  the
activity of the mRNA target of FMRP, phosphatase PP2A, this may be a mechanism,
which regulates FMRP function (Ceman et al., 2003; Castets et al., 2005; Mao et al.,
2005). FMRP shifts between polyribosomes and stress granules after neuronal injury by
either arsenite or hippocampal electrode insertion (Kim et al., 2006).
Gene expression analysis has revealed that 90 and 73 genes are abnormally regulated
in the absence of functional FMRP in human and mouse, respectively (D'Agata et al.,
2002; Bittel et al., 2007). In the brain, the greatest changes in gene expression include
decreased expression of MAP2 as well as MAP1B, and increased expression of APP and
53
Hes1  mRNAs.  The  absence  of  FMRP  has  been  associated  with  brain  region  specific
elevations in protein synthesis (Qin et al., 2005) and decreased Fmr1 expression has been
observed upon aging in mice (Singh et al., 2007).
FMRP function at the molecular level includes mRNA transport from the nucleus to
somato-dendritic synaptic sites, mRNA stabilization, and translational regulation of a
subset of mRNAs via several functional interaction sites. FMRP function may be strictly
restricted in a spatiotemporal manner.
7.6. mGluR5 and synaptic plasticity in FXS
FMRP is associated with actively translating polyribosomes in neurons and therefore is
involved in the regulation of the translation of neuronal transcripts (Khandjian et al., 2004;
Stefani et al., 2004). Protein synthesis is particularly important in the cell bodies and
dendritic spines in neurons since it is a part of synaptic plasticity related events. Synaptic
plasticity can be mediated by receptors for neurotransmitter glutamate, which include
ionotropic N-methyl-D-aspartate (NMDA) and alpha-amino-3-hydroxy-5-methylsoxazole-
4-propionic acid (AMPA) receptors, and G-protein coupled mGluRs (Hollmann and
Heinemann, 1994). Two types of synaptic plasticity, long-term potentiation (LTP) and
long-term depression (LTD) are important for learning and memory (Malenka and Bear,
2004). Pre- and/or postsynaptic forms of LTP and LTD contribute to the creation,
maintenance and elimination of synapses as well as the regulation of synaptic strength.
Postsynaptic LTD is generated by the activation of NMDA receptors or group I mGluRs at
the postsynaptic site. These two types of postsynaptic forms of LTD both involve
increased internalization and consequently decreased surface expression of AMPA
receptors (Huber et al., 2000).
The synthesis of FMRP at the postsynaptic site is increased by activation of mGluR1
and/or mGluR5 (Weiler et al., 1997; Hou et al., 2006). The synthesis of FMRP is
important, since in cortical neurons FMRP levels increase after light exposure stimulation
of dark-reared/light-exposed rats, whereas mRNA levels remain unchanged (Gabel et al.,
2004). FMRP-deficient hippocampal Schaffer collateral synapses of the CA1 area and
cerebellar parallel fiber to Purkinje cell synapses show increased mGluR-mediated LTD
(Huber et al., 2002; Koekkoek et al., 2005). NMDA receptor-mediated LTD is unaffected
and mGluR dependent synaptic translation is increased in FMRP-deficient synapses
(Huber et al., 2002). Previously, LTP was shown to be unaffected in the hippocampus of
Fmr1-KO mice (Godfraind et al., 1996; Paradee et al., 1999; Li et al., 2002; Larson et al.,
2005), however recent findings suggest that hippocampal LTP elicited by threshold levels
of theta burst afferent stimulation is impaired in Fmr1-KO mice (Lauterborn et al., 2007).
LTP in the neocortex is reduced through GluR1 type of AMPA receptor activation (Li et
al., 2002). An anterior piriform cortex showns attenuated LTP in FMRP-deficient brain
(Larson et al., 2005). LTP seems to be abolished in the anterior cingulate cortex of Fmr1-
KO mice (Zhao et al., 2005). In fact, mGluR5-mediated synaptic plasticity is totally absent
in the neocortex of Fmr1-KO mice (Wilson and Cox, 2007). Furthermore, the defect in
neocortical LTP appears to be caused by compromised calcium signaling (Meredith et al.,
2007). In Fmr1-KO brain, LTP is also reduced in the amygdala (Zhao et al., 2005).
These data indicate that FMRP plays a role particularly in mGluR5 dependent
synaptic plasticity and inhibits protein synthesis at synaptic sites (Bear et al., 2004).
FMRP is located at the postsynaptic sites as well as translated in synaptoneurosomes after
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mGluR activation (Weiler et al., 1997; Zalfa et al., 2003). The rapid synthesis of FMRP
during initial synaptic activation that is required for mGluR-mediated LTD leads to the
ubiquitination and rapid proteosomal degradation of FMRP at the postsynaptic site (Hou
et al., 2006). This means that FMRP is normally rapidly degraded to release its binding
partner mRNAs which are to be translated upon activation. mGluR5 activation can no
longer increase translation in the absence of FMRP, since protein synthesis is already at
the maximal level (Nosyreva and Huber, 2006). In the absence of FMRP, target mRNAs
may be made readily available for translation in dendritic spines and this could result in
the maintanence of synapses in an activity-independent manner (Galvez et al., 2003) (Fig.
10).
Figure 10 FMRP contributes to the formation of synaptic connections during the brain
development. In the absence of FMRP, synapse stabilization is impaired which leads to
increased number of immature dendritic spines. Translation of certain mRNAs in the
postsynaptic transport granules can be repressed by FMRP. Knockout, Fmr1-KO. Adapted
and reprinted by permission from Macmillan Publishers Ltd: Nature Reviews
Neuroscience, Bagni and Greenough, copyright 2005.
The following observations may in part explain the enhanced LTD in the absence of
FMRP. AMPA receptor expression seems to be impaired in the Fmr1-KO brain, since
mGluR-dependent (not mGluR5) translation of AMPA receptors and PSD-95 are
dysregulated (Muddashetty et al., 2007). Furthermore, an excessive mGluR mediated
AMPA receptor internalization occurs in the absence functional FMRP (Nakamoto et al.,
2007). The reduced number of mGluR5s appears to be dependent on constitutive Homer
proteins in the postsynaptic density of Fmr1-KO mice neurons (Giuffrida et al., 2005). In
FMRP-deficient cells, the cAMP cascade is altered resulting in reduced production of this
second messenger molecule, which may affect mGluR-dependent or mGluR-independent
pathways  (Kelley  et  al.,  2007).  All  of  these  factors  may  in  part  contribute  to  altered
synaptic plasticity in the FMRP-deficient brain.
In  the  light  of  the  currently  available  data,  the  role  of  FMRP  in  mGluR-mediated
synaptic plasticity involves mRNA transport to synaptic sites, mRNA stabilization, and
dynamic regulation of local protein synthesis at synaptic sites (Fig. 11).
55
Figure 11 Function of FMRP in the postsynaptic protein synthesis and synaptic plasticity.
a Translation  of  FMRP through activation  of  mGluR receptors  can  lead  to  repression  of
translation of certain synaptic mRNAs. Phosphorylation of FMRP upon mGluR activity
may result in phosphorylation of FMRP and release of some mRNAs in a control synapse.
b In FXS spine, lack of FMRP may lead to abnormal translational regulation of
cytoskeleton regulator proteins, which in turn, has an impact on spine morphology. c The
absence of FMRP may lead to exaggerated internalization of ionotropic glutamate
receptors that affects synaptic plasticity. AMPA, alpha-amino-3-hydroxy-5-
methylsoxazole-4-propionic acid; INT, internalization mGluR, metabotropic glutamate
receptor; NMDA, N-methyl-D-aspartate. Adapted and reprinted by permission from
Macmillan Publishers Ltd: Nature Reviews Neuroscience, Bagni and Greenough,
copyright 2005.
7.7. FXS and BDNF signaling
BDNF regulates Fmr1 mRNA expression, since cultured hippocampal neurons display a
transient decrease in Fmr1 mRNA levels after BDNF administration. Furthermore,
transgenic mice overexpressing the full-length TrkB receptor have decreased hippocampal
expression of Fmr1 mRNA and FMRP (Castrén et al., 2002). In addition, TrkB expression
is increased in the neocortex of adult Fmr1-KO mice (Selby et al., 2007). Finally, BDNF
infusion can overcome the impaired hippocampal LTP in young adult Fmr1-KO mice
(Lauterborn et al., 2007). These observations suggest a connection between FMRP
expression and BDNF signaling, which may be occuring temporally and in a brain region-
dependent manner.
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7.8. Mouse models and other animal models to study FXS
An animal model for FXS was required to more thoroughly investigate the neuronal
defects seen in patients. Fortunately, the FMR1 gene is well conserved between species
and the murine Fmr1 nucleotide and amino acid sequences are 95% and 97% homologous
to human gene (Ashley et al., 1993). Murine Fmr1 is  expressed  with  the  same temporal
tissue specificity as the human version (Hinds et al., 1993; Hergersberg et al., 1995).
Consequently, a mouse model for FXS, Fmr1-KO, was generated by inserting a neomycin
cassette into exon 5 of mouse Fmr1 gene by homologous recombination which resulted in
the loss of FMRP in all tissues (The Dutch-Belgian fragile X consortium, 1994).
Although, this model is not an exact representation of the trinucleotide repeat expansion
mutation in FXS, it does cause a total loss of FMRP.
An initial characterization of the mouse model revealed macroorchidism,
hyperactivity, and a learning deficit all of which are also hallmarks of FXS (The Dutch-
Belgian fragile X consortium, 1994). Further characterization, has revealed several
symptoms consistent with the modeled disease including spatial learning defect, attention
and arousal deficits, mild hyperactivity, altered sensorimotor integration, stress response,
susceptibility to audiogenic seizures, and autistic like behavior (Kooy et al., 1996;
D'Hooge et al., 1997; Dobkin et al., 2000; Musumeci et al., 2000; Peier et al., 2000; Van
Dam et al., 2000; Chen and Toth, 2001; Mineur et al., 2002; Nielsen et al., 2002; Brennan
et al., 2006; Markham et al., 2006; Mineur et al., 2006; Moon et al., 2006) (Table 1).
Table 1 Phenotypes observed in Fmr1-KO mouse model of FXS
Phenotype in Fmr1-
KO mouse
Similar phenotype
observed in FXS
Reference(s)
Abnormal stress
response
+ Lauterborn, 2004; Markham et al., 2006
Alterations in
GABAergic system
not shown Gruss and Braun, 2004; El Idrissi et al., 2005;
D'Hulst et al., 2006; Gantois et al., 2006; Selby
et al., 2007
Altered anxiety-related
behavior
+ Spencer et al., 2005
Altered attention and
arousal
+ Moon et al., 2006
Altered sensimotor
integration
+ Chen and Toth, 2001; Nielsen et al., 2002; Yun
et al., 2006
Autistic like behavior + Spencer et al., 2005; Mineur et al., 2006; Moon
et al., 2006
Dendritic spine
dysmorphism
+ Comery et al., 1997; Braun and Segal, 2000;
Nimchinsky et al., 2001; Irwin et al., 2002;
Galvez et al., 2003; Galvez et al., 2005;
McKinney et al., 2005; Grossman et al. 2006b
Hyperactivity + The Dutch-Belgian fragile X consortium, 1994
Learning deficit + The Dutch-Belgian fragile X consortium, 1994;
Kooy et al., 1996; D'Hooge et al., 1997; Paradee
et al., 1999; Dobkin et al., 2000; Peier et al.,
2000; Van Dam et al., 2000; Mineur et al., 2002;
Brennan et al., 2006
Macroorchidism + The Dutch-Belgian fragile X consortium, 1994
Susceptibility to
audiogenic seizures
+ (seizures) Musumeci et al., 2000; Chen and Toth, 2001
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Learning deficits, are an important part of the FXS phenotype, and have been
assessed in Fmr1-KO using Morris water maze test and radial arm maze both of which
gave similar results of defects in reversal phase of the tests suggesting a deficit in spatial
learning (The Dutch-Belgian fragile X consortium, 1994; Kooy et al., 1996; D'Hooge et
al., 1997; Dobkin et al., 2000; Van Dam et al., 2000; Mineur et al., 2002). There have been
some  mouse  strain  dependent  difficulties  in  replicating  these  results  (Fisch  et  al.,  1999;
Paradee et al., 1999). In the acquisition of leverpress escape/ avoidance task, which is
another type of learning test, Fmr1-KO  mice  perform  poorly  compared  to  WT  mice
(Brennan et al., 2006). In contextual fear conditioning, there is evidence that the Fmr1-KO
mice perform poorly in this type of learning, although the deficit is probably very mild
(Paradee et al., 1999; Peier et al., 2000; Van Dam et al., 2000). The acoustic startle
response in Fmr1-KO mice is altered, which is a sign of a deficit in brain mechanisms of
sensorimotor integration (Chen and Toth, 2001; Nielsen et al., 2002). Interestingly, the
development of the startle response is impaired after postnatal week 3 or 4 in Fmr1-KO
mice (Yun et al., 2006). Some FXS individuals are affected by epileptic seizures and a
similar phenotype is also apparent in Fmr1-KO mice, which show susceptibility to
audiogenic seizures (Musumeci et al., 2000; Chen and Toth, 2001). Fmr1-KO mice
exhibit autistic like behavior with social withdrawal consistent with FXS, which is one of
the best-characterised causes for autism (Spencer et al., 2005; Belmonte and Bourgeron,
2006; Mineur et al., 2006; Moon et al., 2006). In addition, impaired inhibitory control,
attention, and arousal regulation are a part of the Fmr1-KO as well as the FXS phenotype
(Moon et al., 2006). Increased anxiety is one of the features of FXS and recently, the stress
response in Fmr1-KO mice was shown to be dysregulated by an impaired glucocorticoid
negative feedback (Hessl et al., 2004; Lauterborn, 2004; Markham et al., 2006).
Neuroanatomical gross-morphology of the Fmr1-KO  mouse  brain  is  normal
compared to the mild alterations observed in FXS brains (The Dutch-Belgian fragile X
consortium, 1994; Kooy et al., 1999). However, structural abnormalities in the
GABAergic inhibitory circuits of the adult Fmr1-KO mouse neocortex have been found
(Selby et al., 2007) alongside with other alterations apparent in an FMRP-deficient
GABAergic system (Gruss and Braun, 2004; El Idrissi et al., 2005; D'Hulst et al., 2006;
Gantois et al., 2006). The dendritic spine deficit, characteristic of the FXS phenotype, is
also present in the visual cortex, the barrel region of somatosensory cortex, olfactory bulb
mitral cells and in cultured hippocampal neurons of Fmr1-KO mice (Comery et al., 1997;
Braun and Segal, 2000; Nimchinsky et al., 2001; Irwin et al., 2002; Galvez et al., 2003;
Galvez et al., 2005; McKinney et al., 2005) (Fig. 6). The hippocampal CA1 region of the
Fmr1-KO brain displays obviously immature spine phenotype, although it is somewhat
morphologically different compared to the phenotype in the neocortex (Grossman et al.,
2006b). In Fmr1-KO mouse, dendritic spine dysmorphism displays a developmentally
dynamic pattern. The deficit in spine morphology is present in 1-week-old mice and then
disappears at the age of 4 weeks (Nimchinsky et al., 2001). Furthermore, the dendritic
spine deficit is again present in 2-month-old Fmr1-KO mice brain, suggesting dynamic
role for FMRP in regulating dendritic spine shape and synapse formation (Galvez and
Greenough, 2005). There is evidence that stabilization, which normally removes excess
dendritic spines during development, is impaired in the FMRP-deficient brain (Greenough
and Chang, 1988; Galvez et al., 2003; Galvez et al., 2005). This may suggest the
occurrence of abnormal increases in excitatory synapses in the FXS brain.
The mouse model for the Fmr1 autosomal homolog Fxr2, Fxr2-knockout, has been
generated, and shows no pathological defects in brain or testes (Bontekoe et al., 2002). Its
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behavioral phenotype includes a learning defect in the Morris water maze task and mild
hyperactivity in the open-field test, less contextual conditioned fear, impairment in the
rotarod test, less sensitivity to a heat stimulus, and reduced prepulse inhibition (Bontekoe
et al., 2002). These features are partially consistent with those of Fmr1-KO mice, and
suggest a similar but not identical function for the Fmr1 gene and the Fxr2 gene.
Similarities are restricted to impaired spatial learning and hyperactivity which are seen in
both of these models. The double knockout mouse Fmr1/Fxr2 exhibits an exaggerated
phenotype suggesting that these homologous genes cooperate in regulating locomotor
activity, sensorimotor gating and cognitive processing (Spencer et al., 2006). The other
autosomal homolog of FMR1, FXR1, has also been been knocked out in mice (Mientjes et
al., 2004). Fxr1-knockout mice display a surprisingly different phenotype compared to
Fmr1-KO mice, as they have abnormalities in muscle development, which leads to early
neonatal death by respiratory or cardiac failure. This implies that the Fxr1 gene may have
a similar function to the Fmr1 gene in the regulation of mRNA transport and/or translation
but in muscle instead of neurons. Recently, a conditional Fmr1-KO mouse model was
created by lox P sites flanking the promoter and the first exon of Fmr1 but  the
characterization of this model is still incomplete (Mientjes et al., 2006).
In Drosophila melanogaster, a structurally and functionally well-conserved ortholog
for the human FMR1 gene, the dFMR1 gene, exists (Wan et al., 2000). Several groups
have independently established null alleles of the dFMR1 gene, which have provided great
deal of additional insight into the molecular biology of FXS (Zhang et al., 2001;
Dockendorff et al., 2002; Inoue et al., 2002; Morales et al., 2002). As in humans, a
mutation in the dFMRI gene in Drosophila causes neuroarchitectural and behavioral
defects (Zarnescu et al., 2005; Zhang and Broadie, 2005).
To summarize, many animal models created to study FXS, have been and will
continue to be very useful in elucidating the molecular, physiological, cognitive, and
behavioral phenotypes caused by a deficit in FMRP.
7.10. Regulators of G-protein signaling (RGS)s and FXS
RGS proteins are a large family of similar proteins (>30 members), which regulate G-
protein coupled receptor-mediated signaling through direct binding to activated Ga
subunits (Hollinger and Hepler, 2002; Willars, 2006). This binding leads to inhibition of
downstream signaling by neurotransmitters and Ca2+ induced  stimulation  of  the  GTPase
activity of the Ga subunits. Some of the RGS proteins can also act as effector antagonists
and guanine nucleotide dissociation inhibitors (Willars, 2006). In addition to regulating
the G-protein signaling, structurally diverse RGS proteins can have other functions by
interacting with phospholipids, effectors, scaffolds, and receptors (Willars, 2006). RGS
proteins play a part in processes such as cell growth, differentiation, cell motility, and
intracellular trafficking (Hollinger and Hepler, 2002). The members of RGS protein
family that are enriched in the telencephalon include RGS2 and RGS4 (Gold et al., 1997;
Ingi et al., 1998; Ingi and Aoki, 2002; Grillet et al., 2003; Ebert et al., 2006). The main
difference between these two members of the same protein family is that RGS4 binds to
Gaq and Gai  subunits,  whereas  RGS2  almost  exclusively  and  potently  binds  to  Gaq
subunits (Hepler et al., 1997; Heximer et al., 1997; Ingi et al., 1998). However, RGS2
regulates presynaptic Ca2+ channel activity by inhibiting Gai subunit activity (Han et al.,
2006). In the brain, RGS2 has been implicated in the control of various stress responses,
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and in the proper development of dendritic spines and synapses in the hippocampal CA1
region  (Oliveira-Dos-Santos  et  al.,  2000).  In  some  cells,  RGS4  binds  to  the  Gaq/11
subunit to modulate the frequency of IP3-mediated Ca2+ oscillations (Xu et al., 1999; Luo
et  al.,  2001).  In  synaptic  transmission,  RGS4  plays  a  role  as  a  GTPase  activator  for
numerous G-protein coupled neurotransmitter receptors including ?- and ?-opiate,
adrenergic ?2A, muscarinic M1-3, mGluR1 and 5, and 5-HT1A/2A (Traynor and Neubig,
2005). Moreover, RGS4 is especially implicated as one of the susceptibility genes for
schizophrenia since there is evidence that it can be absent or downregulated in the brain of
schizophrenic patients (Mirnics et al., 2001; Levitt et al., 2006). FXS and schizophrenia
exhibit some commonalities (Sobesky et al., 1994). Interestingly, RGS4 seems to inhibit
G-protein coupled signaling through mGluR5, which is aberrant in FXS (Saugstad et al.,
1998; Bear et al., 2004). Furthermore, Homer proteins can stimulate RGS4 expression and
mGluR5 aberrances have been associated with Homer proteins in FXS (Shin et al., 2003;
Giuffrida et al., 2005). Therefore, since RGS4 and mGluR5 appear to be closely
associated, a connection between them may exist in FXS pathology.
7.11. Treatment for FXS patients
The therapy for FXS includes both behavioral and physical components of the symptoms
of individual patients including treatments with stimulants, 2-adrenergic agonists,
antidepressants, anticonvulsants, and antipsychotics (Berry-Kravis and Potanos, 2004).
There is no treatment to replace the absent FMRP expression, yet. Inhibitors of
methylation and histone deacetylases have activated the FMR1 gene to some extent
(Chiurazzi et al., 1999) but it seem that long full-mutation transcripts are poorly translated
(Feng et al., 1995). Furthermore, attempts to reactivate the FMR1 gene could affect other
genes in vivo with unpredictable consequences. Regardless of the setbacks in FMR1 gene
activation, our increased understanding about FMRP function in synaptic plasticity has
brought possibilities for new pharmacological interventions in FXS. Since FMRP is a
suppressor of mGluR5 activity mediated translation at postsynaptic sites, an exaggerated
mGluR dependent protein synthesis is prone to occur in the absence of FMRP (Bear et al.,
2004). Activity of mGluR5 can be prevented by administration of a specific antagonist 2-
methyl-6-(phenylethynyl) pyridine (MPEP). The efficiency of MPEP in rescuing
phenotypes in FMRP-deficient animal models has been already demonstrated. In Fmr1-
KO mice, MPEP treatment restored open-field activity to normal and reduced audiogenic
seizure susceptibility (Yan et al., 2005). MPEP improved the neurite branching defect in
zebrafish model of FXS (Tucker et al., 2006). In the Drosophila model of FXS, MPEP
ameliorated the memory defect in experience-dependent courtship behavior and abolished
the defect in neuronal mushroom bodies (McBride et al., 2005).
Recently, a new canditate for therapy in FXR has emerged since inhibition of PAK
activity in Fmr1-KO mice seems to ameliorate a large part of the functional,
neuroanatomical, and behavioral phenotypes in these mice (Hayashi et al., 2007). Fully or
partially rescued phenotypes include aberrant dendritic spines, reduced neocortical LTP,
altered locomotor activity, steroetypy, and altered trace fear conditioning. FMRP and PAK
interaction appears to be mediated through the KH2 domain.
It should be noted that simple stimulatory environment and normal social contacts
may be an important part of improving the individual FXS patients’ condition, since an
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enriched environment improves behavioral and even neuroanatomical phenotypes in
Fmr1-KO mice (Restivo et al., 2005).
The GABAergic system seems to be affected when FMRP is lacking. In the
neocortex of the Fmr1-KO mouse, GABAA receptor expression is decreased as well as
expression of some GABAergic neuron subtypes. Drugs acting on GABAA receptors are
readily available and they have been applied to ameliorate symptoms for example in
Down’s syndrome. Therefore, agonists for GABAA receptors may provide therapeutic
intervention in FXS (D’Hulst and Kooy, 2007).
These data indicate that some of the symptoms in FXS are a consequence of a defect
in mGluR5-mediated signaling. In addition to pharmacological blockade of mGluR5,
signaling pathways downstream of mGluR5 could also provide a target for drug
interventions in FXS. Inhibition of PAK may provide a novel means for drug intervention
in FXS.
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EXPERIMENTAL SECTION
8. AIMS OF THE STUDY
The overall aim was to investigate the intracellular mechanisms, which influence fate
determination of neural stem cells (NSC)s. This was studied by:
1. In vitro and in vivo survival, proliferation, and differentiation of NSCs in
fragile X syndrome
2. Embryonic and early postnatal formation of the FMRP-deficient neocortex
3.  The  effect  of  impaired  BDNF/TrkB  signaling  on in vitro survival,
proliferation, and differentiation of NSCs
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9. MATERIALS AND METHODS
9.1. Animals (I, II, III, IV)
FVB Fmr1-KO and their wild-type (WT) littermates were used in publications I, II, III
(The Dutch-Belgian fragile X consortium, 1994). C57BL/6J Fxr2-KO mice and their WT
littermates were used in publication I (Bontekoe et al., 2002). Heterozygous transgenic
mice overexpressing a truncated TrkB.T1 receptor under the Thy1 promoter and their WT
littermates were used in publication IV (Saarelainen et al., 2000b). Animals were
genotyped from tail samples with PCR amplification by specifically designed primers for
each transgenic animal strain.
Animals were provided with food and water ad libitum and kept on a 12/12 h
light/dark cycle at room temperature (~23°C) in an accredited animal facility in
accordance with National Institutes of Health guidelines. All animal experiments were
conducted according to the guidelines of The Society for Neuroscience and were approved
by the Experimental Animal Ethics Committee of the National Laboratory Animal Center,
Finland.
9.2. Mouse brain tissue (I, II, III, IV)
Before the sacrificing, the mice were anaesthetized with CO2. Adult mice were sacrificed
with  cervical  dislocation  and  the  pups  by  decapitation.  Brain  tissue  was  obtained  at  the
following embryonic and postnatal (P) ages in each publication: E13 (II), E15 (IV), E16
(III), E17 (II, III), P0 (III), P5 (III), P6 (II), P7 (IV), P10 (I), and adult (I, II). Fresh brain
tissue was used for generating NSC cultures (II, IV) but was fixed in 4%
paraformaldehyde (PFA) for frozen or paraffin sectioning (I, II, III).
9.3. Human brain tissue (II)
Fetal human brain tissue was obtained from terminated pregnancies and the age of the
fetus was determined by intrauterine ultrasound examinations.  Human NSC cultures were
generated from an 18-week-old fragile X fetus with a methylated repeat expansion of 276
to 300 trinucleotide repeats in the 5' UTR region of the FMR1 gene and from control
fetuses at 7, 12, and 18 weeks of gestation.
Human  fetal  tissue  was  obtained  in  accordance  with  the  guidelines  of  National
Institutes  of  Health,  the  government  of  Finland,  and  the  local  ethics  committee  of  the
Kuopio University Hospital. All investigations were conducted according to the principles
of the Declaration of Helsinki. Fully informed consents were obtained. A mutation in the
FMR1 gene was detected by polymerase chain reaction (PCR) and Southern analysis.
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9.4. BrdU injections to analyze cell proliferation (II, III)
Pregnant heterozygous Fmr1 female mice received a single series of four intraperitoneal
injections of BrdU (50-100 mg/kg; Sigma) at E13 or E14 on a single day during 12-h time
span to label S-phase cohort of newborn cells.
9.5. Tissue processing (I, II, III)
All brains were collected and fixed in 4% paraformaldehyde overnight at 4°C. Brains were
processed either for frozen sectioning or paraffin sectioning. For frozen sectioning, brains
were washed twice in PBS after fixation and then cryoprotected in 30% sucrose solution
over  night  at  4°C before  the  freezing.  Brains  were  cut  into  14  ?m (I)  or  20  ?m (II,  III)
coronal sections with a microtome or a vibratome and thaw-mounted onto object glasses.
For paraffin sectioning, brains were washed twice in PBS after fixation. Then brains were
dehydrated through the following alcohol series: 2 h in both 70% ethanol and in 96%
ethanol, and 100% ethanol over night at 4°C. This was followed by treatment with xylene
(twice for 2 h) before immersion in paraffin over night at 60°C. The next day, brains were
molded into paraffin and then cut with a rotatory microtome into 20 ?m (III) coronal
sections onto object glasses.
9.6. NSC culturing (II, IV)
NSCs were isolated and propagated from the walls of the lateral ventricles of embryonic
and postnatal brain with a previously described method (Clarke et al., 2000). NSCs were
derived  from animals  of  different  ages:  E13 (II),  E15 (IV),  P6  (II),  and  P7  (IV).  Tissue
was dissected from the brains, incubated in Hank's balanced salts solution containing 1.33
mg/ml trypsin, 2 mM glucose, 0.7 mg/ml hyaluronidase and 0.2 mg/ml kynurenic acid (30
min, 37 °C), and dissociated mechanically. Cells were centrifuged at 200 x g for 5 min,
resuspended in 0.9 M sucrose in 0.5× Hank's balanced salts solution, and centrifuged for
10 min at 750 x g. The cells were then resuspended in 2 ml Earl's balanced salts solution
and centrifuged  through a  gradient  of  the  same salt  solution  with  4% bovine  albumin  at
200 x g for 7 min. Dissociated cells were plated in the DMEM-F12 culture medium (Life
Technologies) containing 2 mM L-glutamine, 15 mM HEPES, 100 U/ml penicillin, 100
mg/ml streptomycin, B27 supplement, 20 ng/ml epidermal growth factor (EGF, Life
Technologies), and 10 ng/ml basic fibroblast growth factor (FGF2, PeproTech EC Ltd,
London, UK). Mitogens EGF (20 ng/ml) and FGF2 (10 ng/ml) were added every third
day,  and  50% of  the  medium was  refreshed  every  3  to  4  days.  The  resulting  clusters  of
NSCs/NPCs termed neurospheres were passaged every 7 to 9 days with papain treatment
(0.5 mg/ml, Sigma).
9.7. Transduction of NSCs/NPCs with lentivirus vectors (IV)
Viral transduction has been described as viable method to express transgenes in NSCs
(Englund et al., 2000; Falk et al., 2002; Consiglio et al., 2004). Mouse NSCs/NPCs from
dissociated neuropsheres were tranduced with a recombinant lentivirus (LV) expressing
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TrkB.T1 tagged with Flag and green fluorescent protein (GFP) driven by the CMV
promoter (lenti-CMV-Flag-TrkB.T1-ires-GFP; TiG4) and control viruses expressing
enhanced GFP (lenti-CMV-EGFP; G3) or Flag- and GFP-tagged full-length TrkB receptor
(lenti-CMV-Flag-TrkB.FL-ires-GFP; FiG4).  The multiplicity of infection was 10 to 40.
9.8. In  utero electroporation and transgene delivery into the fetal mouse
brain (III)
In utero electroporation was carried out as described earlier (Saito and Nakatsuji, 2001;
Tabata and Nakajima, 2001). Previously described expression plasmids, FMRP with
I304N mutation in the KH2 domain with EGFP (FMRPmt-EGFP) (1.3 ?g/?l), and
overexpressing FMRP with EGFP (FMRP-EGFP) (1.3 ?g/?l) were delivered into the
mouse brain (Castrén et al., 2001). The expression plasmid encoding EGFP (1 ?g/?l) was
used as a control. Brains were collected at E17.
9.9. In situ hybridization (I, II)
In situ hybridization was done as described previously (Wisden and Morris, 1994) with
complementary oligonucleotide probes for mouse Rgs4, Rgs2, and Fmr1 mRNA. The
probes were 3? end-labeled with [?-33P]dATP (2000 Ci/mmol, New England Nuclear,
Boston, MA). Sense and scramble oligonucleotide sequences were used as negative
controls. Hybridization was performed overnight (42°C) on postfixed sections with 1 x 103
to  3  x  103 cpm/ml of labeled probe in buffer containing 50% formamide, 4 x standard
saline citrate (SSC), 10% dextran sulfate, and 10 mM DTT. After overnight hybridization,
sections were briefly immersed in 1 x SSC at RT followed by a wash for 30 min at 50°C
in 1 x SSC. This was followed by washes in 1 x SSC, 0.1 x SSC, 70% ethanol, and 94%
ethanol  for  3  min  each  at  RT.  Hybridized  sections  were  exposed  to  Kodak Biomax MR
films (I) (Kodak, France) or Hyperfilm-ßmax films (II) (Amersham Biosciences/GE
Healthcare) for 3 to 6 weeks. In publication I, quantification of autoradiograms was
performed with MCID image analysis system (Imaging Research, St. Catharines, Ontario,
Canada), and optical densities were converted to specific radioactivity (nCi/g) with 14C
microscales (ARC, St.Louis, MO).
9.10. NSC proliferation in vitro (II, IV)
9.10.1. Clonal analysis of NSCs/NPCs (IV)
For clonal analysis, NSCs/NPCs were derived from E15 embryos overexpressing TrkB.T1
transgenic and their WT littermates. Neurospheres at the second or seventh passage were
cultured for 7 days and dissociated with papain into a single cell suspension. After
dilution, single progenitors were plated in 10-µl aliquots at a clonal density of 1-2 cells per
well into 96-well plates containing 100 µl of culture medium containing normal
concentrations of mitogens (EGF and FGF2). In addition to normal mitogens, some of the
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cell cultures contained BDNF (10 ng/ml; PeproTech). After 24 h, plates were scored and
the wells containing a single cell were marked. Fresh culture medium (40 µl) was added to
the plates following 11 days in culture. Plates were finally screened for the presence of
spheres at day 13 from the start of the culture.
For low-density analysis, 20 cells/100 µl/well were plated onto a 96-well plate. The
number of spheres was counted after 4 days and the size of the spheres was measured after
6, 8 and 10 days in vitro.
9.10.2. 3H-thymidine incorporation (II, IV)
Cell proliferation was studied by measuring the incorporation of 3H-thymidine during the
S-phase of the cell cycle. Cells were plated at a density of 100 000 cells/ml in DMEM-F12
culture medium supplemented with mitogens (EGF and FGF-2). After one day of
incubation with 3H-thymidine (0.5 µCi/ml, Amersham Biosciences/GE Healthcare), cells
were precipitated with 50 µl/ml trichloric acid for 20 min at 4°C, solubilized in 80 µl of 1
M NaOH for 20 min at room temperature (RT), and neutralized with 250 µl of 1 M HCl.
The radioactivity of the complete lysate was measured with scintillation fluid (OptiPhase
HiSafe 3) in a liquid scintillation counter (1450 MicroBeta, Wallac).
9.10.3. Cell viability: MTT assay (IV)
MTT is a tetrazolium salt [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide], which forms a formazan dye only in metabolically active cells. This allows a
quantitative analysis of viable cells in the presence of MTT. Cells were plated at a density
of 10 000 cells/100 µl onto 96-well tissue culture plates and cultured as floating
neurospheres. After specific times in culture, cells were incubated with MTT (1 mg/ml;
Sigma) for 2 h in a cell culture incubator (37°C, 5% CO2, humid). The reaction was
stopped by adding 100 µl of a solution composed of 20% sodium dodecyl sulphate in 50%
N,N-dimethyl formamide, pH 4.7. Cells were incubated overnight to completely solubilize
the formazan dye crystals. The absorbance value of the solution was measured in a
spectrophotometer at 570 nm. Assays were performed with eight replicates.
9.11. Differentiation of NSCs in vitro (II, IV)
In general, neurospheres and papain-treated single cells (100 000 cells/ml) were plated on
cover glasses coated with poly-D-lysine (10 µg/ml; Sigma) and laminin (5 µg/ml;
GIBCO/BRL) in culture medium without mitogens. In publication II, plated cells were
allowed to differentiate for 1, 5, 7, 14, 21 days in culture. For apoptosis studies in
publication IV, cells were differentiated at the same density on poly-D-lysine-coated cover
glasses  for  4  or  7  days.  When  assessing  the  number  of  cells  positive  for  proliferation
marker Ki67 (IV), dissociated cells were allowed to attach for 6 h on poly-D-lysine-coated
cover glasses before fixation.
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9.12. RNA extraction and real-time quantitative PCR (IV)
Total RNA was extracted with Trizol reagent (Life Technologies Ltd), treated with
DNAse I at 37°C for 45 min, and inactivated at 65°C for 10 min. RNAs were quantified
according to optical density. cDNA was synthesized from 1 mg  of  the  total  RNA  with
oligo(dT)12-18 primers  and  Multi  Scribe  reverse  transcriptase  enzyme  (Applied
Biosystems). Real-time quantitative PCR was performed with an ABI PRISM 7700
instrument  (Applied  Biosystems)  using  the  GeneAmp  Gold  RNA  PCR  reagent  kit
(Applied Biosystems) with 10 ng of total cDNA for each sample in 25 µl of PCR reaction
mixture. The product was amplified up to 33 PCR cycles, after uracil removal (2 min at
50°C) and polymerase activation (9.5 min at 96°C). One PCR cycle consisted of
denaturation for 30 s at 94°C and annealing/extension for 1.5 min at 62°C. The
amplification specificity of the PCR products was confirmed with agarose gel
electrophoresis. Quantitative results were provided and analyzed by Sequence Detection
Systems 1.9.1 (Applied Biosystems) analysis software. The baseline for each reaction was
equalized by determining the mean value of the 3 to 15 cycles of the lowest measured data
points for each sample and subtracting this from each reading point. Glyceraldehyde-3-
phosphate dehydrogenase and 36B4 acidic riboprotein were used as internal references
and to normalize the data. All assays were run in triplicate.
9.13. Ca2+ imaging (II)
Intracellular Ca2+ measurements were performed as described previously (Larsson et al.,
2005). After differentiation overnight, neurosphere-derived cells were incubated (20 min
at 37°C) with 4 ?M fura-2 acetoxymethyl-ester in a Na+-Ringer solution (pH 7.4)
consisting of 137 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1.2 mM MgCl2, 0.44 mM KH2PO4,
4.2  mM  NaHCO3, 10 mM glucose, 1 mM probenecid, and 20 mM HEPES. After
incubation, the cover glasses were attached to the bottom of a thermostat heated perfusion
chamber  (37°C).  Between  10  to  50  of  the  single  layer  of  cells  at  the  edge  of  the
neurospheres, were simultaneously monitored by 340 and 380 nm light excitation using a
filter changer under the control of an InCytIM-2 system (Intracellular Imaging, Cincinnati,
OH) and dichroic mirror (DM430, Nikon). The emission was measured through a 510-nm
barrier filter with an integrating charge-coupled device camera. Cells attached to cover
glasses were bathed at a rate of 2 ml/min with the Na+-Ringer solution containing the
different substances tested when specified. When the high K+ concentration solution was
used to stimulate the cells, the Na+-Ringer solution was mixed with a Ringer solution in
which the NaCl had been replaced with KCl to achieve the proper extracellular K+
concentration (70 mM).
9.14. Apoptosis assay (II, IV)
Apoptosis was detected using the terminal transferase-mediated dUTP nick end labelling
(TUNEL) method. The DeadEndTM Colorimetric  TUNEL  system in situ apoptosis
detection kit (Promega) was employed according to the manufacturer's instructions. Fixed
neurosphere sections, differentiated NSCs, and differentiated neurosphere cells were
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rinsed with PBS and permeabilized with ice-cold 100% methanol before the TUNEL
labeling.
9.15. Immunohistochemistry (II, III, IV)
In publication II and IV, cultured cells on the cover glasses were fixed with 4% PFA in
PBS, pH 7.4, for 10 min and permeabilized with ice-cold 100% methanol for 20 min.
After blocking with PBS containing 20% normal goat serum (II, IV) or rabbit serum (IV)
for 20 min, cells were incubated with primary antibodies from 1 h at 37°C to over night at
4°C, and secondary antibodies from 45 min to 1 h at RT (Table 2). For the
immunocytochemical staining of neurosphere cells in publication IV, neurospheres were
cultured for 8 to 10 days after dissociation, fixed with 4% PFA in PBS, pH 7.4 at RT for 1
h, and cryoprotected by an overnight incubation in 10% sucrose solution at 4°C. The next
day, neurospheres were suspended in Tissue-Tek mounting compound (Sakura Finetek,
Zoeterwoude, The Netherlands) and frozen quickly in dry ice. 14-µm microtome sections
of neurospheres were processed for immunocytochemistry. For Ki67 staining in
publication IV, cells were carefully fixed with 2% PFA for 5 min and 4% PFA for 15 min
at RT before permeabilization. When biotinylated anti-Flag was used (IV), endogenous
biotin background staining was eliminated with Endogenous Biotin-Blocking kit
(Molecular Probes) according to the manufacturer's instructions. Cover glasses were
rinsed and mounted with SlowFade antifading reagent (Molecular Probes) (II, IV).
In publications II and IV, the immunoperoxidase reaction was developed using
ammonium nickel sulphate (0.015%)-intensified 0.3% 3,3'-DAB as a chromogen, giving a
blue-to-black granular reaction end product (0.005% H2O2).
For BrdU detection in publication II, sections were treated with 1% H2O2 to remove
the endogenous peroxidase activity and immonohistochemical staining was performed
with biotin-streptavidin detection reagents and conjugated peroxidase (Boehringer
Mannheim) or fluorescent detection.
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Table 2 Antibodies in the immunohistochemical stainings. * = dilution made according to
manufacturer’s instructions.
Antibody Dilution Provider Ref
anti-actNotch1 (rabbit)  1:100 Abcam III
anti-BLBP (rabbit)  1:1000 Chemicon III
anti-BrdU-kit (mouse) * Amersham/GE Healthcare II, III
anti-ER81 (rabbit)  1:5000 Abcam III
anti-Flag biotinylated M2 (mouse)  1:1000 Sigma IV
anti-FMRP (clone 1C3-1a) (mouse)  1:10000 Euromedex II
anti-galactocerebroside (rabbit)  1:1000 Sigma IV
anti-GFAP (rabbit)  1:250 Sigma II, IV
anti-GFP (rabbit)  1:500 Nordic Biosite AB III
anti-GLAST (guinea pig)  1:400 Chemicon III
anti-goat IgG (FITC-conjugated)  1:100 Jackson ImmunoResearch IV
anti-guinea pig IgG (Cy2-conjugated)  1:200 Chemicon III
anti-Ki67 (goat)  1:200 Santa Cruz Biotechnology IV
anti-mouse IgM (CY2-conjugated)  1:250 Jackson ImmunoResearch IV
anti-mouse IgG (Alexa Fluor 488-neutravidin-
conjugated)
 1:1000-2000 Molecular Probes II, IV
anti-mouse IgG (Cy3-conjugated)  1:500 Jackson ImmunoResearch II, III, IV
anti-nestin (clone rat-401) (mouse)  1:200-400 DSHB, University of Iowa III,IV
anti-neuronal nuclei (NeuN) (mouse)  1:500 Chemicon IV
anti-oligodendrocyte marker O4 (mouse)  1:200 Chemicon IV
anti-rabbit IgG (Alexa Fluor 488-conjugated)  1:1000 Molecular Probes III
anti-rabbit biotinylated IgG  1:150 Vector Laboratories III
anti-rabbit IgG (7-amino-4-methylcoumarin-3-
acetic acid (AMCA)-conjugated)
 1:250 Jackson ImmunoResearch II, IV
anti-Tbr2 (rabbit)  1:2000 Chemicon III
anti-?III-tubulin (clone TuJ1) (mouse)  1:500 BabCO II, IV
In publication III, frozen sections were incubated in 1:1 ethanol/chloroform solution to
remove fat from the brain tissue and re-hydrated through a descending alcohol series
before the Nissl staining. For Nissl staining, sections were incubated in cresyl violet
solution (Sigma) for 30 to 60 s and washed briefly twice with distilled H2O. Sections were
immersed in 70% ethanol for 5 min and in 96% ethanol for 10 min, and dehydration was
done by immersing the sections in 100% ethanol and xylene both twice for 5 min.
Sections were mounted with DePex medium (BDH Laboratory Supplies, England).
Paraffin sections were deparaffinized sequentially three times in xylene for 10 min, and
thereafter, re-hydrated in 100% ethanol, 96% ethanol, 70% ethanol and distilled H2O for 5
min each. For antigen retrieval, sections were boiled in 10 mM citrate buffer (pH 6.0) for
15 min. Permeabilization and background blocking was done by treating sections with a
solution  of  0.5%  Triton-X  100  and  20%  normal  goat  serum  in  PBS  for  1  h  at  RT.
Thereafter, sections were incubated with primary antibodies over night at 4°C  and  with
secondary antibodies for 1 h at RT (Table 2). Sections were mounted with Gel Mount
media (Sigma). The colorimetric staining of sections was performed with the Vectastain
ABC kit (Vector Laboratories) and the DAB-substrate kit for peroxidase including nickel
(Vector Laboratories) according to manufacturer’s instructions.
Nuclei were counterstained with 4',6-diaminodino-2-phenylindole (DAPI) (II, III,
IV) (0.1 µg/ml, Boehringer Mannheim Biochemica) or hematoxylin (II, III).
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9.16. Brightfield, epifluorescence and laser scanning confocal imaging (II, III,
IV)
Live cell imaging was performed by using a CC-12 digital camera (Soft Imaging System,
Lakewood, USA) under an Olympus IX70 (Olympus, Tokyo, Japan) inverted microscope.
Immunocytochemically stained cells were imaged with an epifluorescence Axioplan 2
microscope system (Zeiss, Jena, Germany) connected to a high-resolution AxioCam
camera (Zeiss) and AxioVision 4.1 (Zeiss) software. Alternatively, high-resolution digital
camera with epifluorescence microscope Olympus Provis (Olympus) or Zeiss N HBO100
(Zeiss) were used. Laser scanning confocal microscopy was performed with the LSM 5
Pascal system (Zeiss) or Leica TCS SP2 AOBS (Leica). To obtain high resolution images
from brain sections and to perform stereological analyses, a digital MicroFire S99808
camera (Optronics, CA, USA) attached to Olympus BX51 epifluorescence microscope
(Olympus) were applied.
9.17. Analysis of the imaging data (II, III, IV)
To count cell numbers, determine the diameters of cells and neurospheres, and to measure
neurite lengths, images were analyzed using AIDA (version 3.44, Raytest
Isotopenmessgeräte GmbH, Straubenhardt, Germany) or Image-Pro Plus (Media
Cybernetics, Inc., Silver Spring, MD, USA) or Neurolucida Software (NeuroBright Field,
VT, USA). In in vitro experiments, measurements were performed from images of
uniformly plated cells on cover glasses or from plated neurospheres with uniform size
and/or propagation period (II, IV). Differentiated viable and apoptotic neurons in
publications IV, were counted directly under a microscope from cover glasses after the
cells were fixed and immunostained. Brightness and contrast were optimized before
counting.
For semiquantitative analyses of brain sections in publication III, cells were counted
in the dorsolateral neocortex as described previously with minor modifications (Fukumitsu
et al., 2006). The coronal somatosensory neocortical level at E16 was approximately 860
mm posterior to the rostral border of the olfactory bulbs. At E17, the analyzed cortical
level was approximately 1.3 mm posterior to the rostral border of the olfactory bulbs.
Cells in the neocortical sections were counted from images of cortical columns with
defined dimensions or from confocal images with defined size.
9.18. Stereological analyses (II, III)
Stereological  analyses  of  brain  sections  were  performed  with  the  Stereo  Investigator
software (MicroBrightField, Inc., Vermont, USA) attached to Olympus BX51 (Olympus)
epifluorescence microscope with MicroFire S99808 digital camera (Optronics). In
publication II, randomly selected serial sections through the anterior part of the lateral
ventricles of WT and Fmr1-KO embryonic brains at E17 were analyzed stereologically to
assess  BrdU-labeled  newborn  cells.  The  final  counting  was  performed  with  100x  oil
objective. In publication III, the stereological assessment of ER81-positive cells at P5 was
done on cortical coronal serial sections spanning Bregma 1.18 mm to -0.94 mm
approximately. Optical dissector counting frame dimensions were 60 mm x 60 mm x 20
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mm (20 mm is z-axis) and the sampling grid dimensions were 130 mm x 120 mm both of
which were optimized for cell counting which was performed with a 60x oil objective
(Olympus).
9.19. Statistical analysis (I, II, III, IV)
Data was analysed using Student's  t-test  (I,  II,  III,  IV),  ANOVA (II,  IV),  and the Mann-
Whitney test (II, IV). P values £ 0.05 were considered to be statistically significant.
10. RESULTS
10.1. Expression of Rgs mRNAs in the Fmr1-KO mouse brain (I)
We examined the expression of genes encoding Rgs proteins, which are tightly regulated
modulators of G-protein signaling (Hollinger and Hepler, 2002), and thus can have an
effect in mGluR mediated signaling as well as intracellular Ca2+ release. The expression of
neuronal transcripts of the Rgs family, Rgs2 and Rgs4, were investigated in the brain of
Fmr1-KO and Fxr2-KO  mice  by in situ hybridization. We initially chose to study the
expression of these Rgs mRNAs at P10 when the dendritic spine abnormalities are present
in the Fmr1-KO brain. At this time point, we found abundant expression of Rgs4 mRNA
in  the  distinct  neocortical  and  hippocampal  regions  of  the  WT  mouse  brain,  which  was
consistent with previous observations (I, Fig. 1A) (Ingi and Aoki, 2002). We found that
the Rgs4 mRNA levels were significantly decreased in the CA1 region of the
hippocampus and the retrosplenial cortex of the Fmr1-KO brain compared to the control
(I, Fig. 1A). This may suggest a developmental delay, since the temporally uniform
expression pattern of Rgs4 in the postnatal piriform cortex was unchanged in Fmr1-KO
mice brain (I, Fig. 1B). In the adult mouse retrosplenial cortex and hippocampus, Rgs4
mRNA levels showed no significant differences between Fmr1-KO and WT mice,
although, a trend toward decreased Rgs4 levels in the adult Fmr1-KO  brain  could  be
observed. Another Rgs family transcript, Rgs2 mRNA was expressed predominantly in the
hippocampal pyramidal neuron layer, in the granule neuron layer of the dentate gyrus, and
in the superficial layers of the neocortex. The expression pattern of Rgs2 was normal in
the  brain  of  P10 Fmr1-KO mice suggesting Rgs4-specific alterations in the absence of
FMRP (I, Fig. 2) (Ingi and Aoki, 2002).
To examine whether Rgs4 mRNA expression was specifically reduced in the FMRP-
deficient brain, we studied the expression of Rgs4 in brain sections of the Fxr2-KO mice,
which lack FMRP homolog FXR2P and have a partially congruent behavioral phenotype
with Fmr1-KO mice (Bontekoe et al., 2002). FMRP and FXR2P may be able to fill each
others place, since they have highly overlapping expression patterns in the brain and
interact in the same protein complexes (Zhang et al., 1995; Bakker et al., 2000). Rgs4
levels in the brain of Fxr2-KO mice were normal (I, Fig 3) further supporting a specific
defect in Rgs4 expression in the absence of FMRP.
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10.2. Differentiation of mouse and human NSCs in the absence of FMRP (II)
FMRP expression is highest during early murine development (Abitbol et al., 1993). We
found substantially high FMRP expression in the embryonic as well as adult mouse brain
at the periventricular region, which contains self-renewing NSCs throughout the mouse
life span (II, Fig. 1A).
We compared the differentiation of NSCs derived from Fmr1-KO  mice  to  WT
NSCs. After 5 days of differentiation on coated cover glasses, the neurospheres derived
from Fmr1-KO brains at E13 and P6 produced 3-fold and 4.5-fold more TuJ1-positive
neurons than the WT neurospheres did (II, Fig. 1B). Furthermore, TuJ1-positive Fmr1-KO
cells exhibited a reduced number of primary neurites compared with WT cells after 1 day
of  differentiation  (II,  Fig.  1C  and  D).  The  maximum  length  of  the  neurites  was
significantly shorter and the cell-body volumes were smaller in Fmr1-KO  cells  than  in
WT  cells  after  differentiation  for  1  or  5  days  (II,  Fig.  1D).  When  observing  the  glial
differentiation  of  NSCs,  we  found  that  the  number  of  GFAP-expressing  cells  was
significantly reduced among the differentiated cells derived from E13 or P6 Fmr1-KO
mice compared with the respective controls (II, Fig. 1E). The number of apoptotic
TUNEL-positive cells was increased in differentiating TuJ1-negative Fmr1-KO cells
reflecting the reduced amount of differentiated GFAP-positive astrocytes among these
cells (Fig. 1F). Proliferation was unaltered in the neurosphere cultures derived from WT
and Fmr1-KO  brains  (II,  Fig.  1G  and  H).  The  data  suggest  that  the  absence  of  FMRP
directed the differentiation of mouse NSCs toward neuronal lineage.
We also isolated and propagated human NSCs from postmortem tissue of a FXS
fetus and control fetal brains (II, Fig 4A). The FXS derived NSCs showed no
immunoreactivity for FMRP in contrast to control human NSCs (II, Fig. 4B). The
differentiation of these NSCs could be induced by removal of mitogens (II, Fig 4A), and
upon differentiation FMRP labeling was predominantly present in GFAP-negative
neuronal cells (II, Fig. 4C) (Devys et al., 1993). We compared the differentiation of NSCs
generated from the 18-week-old fetal FXS brain with age-matched control cells. During
the first day of differentiation, FXS neurosphere cells generated shorter radial processes
and more TuJ1-positive cells than controls (II, Fig. 4D). After 14 days of differentiation,
5.3-fold more TuJ1-positive cells and 70% less GFAP-positive cells were generated from
FXS neurosphere cells than from the age-matched control neurosphere cells (II, Fig. 5A
and B). The increased number of TuJ1-positive and reduced number of GFAP-positive
cells differentiated from FXS NSCs were also observed when compared to control NSCs
derived from human fetal brains at different developmental stages. Consistent with the
morphological alterations of newborn TuJ1-positive cells derived from Fmr1-KO mouse
neurospheres, the average neurite length and cell-body volume of the TuJ1-positive cells
derived from FXS neurospheres were significantly reduced compared with the age-
matched fetal control (II, Fig. 5C).
10.3. Ca2+ responses of differentiating NSCs derived from FMRP-deficient
brain (II)
An intracellular Ca2+ ([Ca2+]i) response to acetylcholine (ACh) during the first day of NSC
differentiation has been shown previously (Ma et al., 2000). Almost all of the mouse cells
we measured  responded to  ACh (II,  Fig.  2A).  Cells  were  treated  with  glutamate  with  or
without extracellular Ca2+ to assess the presence of mGluRs and ionotropic glutamate
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receptors. Elevated K+ concentration (70 mM) was used to demonstrate the presence of
voltage-gated Ca2+ channels in these cells. Three different populations in both Fmr1-KO
and WT cells could be distinguished based on their response to neurotransmitters.
Approximately 30% of the cells responded to glutamate in the absence of Ca2+ with  a
metabotropic type of response but showed a minor response to K+ (type I cells) (II, Fig.
2A). Another cell population, which did not display metabotropic [Ca2+]i response to
glutamate, responded to increased K+ concentration with a robust rise in [Ca2+]i (type II
cells) (II, Fig. 2B). The remaining cell population had minor or no metabotropic responses
to glutamate and K+ (type  III  cells).  Interestingly,  type  I  cells  usually  displayed
oscillations with a frequency of 4 to 6 spikes/min in response to ACh and glutamate. The
oscillatory response for 100 µM ACh was significantly accentuated in the Fmr1-KO
mouse cells compared with WT cells (II, Fig. 2C). These cells also exhibited metabotropic
response to glutamate (II, Fig. 2D). To investigate which mGluR subtype was responsible
for the [Ca2+]i elevation in type I cells, antagonists for the mGluR1 and mGluR5 subtypes
were administered with different concentrations of glutamate. The challenge of cells with
low concentrations of glutamate in the presence of 10 µM of the mGluR5 antagonist
MPEP abolished the [Ca2+]i response, but this was not seen with an antagonist for mGluR1
or with high glutamate concentration (30 µM) (II, Fig. 2E and F).
An ACh-induced [Ca2+]i response was also seen in the majority of the neurosphere-
derived human cells during the first day of differentiation. The typical response comprises
a peak and a stable phase similar to that seen in mouse cells. While the ratio between the
initial peak and the stable phase was found to be intact in cells derived from FXS
neurospheres, a significant fraction of these cells responded to ACh with [Ca2+]i
oscillations during the stable phase and the response was almost absent in control cells (II,
Fig. 5D and E).
10.4. The production of new cells in the Fmr1-KO brain (II)
To investigate NSCs in vivo, BrdU was injected into the embryonic brain of Fmr1-KO and
WT mice and the production of new, BrdU-positive cells was measured using
immunohistochemistry. The total number of BrdU-positive cells 4 days after BrdU
administeration was not significantly altered in the developing neocortex of Fmr1-KO
mice when compared with WT mice (II, Fig. 3A). However, a relatively high number of
BrdU-positive  cells  was  observed  in  the  SVZ  of  the Fmr1-KO telencephalon compared
with the corresponding region in WT brains (II, Fig. 3B and C).
10.5. Formation of the neocortex in the presence of the dominant negative
form of FMRP (III)
We studied the effects of FMRP with the I304N mutation by in utero electroporation of
the expression plasmid FMRPmt-EGFP (Castrén et al., 2001) into embryonic mouse brain
at E14. Three days later, the number of FMRPmt-EGFP-positive cells was significantly
higher in the VZ/SVZ and in the IZ than the number of EGFP-positive cells after
transfection of a control plasmid encoding EGFP (III, Fig. 1A) or after transfection of
wild-type FMRP-EGFP plasmid. These FMRPmt-EGFP-positive cells in the VZ/SVZ and
in the IZ also exhibited more immunoreactivity for nestin than EGFP-control cells (Fig.
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1B and C). The expression of FMRPmt-EGFP greatly increased the proportion of
nestin/EGFP-positive cells amongst the transfected cells in the VZ/SVZ when compared
to controls (III, Fig. 1D). The mutated FMRP caused only minor alterations in the
proportion  of  nestin/EGFP-positive  cells  in  the  IZ,  in  the  cortical  plate  (CP),  or  in  the
marginal zone (MZ) (III, Fig. 1D). These findings agree with our previous studies which
showed altered neurogenesis in vitro and an increase of newborn cells in the SVZ of the
Fmr1-KO mouse (E17) in vivo (II).
10.6. Differentiation of glutamatergic neurons in the neocortex of Fmr1-KO
mice (III)
We decided to study neocortical glutamatergic neurogenesis in Fmr1-KO mice, based on
previous observations of alterations in glutamatergic differentiation of FMRP-deficient
NPCs in vitro and enlarged newborn cell population in the embryonic SVZ of knockout
mice (II). Glutamatergic neuron diversity is generated from radial glial NPCs and from
intermediate  progenitor  cells  (IPCs)  in  a  manner  that  is  strictly  spatially  and  temporally
controlled. IPCs (basal progenitors), which are actually the progeny of surface dividing
NPCs  of  the  VZ,  proliferate  at  non-surface  positions  within  the  VZ  and  SVZ,  and  they
express Tbr2 when they are already committed to glutamatergic fate (Englund et al.,
2005). When assessing Tbr2-positive cell populations in the Fmr1-KO neocortex and
comparing  them with  WT,  we found an  increase  in  the  density  of  Tbr2-positive  cells  at
E17  (III,  Fig.  2A  and  B)  but  not  at  E16.  However,  in  the Fmr1-KO neocortex at E16,
Tbr2-positive cells in the BrdU-positive cell cohort born at E13 were significantly
increased (III, Fig. 2C-E). These findings suggested that the proliferation, fate
specification, or differentiation of NPCs/IPCs into the glutamatergic lineage is abnormal
in the embryonic neocortex of Fmr1-KO mice (Englund et al., 2005; Hevner et al., 2006).
10.7. Formation of the layered structure of the developing Fmr1-KO mouse
neocortex (III)
Newborn neurons acquire their specific laminar positions in the developing neocortex
according to their birth date. We wanted to find out if the putatively aberrant Tbr2-positive
cell population born around E13-E14 caused any alterations in cortical neuron lamination
or positioning. Analysis of neocortex formation from Nissl-stained Fmr1-KO brain
sections at E16 showed that the cell density in the CP of Fmr1-KO mice was significantly
increased when compared to controls (III, Fig. 3A and B), but the thickness and the cell
number were almost intact (III, Supplemental Fig. 2A and B) thus suggesting that the
alterations seen in the SVZ could affect cell lamination. When analyzing the structure and
lamination of the anterior somatosensory neocortex at P5, an increase in the overall
density of cells in the Fmr1-KO neocortex was observed compared to WT (III, Fig. 3C-E).
The cell density in layer V was significantly higher in the Fmr1-KO neocortex than in WT
controls,  and  the  same  trend  was  also  seen  in  layer  II/III  (III,  Fig.  3F).  The  relative
thickness of the layer V was not affected; however, we could observe a slight but
significant decrease in the relative thickness of layer VI (III, Fig. 3G). To further
investigate the alteration seen in layer V formation in the neocortex of Fmr1-KO mice, we
assessed the expression of the transcription factor ER81, which is a specific marker for
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layer V neurons (de Launoit et al., 1997; Yoneshima et al., 2006). Quantitative analysis
revealed an increase in the number of ER81-positive cells in the Fmr1-KO neocortex at P5
compared to WT controls (III, Fig. 3H, I, and Supplemental Fig. 3A and B). This
suggested alterations in the development of ER81-expressing cortico-cortical and
subcerebral projection neurons in the Fmr1-KO neocortex (Hevner et al., 2003).
10.8. Radial glia in the developing neocortex of the Fmr1-KO mouse (III)
Tbr2-positive cells were increased in the SVZ of the Fmr1-KO mouse brain and this may
also  involve  alterations  in  the  differentiation  of  radial  glia.  When  we  assessed  the
expression of known radial glial markers, we observed that the expression of BLBP was
not changed at E16 in the Fmr1-KO mouse neocortex when compared to controls (III, Fig.
4A), whereas the expression of GLAST was slightly but not significantly increased (III,
Fig. 4B). In the neonatal neocortex of Fmr1-KO mice, actNotch1 showed a trend towards
higher expression than in the WT brain (III, Fig. 4C). These findings suggest that the
radial glia is not significantly altered during the early development of Fmr1-KO
neocortex.
10.9. Expression of TrkB.T1 receptor in NSCs/NPCs derived from transgenic
TrkB overexpressing mice (IV)
Neurospheres consist of NSCs/NPCs with a limited capacity to proliferate in the presence
of mitogens in vitro. In the absence of mitogens, we could induce cells in neurospheres to
differentiate  into  neurons,  astrocytes  and  oligodendrocytes  (IV,  Fig.  1A  and  B).  NPCs
express both full-length TrkB (TrkB.TK) and TrkB.T1 (Ahmed et al., 1995; Barnabe-
Heider and Miller, 2003) and we found that TrkB.T1 and TrkB.TK had similar mRNA
expression levels in proliferating neurosphere NPCs derived from P7 mice.
Transgenic mice that overexpress Flag-tagged TrkB.T1 under the neuron-specific
Thy1 promoter have been previously characterized (Saarelainen et al., 2000b).
Neurospheres derived from the transgenic mice co-expressed the transgene with nestin
(IV, Fig. 1C). These neurospheres did not express markers for differentiated neuronal cells
(IV, Fig. 1D). The Thy1 antigen, which has been previously shown to be expressed in
several tissue-derived stem cells (Fiegel et al., 2003), was shown here to be expressed in
NPCs. Furthermore, the TrkB.T1 transgene was co-expressed with the proliferation
marker Ki67 in neurospheres (IV, Fig. 1D). Upon differentiation, the TrkB.T1 transgene
was expressed in the majority of neurosphere-derived cells (IV, Fig. 1E). Consistent with
the previously observed neuron-specific expression of TrkB.T1 transgene in vivo, the
expression of the transgene was neuron-specific in differentiated cells (IV, Fig. 1F-H)
(Saarelainen et al., 2000b). When studied by quantitative real-time PCR, TrkB.T1
expression (transgene and endogenous combined) was significantly higher in neurosphere
cells derived from P7 mice overexpressing TrkB.T1 than in WT cells and the ratio of
TrkB.TK expression to TrkB.T1 expression was significantly decreased in the transgenic
cells (IV, Fig. 2A-C).
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10.10. Formation of neurospheres by NSCs/NPCs derived from mice
overexpressing TrkB.T1 (IV)
We compared the properties of neurosphere-forming cells derived from WT mice with
those of cells derived from mice overexpressing TrkB.T1. Dissociated neurosphere cells
were propagated in the presence of mitogens at clonal density and the absolute numbers of
neurospheres were counted after 13 days in vitro.  Both  types  of  NPCs  formed
neurospheres in single cell as well as in low-density cultures, whereas sphere formation
was significantly reduced in the presence of the TrkB.T1 transgene (IV, Fig. 3A). The
reduced number of Ki67-positive cells was observed in the presence of the TrkB.T1
transgene after plating the dissociated neurosphere cells onto a coated matrix in the
absence of mitogens (IV, Fig. 3B). To investigate whether TrkB.T1 overexpression had an
effect on the survival of neurosphere NPCs, we counted the number of apoptotic cells in
transgenic and WT neurospheres. The number of TUNEL-positive cells in transgenic
neurospheres after 8 days of passaging was significantly increased (IV, Fig. 3C). These
data suggest that the transgenic TrkB.T1 neurospheres contained less NPCs, and upon
differentiation had increased number of cells that were not in the active cell cycle. In
addition, overexpression of TrkB.T1 reduced the survival of NPCs. However, exogenous
BDNF was able to abolish the differences in the number of neurosphere-forming cells and
Ki67-positive cells between WT and transgenic TrkB.T1 cells (IV, Fig. 3D and E),
indicating that overexpressed TrkB.T1 inhibited the interaction of endogenous BDNF with
the TrkB.TK receptor.
10.11. Proliferation of NSCs/NPCs overexpressing TrkB.T1 (IV)
The transgenic TrkB.T1 cells from dissociated neurospheres generated larger neurospheres
than WT cells when observed after 6, 8, and 10 days of proliferation in culture thus
suggesting that the transgenic spheres propagated more readily (IV, Fig. 4A).
Furthermore, the increase in the average diameter of transgenic TrkB.T1 neurospheres
derived from P7 mice was significant within 3 days of the onset of neurosphere formation
(IV, Fig. 4B and C). The increased proliferation and growth of neurospheres
overexpressing TrkB.T1 compared with WT neurospheres were shown by 3H-thymidine
incorporation and MTT assays (IV, Fig. 4D and E). The effects of culture media mitogens
were synergistic in transgenic cultures. FGF-2 had no effect on growth alone, whereas
EGF alone induced cell growth to 40% of the increase seen in the presence of both growth
factors.
We  wanted  to  see  whether  the  properties  of  the  NSCs/NPCs  derived  from  the
transgenic mice overexpressing TrkB.T1 were attributable to the increase in TrkB.T1
expression. Therefore, we generated NSCs/NPCs with viral-mediated (LV-mediated)
overexpression of TrkB.T1 (Englund et al., 2000; Falk et al., 2002). For the LV construct,
TiG4, encoding mouse TrkB.T1, GFP, and Flag-tag we achieved transduction efficiency
(10%) similar to that in previous studies (Falk et al., 2002) (IV, Fig. 6A). The TrkB.T1
transgene was expressed in undifferentiated NSCs/NPCs (IV, Fig. 6B). Upon
differentiation, the LV-transduced cells gave rise predominantly to TuJ1-negative and
GFAP-positive glial cells and a few TuJ1-positive cells (IV, Fig. 6C and D). Despite the
low transduction efficiency, 3H-thymidine incorporation (IV, Fig. 6E), average diameter of
neurospheres (IV, Fig. 6F), and cell growth in the MTT assays were all significantly
increased after virus-mediated overexpression of TrkB.T1 compared with controls (IV,
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Fig. 6G). The data consistently show that overexpression of TrkB.T1 increases
proliferation of NSCs/NPCs in both a transgenic mouse model and after viral-mediated
transgene delivery.
10.12. Increased neurogenesis of differentiating NSCs/NPCs derived from
mice overexpressing TrkB.T1 (IV)
We  studied  differentiation  of  transgenic  TrkB.T1  NSCs/NPCs in vitro. After
differentiation, TrkB.T1 expression continued to be significantly higher in TrkB.T1
overexpressing cells than in WT ones.Both the number of TuJ1-positive neurons derived
from NPCs overexpressing TrkB.T1 and the apoptosis of these TuJ1-positive cells were
increased compared with WT after 4 days and 7 days of in vitro differentiation (IV, Fig.
5A and B). This suggested increased turnover of newborn neurons, which overexpress
TrkB.T1.
11. DISCUSSION
Since isolation of human ES cells in 1998, stem cells have been a hot topic in research
with  their  wide  array  of  possible  therapeutic  applications  (Thomson  et  al.,  1998).  The
CNS in particular, is an attractive target for stem cell therapy and CNS tissue specific
NSCs have been under vigorous investigation (Muller et al., 2006). Neuropathological
conditions such as Alzheimer’s disease, Parkinson’s disease, and spinal cord injury are
putative targets for NSC therapy. However, studying genetically mutated NSCs derived
from diseased brain can provide valuable information about the properties of NSCs in
general and also allow the design of possible drug interventions. The present studies show
alterations in the proliferation, survival and differentiation of NSCs/NPCs in two different
but  related  models  of  impaired  learning.  In  models  of  FXS (II,  III),  which  is  a  common
form of inherited mental retardation, the differentiation of NSCs and early brain
development were altered when FMRP was absent or functionally inactive. These
alterations were associated with group I mGluR5 action and glutamatergic neuronal
lineage. Furthermore, mRNA levels of RGS4 (I), which can modify G-protein-mediated
signaling through mGluR5, were down regulated in the Fmr1-KO mouse brain. The
findings show novel pathological features in NSCs and early brain development of the
FXS.  In  the  model  with  overexpression  of  the  TrkB.T1 receptor  (IV),  which  affects  the
BDNF signaling, NSC proliferation, survival and differentiation were altered. This
illustrates the importance of BDNF/TrkB signaling in directing NSCs to proliferate, to die
by apoptosis, or to differentiate into neuronal cells. Interestingly, FXS and BDNF/TrkB
signaling have been linked to each other (Castrén et al., 2002; Selby et al., 2007). In
summary, FMRP and BDNF/TrkB signaling are important to the normal development of
neurons and neuronal networks in the brain and already have an impact at the level of
NSCs and NPCs.
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11.1. The properties of NSCs in FXS
FXS is a developmental disorder, however very little is known about the actual
mechanism of the disease during early development. The absence of functional FMRP is
the cause of the disease (Pieretti et al., 1991) and the function of this protein in
differentiated neurons is beginning to be elucidated (Galvez et al., 2003; Bagni and
Greenough, 2005; Galvez et al., 2005). Several studies have reported neuroanatomical
alterations in the human FXS brain, which include some developmentally transient
features such as increased hippocampal volume in young adults (Kates et al., 2002; Lee et
al., 2007). In addition, the structure of the visual pathway seems to be altered in the adult
FXS brain (Kogan et al., 2004b). These alterations correlate with the cognitive
performance of the FXS patients (Kogan et al., 2004a; Gothelf et al., 2007). The mouse
model, however, lacks some of the neuroanatomical features seen in FXS patients’ brains
(Kooy et al., 1999), although the GABAergic system seems to be altered in the neocortex
of adult Fmr1-KO mice (D'Hulst et al., 2006; Selby et al., 2007). Specifically, the number
of GABAA receptors is reduced together with the overall number of GABAergic
interneurons. More careful analysis shows that the number of parvalbumin expressing
GABAergic neurons is decreased, their morphology is changed, and the remaining cells
are mostly located at the deeper neocortical layers (Selby et al., 2007). This finding
suggests that the neuroanatomy of the adult Fmr1-KO neocortex is altered where the
GABAergic system is concerned. These data show that in the absence of functional
FMRP, neuroanatomy is altered and it affects the cognitive phenotype. On the other hand,
whether the dysfunction of FMRP causes the neuroanatomical alterations or whether it is
only a secondary effect is still unclear. Our studies provide new data about the
developmental aspects of FXS brain anatomy. We show that the glutamatergic system is
also altered in the Fmr1-KO mouse brain. This suggests that the altered neuroanatomy is
caused by the absence of FMRP.
Here, we report altered morphology of human and mouse FMRP-deficient NSC-
derived differentiated neurons in vitro. These young neurons displayed a decreased
number of neurites, which were shorter than normal. In addition, these neurons had a
smaller soma size compared to control. This immature morphology suggests a delayed
maturation of FMRP-deficient neurons differentiated from NSCs. Immature neuronal
morphology  is,  in  fact,  one  of  the  key  features  in  the  FXS  and Fmr1-KO mouse brain.
FMRP-deficient neocortical and hippocampal pyramidal neurons display an immature
dendritic spine phenotype, and the morphology of GABAergic interneurons in the
neocortex of Fmr1-KO mice is altered (Irwin et al., 2001; Nimchinsky et al., 2001; Irwin
et al., 2002; Grossman et al., 2006b; Selby et al., 2007). Altered neurite and spine
phenotypes have also been observed in cultured hippocampal neurons (Braun and Segal,
2000). In Fmr1-KO mice, the aberrant spine phenotype is present during first few
postnatal weeks and in the adult brain (Nimchinsky et al., 2001; Galvez and Greenough,
2005). However, at the age of 4 weeks, Fmr1-KO mice neocortical neurons do not exhibit
an aberrant dendritic spine phenotype (Nimchinsky et al., 2001). Thus, this feature appears
to be postnatally dynamic. Why this is occurring and whether it occurs in the human FXS
brain is not known. Our data suggest that this feature may already be prevalent at the level
of NSCs and in early differentiating neurons when functional FMRP is absent.
In addition to the immature morphology of neurons derived from the FMRP-
deficient NSCs, the overall production of neurons from these NSCs in vitro is increased
compared to controls. On the other hand, the glial cell population is reduced and is
proposed to exhibit increased apoptosis during early differentiation of FMRP-deficient
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NSCs. During early neocortical development induction of gliogenesis has been proposed
to be initiated by factors secreted by newborn neurons. Cardiotrophin-1 could be one of
these factors secreted by differentiating neurons, since it is has been proposed to be a
strong  candidate  to  initiate  glial  differentiation  through  activation  of  the  JAK-STAT
pathway  and  the  GFAP  promoter  during  neocortex  formation  (Barnabe-Heider  et  al.,
2005; Miller and Gauthier, 2007). It could be that FMRP-deficient newborn neurons do
not mature sufficiently or fast enough to secret cardiotrophin-1 and provide trophic
support for glia. This is, however, only speculation since the evidence of a connection
between cardiotrophin-1 and FMRP is lacking. Signaling by WNT/b-catenin promotes
neural  proliferation  cooperation  with  FGF2  (Hirabayashi  et  al.,  2004;  Israsena  et  al.,
2004). Interestingly, FGF2 mRNA is a target for FMRP and in the absence of FMRP,
FGF2 may be overexpressed thus contributing to the increased production of neurons
(Miyashiro et al., 2003). However, in our experimental system, we also included FGF2 in
the propagation culture media of NSCs/NPCs, which may make interpretation of FGF2
function complicated. A novel mechanism promoting the glial differentiation of
NSCs/NPCs through TrkB.T1 receptor activation has been found recently (Cheng et al.,
2007). This pathway involves G-protein coupled activation of protein kinase C (PKC),
thus suggesting that PKC activation is promoting glial differentiation. The mRNA of one
subtype  of  PKCs  is  a  target  for  FMRP  regulation  thus  indicating  a  possible  connection
with increased neuronal differentiation in the absence of functional FMRP (Miyashiro et
al., 2003). Until our observations, there were no other reports of neuron overproduction in
the FMRP-deficient brain or in FMRP-deficient neuronal cell cultures until our
observations in vitro and in vivo, however, a recent report showed that FMRP is crucial for
the  maintenance  and  repression  of  the  differentiation  of  germ  line  stem  cells  (GSC)s  in
Drosophila (Yang et al., 2007). This suggests that in the absence of functional FMRP, the
differentiation of stem cells may be induced.
Although the proliferation NSCs appears to be unaffected by the defect in FMRP, we
observed an abnormally enlarged newborn cell population in the SVZ of the Fmr1-KO
mouse neocortex at E17. BrdU labelling showed that these cells had been in active cell
cycle during the time of late deeper layer neurogenesis in the neocortex. This alteration
was associated with abnormal migration or positioning of newborn cells in the Fmr1-KO
neocortex rather than the proliferation of NSCs/NPCs, since the overall number of
neocortical BrdU-labeled cells was not changed. Thus, the absence of functional FMRP
does not seem to affect the proliferation of NSCs/NPCs.
11.2. Ca2+ oscillations in mGluR5 responsive differentiating FMRP-deficient
NSCs
We found that most of the differentiating FMRP-deficient NSCs cells have an aberrant
oscillatory intracellular Ca2+ response to ACh. Furthermore,  this response was not ACh-
specific and could be evoked with other neurotransmitters including glutamate. We were
able to associate the oscillating cells with cells that are especially responsive to mGluR5
receptor activation. It is known that oscillating [Ca2+]i release can significantly enhance
gene expression (Dolmetsch et al., 1998), thus the absence or lack of FMRP may induce
gene expression. The [Ca2+]i signaling is involved in early morphological maturation and
the neurotransmitter phenotype acquisition of neurons (Ciccolini et al., 2003). Therefore,
aberrant [Ca2+]i release may be causative for the immature phenotype of newborn neurons
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that we observed after differentiation of FMRP-deficient NSCs in vitro. Furthermore, the
increased number of neurons differentiated from FMRP-deficient NSCs in vitro may  be
explained by an accelerated fate determination into neurons as a result of intense
oscillatory [Ca2+]i transients (Gu and Spitzer, 1995). The aberrant [Ca2+]i transients are not
only present in FMRP-deficient differentiating NSCs. Recently, spines and dendrites of
neurons in the mature prefrontal cortex have been shown to exhibit similar alterations thus
suggesting that alterations in Ca2+ signaling may be a general feature of FMRP-deficient
neural cells (Meredith et al., 2007). The altered Ca2+ signaling in the FMRP-deficient
neural cells may substantially intensify overall gene expression in concert with mGluR5
dependent protein synthesis in these cells.
11.3. Embryonic neocortex development of the Fmr1-KO mice
We observed alterations during embryonic neocortex development of Fmr1-KO mice.
First, at E17 we found an aberrant cell cohort born at E14 at the SVZ. Second, we showed
that the dominant negative FMRP mutation I304N resulted in an increased proportion of
nestin-positive cells in the VZ/SVZ at E17. In this experiment, the transfection of
undifferentiated VZ NSCs that line the lateral ventricle wall was performed at E14 by in
utero electroporation. Therefore, these two separate findings support each other despite
the fact that in utero electroporation is a relatively crude method to deliver transgenes into
a developing brain. Nevertheless, delivering FMRP with the I304N mutation in the KH2
domain into neocortical NSCs/NPCs, illustrates that the KH2 domain is important for
FMRP function in NSCs/NPCs during neocortex formation. Third, we went back to assess
the embryonic neocortex of Fmr1-KO mice and found that the Tbr2-positive cell
population was increased in the SVZ at E17. Tbr2 is a transcription factor, which is
expressed in immature SVZ cells (mainly in IPCs) that are committed to glutamatergic
fate (Englund et al., 2005). This was in agreement with our previous observation that cells
generated from FMRP-deficient NSCs display intense oscillatory [Ca2+]i responses to
glutamate in vitro. The finding that Tbr2 and BrdU double labeling in the Fmr1-KO
neocortex increased at E16 when the mice received BrdU at E13, showed that the
maturation of the Tbr2-positive cell population was impaired. This may involve
exaggerated turning of the apical VZ progenitors into Tbr2 expressing basal progenitors
by Ngn2 activity (Miyata et al., 2004). The absence of Ngn2 is known to impair
differentiation of neocortical neurons born before E14.5 and results in dysformation of the
deeper neocortical layers (Schuurmans et al., 2004). Direct upstream regulators of Ngn2
expression including WNT/b-catenin signaling and Pax6 may be involved in increasing
the Tbr2-positive cell population (Scardigli et al., 2003; Hirabayashi et al., 2004; Israsena
et al., 2004). The GABAA receptor subtype has been shown to be downregulated in the
FMRP-deficient neocortex (D'Hulst et al., 2006). GABAA receptors participate in
regulating the migration of NPCs or newborn neurons from VZ/SVZ to IZ, which suggests
the involvement of these receptors in the accumulation of Tbr2-positive cells in the SVZ
in the absence of FMRP (Behar et al., 2000). All these experiments suggest that the cell
population, which is altered in the FMRP-deficient brain, is born during the early phase of
the neurogenesis when the deeper layer neurons are generated (Götz and Huttner, 2005;
Molnar  et  al.,  2006).  Now  that  we  have  seen  the  FMRP-deficient  glutamatergic  cell
population derived from NSCs to be responsive for mGluR5 activation in vitro we can
consider whether this is occurring in vivo as well. ES cells and NSCs are known to express
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mGluR5s (Melchiorri et al., 2007). In ES cells, mGluR5s promote self-renewal in
cooperation with cytokine LIF signaling (Melchiorri et al., 2007) and in NSCs/NPCs
mGluR5 activation increases survival and proliferation (Di Giorgi-Gerevini et al., 2005).
This suggests that mGluR5 expressing NPCs may survive better than other NPCs in the
absence of FMRP. In neurons, synaptic expression of FMRP is group I mGluR-dependent
and protein synthesis through group I mGluR activation in synaptoneurosomes is FMRP-
dependent (Weiler et al., 1997; Weiler et al., 2004). This kind of interplay suggests
alterations in NSC properties when FMRP is functionally absent. The FMRP target
mRNAs in NSCs should be mainly affected but unfortunately they are still unknown.
11.4. Early postnatal neocortex formation in the Fmr1-KO mouse brain
In the postnatal neocortex of Fmr1-KO mice, we detected alterations in the structure of the
deeper layers. Layer V showed increased density of Nissl-stained cells in the absence of
FMRP,  and  layer  VI  had  a  putative  lamination  defect.  The  cell  density  increase  seen  by
Nissl staining was only mild, therefore we decided to use a layer V specific marker ER81
to confirm the observed defect. Consequently, we could indeed see an increase in the
density of ER81-positive neurons in layer V of the Fmr1-KO neocortex at P5. This finding
can be related to our observations on an aberrant glutamatergic cell population born
around E13 to E14 in the neocortex of Fmr1-KO mice, because layer V and VI neurons
are born at that time. Furthermore, the increase in certain glutamatergic cell populations in
the postnatal FMRP-deficient brain during the first week of postnatal development may be
transient, because adult Fmr1-KO brains have grossly normal neuroanatomy (The Dutch-
Belgian fragile X consortium, 1994; Kooy et al., 1999). However, recent reports about
differences in GABAergic interneuron populations in the adult Fmr1-KO neocortex imply
that alterations in the glutamatergic system may persist into adulthood. On the other hand,
FMRP expression declines during aging in the mouse brain, which suggests a
developmentally dynamic function for FMRP (Singh et al., 2007). This is supported by
dynamic alterations in dendritic spine morphology during the first two postnatal months of
Fmr1-KO mouse development (Nimchinsky et al., 2001; Galvez and Greenough, 2005).
We show that this altered cell population in the Fmr1-KO mouse neocortex includes
subcerebrally and cortico-cortically projecting pyramidal neurons (spiny giant pyramidal
neurons), which express ER81 (Sugitani et al., 2002; Beggs et al., 2003; Hevner et al.,
2003; Yoneshima et al., 2006). Phosphorylation of Ngn2, which is an upstream effector of
Tbr2, promotes a dendritic phenotype of pyramidal neurons (Hand et al., 2005). In the
adult and developing Fmr1-KO neocortex, dendritic spine abormalities have also been
observed on pyramidal neurons of layer V (Nimchinsky et al., 2001; Irwin et al., 2002;
McKinney et al., 2005). This suggests that the enlarged ER81-positive cell population may
be the one that exhibits the spine abnormalities. The stabilization of dendritic spines,
which means activity dependent elimination of unused synaptic connections (spines), is
defective in the absence of functional FMRP (Galvez et al., 2003; Bagni and Greenough,
2005; Galvez et al., 2005). FMRP appears to be a selective factor for synapses that will be
preserved and this selection likely occurs through group I mGluR activation. Our
observations suggest that this kind of stabilization may actually occur in whole cell
populations during neocortex development.
Epileptic seizures caused by exaggerated excitatory activity are part of the phenotype
in FXS and in Fmr1-KO mice (Incorpora et al., 2002; Nielsen et al., 2002). Alterations in
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the stabilization of dendritic spines suggest increased overall excitatory activity. However,
if the overall number of excitatory neurons was increased, the effect might be even more
prominent. The reported increase in the density of parvalbumin-positive interneurons and
their altered morphology in the neocortical layer V of the adult Fmr1-KO mice may be a
compensatory effect to reduce excitatory activity (Selby et al., 2007). Therefore,
alterations in the neocortical glutamatergic populations may underlie the epileptic seizure
susceptibility in the FMRP-deficient brain.
Further evidence that FMRP may act on specific excitatory neuron populations
comes from studies of the visual pathway of FXS patients (Kogan et al., 2004b). This
study is based on an observed defect in visual-motor function among FXS individuals
(Kogan et al., 2004a). The mangocellular cells in the lateral geniculate nucleus are
specifically expressing FMRP and are affected in FXS brains (Kogan et al., 2004b). The
lateral geniculate nucleus is formed from layers of magnocellular and parvocellular cells,
which are neurons that project to the visual cortex. In the absence of FMRP, this structure
is aberrant due to defects in the magnocellular cells. Parvocellular cell layers do not
express FMRP and are primarily unaffected by the FMRP-defect. This is evidence of cell
population based function of FMRP in neurons.
The mRNA and protein-binding partners of FMRP in the NSCs are unknown.
Therefore, we can only use the information available on FMRP-binding mRNAs in the
mature brain. Nevertheless, some potentially interesting mRNAs binding to FMRP may
affect neocortical formation and/or NSCs differentiation. Two possible candidates are
messages encoding FGF2 and IGF-I (via IGFBP-5) (Ye and D'Ercole, 1998; Miyashiro et
al., 2003). Both of these proteins have a profound effect on the neocortex formation
(Ortega et al., 1998; Hodge et al., 2005). These proteins have an especially strong impact
on layer V development, which provides another link between them and FMRP. Thus,
developmental neocortical defects in Fmr1-KO mice brain may be related to cell growth
associated proteins, which are likely regulated by FMRP action.
11.5. Radial glial markers during the development of the Fmr1-KO neocortex
We found only very subtle alterations in radial glial marker expression in the developing
neocortex of Fmr1-KO  mice.  Radial  glial  markers,  BLBP,  GLAST,  and  actNotch1  are
expressed in distinct spatiotemporal patterns during neurogenesis (Hartfuss et al., 2001;
Tokunaga et al., 2004). BLBP-positive radial glia is associated with the migration of
immature neurons in the neocortex (Feng et al., 1994). GLAST is expressed in NPCs of
neocortical proliferative zones (Gal et al., 2006) and is associated with the differentiation
of astrocytes (Chaudhry et al., 1995; Ullensvang et al., 1997). ActNotch1 is important for
maintaining the proliferative potential of NPCs during neurogenesis and later induction of
glial differentiation in the neocortex (Yoon and Gaiano, 2005). In NPC cultures,
actNotch1 was shown to increase proliferation at low doses and to induce cell cycle arrest
at high doses in a cell density dependent manner (Guentchev and McKay, 2006). In the
VZ and the SVZ NPCs, Notch signaling inhibits neurogenesis through C-promoter
binding factor 1 (CBF1) -related and non-CBF1-related pathways (Mizutani et al., 2007).
The  expression  of  BLBP  is  directly  regulated  by  CBF1  in  radial  glia  (Anthony  et  al.,
2005). A recent microarray study demonstrated that Hes1, which is a target of
Notch1/CBF1 signaling and an inhibitor of proneural genes (Nakamura et al., 2000), is
overexpressed in the adult FXS brain (Bittel et al., 2007). Furthermore, a proneural gene
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target repressed by Hes1, Ngn2, regulates the transcription of Tbr2 (Schuurmans et al.,
2004). Although links between radial glial cells and Tbr2-positive cells exist, we were not
able to show statistically significant differences in radial glial marker expression in the
Fmr1-KO neocortex. However, we observed trends toward increased GLAST expression
at E16 and actNotch1 expression at P0. An increase in GLAST expression may reflect
abnormalities in radial glial cells, which are precursors of Tbr2-positive cells whereas
increased actNotch1 expression may be related to increased proliferation of Tbr2-positive
cells and to increased Hes1 expression postnatally. Nevertheless, the connection between
FMRP and Notch-signaling remains to be investigated.
11.6. The significance of decreased expression of RGS4 in the Fmr1-KO
brain
We have shown that RGS4 mRNA is decreased in the hippocampal CA1 area and in the
retrosplenial  cortex  of  the Fmr1-KO brain. However, a direct link is missing between
FMRP and RGS4. RGS4 is a protein that is involved with G-protein signaling and it has
been shown to regulate mGluR5 dependent signaling. As RGS4 increases GTPase activity
and in this manner is repressing or modulating G-protein coupled signaling, the observed
decrease in RGS4 expression levels may lead to aberrant [Ca2+]i oscillations  (Xu  et  al.,
1999; Luo et al., 2001; Hollinger and Hepler, 2002). Homer proteins are involved with
RGS4 and mGluR5 receptors at the postsynaptic sites of neurons and phosphorylation of
Homers is impaired in the absence of functional FMRP (Shin et al., 2003; Giuffrida et al.,
2005). RGS4 expression has developmental patterns in the hippocampal CA1 area and
neocortical layer II/III suggesting that reduced RGS4 expression in the Fmr1-KO brain at
P10 may be caused by a developmental delay (Ingi and Aoki, 2002). Defects in RGS4
expression have been frequently associated with schizophrenia (Mirnics et al., 2001;
Levitt et al., 2006). Also, a group of FXS patients have been found to exhibit schizotypal
traits, which suggests a connection between the phenotypes of these two common mental
disorders (Sobesky et al., 1994). Thus, RGS4 may prove to be an important molecule in
FXS pathology and could provide novel possibilities in drug intervention of this disease.
11.7. BNDF/TrkB function in NSCs
We found that overexpression of TrkB.T1 in NSCs/NPCs can result in increased
proliferation and decreased clonal survival. After dissociation and brief plating on coated
matrix (6 h), expression of Ki67, which a marker for dividing cells, was reduced in these
NSCs/NPCs. Exogenous BDNF was able to rescue the survival of neurosphere forming
cells and the expression of Ki67 in TrkB.T1 overexpressing NSCs/NPCs. Upon
differentiation, these NSCs/NPCs generated more neurons than control cells but the
apoptosis of these newborn neurons was simultaneously increased.
BDNF signaling through TrkB receptors is crucial for the differentiation and
survival of maturing neurons (Huang and Reichardt, 2001). The traditional function of the
truncated TrkB.T1 isoform was to inhibit BDNF signaling occurring through catalytically
active TrkB receptor (Biffo et al., 1995; Eide et al., 1996; Ninkina et al., 1996; Haapasalo
et al., 2001). This type of function can be executed through ligand sequestering or a
dominant-negative heterodimerization of the receptors. However, TrkB.T1 receptors can
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relate signals on their own by regulating the activity of small Rho GTPases (Ohira et al.,
2005) and by the neurotrophin-dependent release of intracellular Ca2+ in astrocytes
through phospholipase C (PLC) activation (Rose et al., 2003). Recently, one group
reported that TrkB.T1 signaling directs NSCs to glial lineage and inhibits neurogenesis in
culture and in vivo (Cheng et al., 2007). Inhibition of neurogenesis occurs through a
dominant-negative action; however, the induction of glial fate occurs through activation of
PKC via G-protein signaling. The activated G-protein sub-unit is still unknown, which
raises possibilities that it may be the same one involved with RGS4 and mGluR5.
Interestingly, TrkB.T1 can induce the outgrowth of dendritic filopodia in hippocampal
neurons by cooperating with p75NTR or induce process growth in neuroblastoma cells
(Haapasalo et al., 1999; Hartmann et al., 2004). Evidence in NSCs show that TrkB.T1
does not inhibit catalytic TrkB receptor signaling in NSCs, since Akt is not blocked,
which occurs in PC12 cells (Cheng et al., 2007). Our model of TrkB.T1 overexpression is
a bit problematic, since the transgene is under a Thy1 promoter, which limits the
expression  to  neurons  (Saarelainen  et  al.,  2000a).  Despite  this,  we  have  shown  that  the
transgene is expressed in NSCs/NPCs but in these cells TrkB.T1 likely functions as a
ligand sequestering agent instead of a dominant-negative blocker (Cheng et al., 2007). We
have confirmed this by viral-induced overexpression of the TrkB.T1 receptor in
NSCs/NPCs, which consequently resulted in increased proliferation of these cells. BDNF
is known to reduce NPC proliferation and induce neuron differentiation indirectly by
acting in a positive feedback loop with nitric oxide (Cheng et al., 2003). Overexpressed
TrkB.T1 may overcome this effect by sequestering BDNF and thus promote proliferation
(Fig. 12). The clonal survival of human ES cells seems to be improved by BNDF/TrkB
signaling (Pyle et al., 2006), thus ligand sequestering action may explain the reduced
clonal survival of TrkB.T1 overexpressing NSCs/NPCs. This may be related to improved
survival of malignant tumor cells in the presence of TrkB expression (Douma et al., 2004).
Furthermore, similar signaling pathways may apply in brain tumor stem cells and
NSCs/NPCs, since they seem to be closely related (Vescovi et al., 2006). Our findings
suggest that TrkB.T1 may have a ligand sequestering effect on BDNF induced survival
and suppression of self-renewal in a certain subpopulation of NPCs.
The increased neuronal differentiation may require further explaining, since
normally TrkB.T1 expression promotes glial differentiation. Our model may somehow
activate both mechanisms; aberrant neuronal differentiation via PKC activation and
inhibition of neuronal survival via a ligand sequestering action within the same cell
population. This same feedback mechanism may function in the dentate gyrus of the adult
TrkB.T1 overexpressing mice, where the turnover of newborn granule neurons was
increased (Sairanen et al., 2005). Thus, in our model, TrkB.T1 expression in NPCs
enlarges the cell population committed to neuronal lineage possible through novel
signaling mechanism which is normally active in glial NPCs and involves G-protein
coupled  receptors  and  PKC  (Cheng  et  al.,  2007).  On  the  other  hand,  some  kind  of
feedback mechanism may induce precursor proliferation in these cells. In contrast,
survival of these newborn neurons is reduced due to the ligand sequestering action of
overexpressed TrkB.T1 on BDNF/TrkB signaling in our model. This provides a new
insight into BDNF/TrkB signaling in NSCs/NPCs during development.
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Figure 12 A model of the proposed impact of TrkB.T1 on BDNF signaling in NSCs/NPCs
when TrkB.T1 overexpression is directed to neurons. This figure shows three different
systems:  NSC  pool  in  intact  brain,  NSCs  in  culture,  and  NSCs  during in vitro
differentiation. EGF, epidermal growth factor; FGF-2, fibroblast growth factor-2; NO,
nitric oxide.
The decrease in Ki67-positive cells upon plating of TrkB.T1 overexpressing NSCs/NPCs
on a coated matrix may be explained by the anoikis effect, which suppresses tumor growth
in cells that have lost contact with the extracellular lamina (Douma et al., 2004). In this
case, TrkB.T1 acts by ligand sequestering to inhibit TrkB signalling. TrkB expression has
been shown to accompany malignant tumor growth. In addition, blocking endogenous
BDNF in NPCs plated on a coated matrix results in a decrease in Ki67 expression in these
cells (Barnabe-Heider and Miller, 2003). Therefore, TrkB.T1 may counteract TrkB
signaling in malignant tumors thus suggesting a possible role for TrkB.T1 in preventing
cancer growth.
11.8. Similarities between FMRP action and BDNF/TrkB signaling
The FXS and Fmr1-KO NSCs produce an increased number of neurons upon
differentiation and BDNF signaling through the TrkB receptor promotes the
differentiation of neurons (Huang and Reichardt, 2001). Exogenous BDNF and increased
TrkB  receptor  expression  reduces  expression  of  mRNA  encoding  FMRP,  which  may
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affect  the  actual  expression  of  FMRP  (Castrén  et  al.,  2002).  The  suppression  of  FMRP
mRNA expression by BDNF/TrkB signaling may mimic the loss of functional FMRP and
result in partially similar phenotypes in models of FXS and exaggerated BDNF/TrkB
signaling.
We observed alterations in the formation of the FMRP-deficient neocortex. BDNF
and TrkB receptors are also important for neocortex formation, since alterations occur
when  BDNF/TrkB  signaling  is  disrupted.  BDNF  has  an  apparent  role  in  the  neocortical
lamination in a specific temporal window (Ohmiya et al., 2002; Fukumitsu et al., 2006).
When BDNF is administered to the lateral ventricles of the mouse brain at E13.5, it alters
the  properties  of  cells  destined  to  become layer  IV neurons  to  those  of  layers  V and  VI
whereas blocking the BDNF results in the opposite effect. Only neocortical NPCs that are
in the S-phase of the cell cycle at the time of BDNF administration are affected. BDNF
accelerates neuronal differentiation by promoting cell cycle completion in affected cells
and increases interkinetic nuclear migration of neocortical NPCs in the VZ. Therefore,
BDNF has an important role in laminar formation of neocortex. In the absence of TrkB
receptor expression, developmental migration in the neocortex is delayed and neuronal
and oligodendrocyte differentiation is altered (Medina et al., 2004). Furthermore, the
migration of neocortical newborn neurons is enhanced after increased BDNF/TrkB
signaling (Behar et al., 1997; Brunstrom et al., 1997; Ringstedt et al., 1998). In the adult
Fmr1-KO neocortex, TrkB receptor expression is increased in the parvalbumin expressing
interneuron population (Selby et al., 2007). Furthermore, indirectly FMRP-related protein,
IGF-I, enhances TrkB receptor expression and BDNF induced ERK1/2 phosphorylation in
neocortical neurons (McCusker et al., 2006). Thus BDNF/TrkB signaling may contribute
to the phenotype seen during FMRP-deficient neocortex formation. Some FXS patients
display schizotypal traits, and BDNF with other neurotrophins has been associated with
the pathology of schizophrenia (Sobesky et al., 1994; Shoval and Weizman, 2005).
Furthermore, reduced BDNF signaling may cause symptoms present in schizophrenia. As
we have shown that expression of RGS4, which is a strong candidate in schizophrenia
susceptibility (Mirnics et al., 2001), was reduced in the Fmr1-KO mouse brain, the
increased TrkB expression may counteract some symptoms of schizophrenia in FXS
(Sobesky et al., 1994; Selby et al., 2007). A recent report showed that hippocampal (CA1)
LTP induced by afferent theta burst stimulation was impaired in the Fmr1-KO brain
(Lauterborn et al., 2007). This is remarkable, because earlier studies have reported no
changes in hippocampal LTP in the absence of functional FMRP (Godfraind et al., 1996;
Paradee et al., 1999; Li et al., 2002; Larson et al., 2005). Moreover, exogenous BDNF was
able to abolish this defect, which establishes yet another link between FMRP and BDNF.
Authors suggest that this type of BDNF action may occur downstream of cytoskeleton
rearrangement (Lauterborn et al., 2007). These data suggest that FMRP and BDNF/TrkB
signaling have largely intertwined functions in NSCs/NPCs and in the developing brain.
11.9. Therapeutic implications of NSCs in FXS and future aspects
The cognitive pathology of FXS has been suggested to be caused by impaired activation
of mGluR5 dependent protein synthesis at the postsynaptic sites of CNS neurons (Bear et
al., 2004). This leads to improper synaptic maturation of certain neurons including
pyramidal neurons of the neocortex. Consequently LTP and LTD are affected in the
neocortex and in the hippocampus resulting in defects in learning and memory.
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Antagonists of mGluR5 have been shown to overcome some of these defects in the adult
Fmr1-KO mouse brain suggesting a possible clinical use. However, our results implicate
that alterations in the FMRP-deficient brain are present already during very early
development. The mGluR5 receptor is already expressed in NSCs, therefore FMRP likely
has an important function in regulating mGluR5 induced translation in those cells.
However, mRNA targets for FMRP in NSCs/NPCs are unknown and future studies should
be  directed  to  identify  these  messages.  Our  findings  imply  that  antagonists  for  mGluR5
receptors may have to be administered already at embryonic stage and this may prove to
be impossible. This information may be disappointing to FXS patients, since some of the
symptoms of the disorder cannot be overcome with drug treatment at adult ages. Still the
mGlur5 antagonists may provide a significant improvement to the performance and life
quality of FXS patients. A novel possibility for pharmaceutical intervention in FXS was
recently found. Reduced expression of PAK, which is involved in the formation of
synaptic structure, was able to abolish the great majority of FXS symptoms in mice
lacking FMRP (Hayashi et al., 2007). PAK is expressed during postnatal development,
and therefore it may provide an interesting target for drug intervention in the adult FXS
brain.
Properties of FMRP in NSCs/NPCs and their differentiation during normal brain
development are only partially understood. The signaling pathways involved in neuronal
and glial differentiation that should be investigated including WNT, BMP, Notch, LIF
related signaling upstream of proneural genes (Ngn1, Ngn2, and Mash1) and inhibitors of
proneural genes (Hes1 and Hes5). Direct or indirect connection between these factors and
FMRP should be investigated. Interestingly, the mRNAs that target the important
functional KH2 domain of FMRP are largely unknown, and solving these targets may
provide important information about the action of FMRP in general. Furthermore, FMRP
mRNA targets  are  unknown in  the  NSCs/NPCs,  which  are  likely  important  during  early
differentiation of NSCs/NPCs, since mGluR5 is already expressed in these cells
(Melchiorri et al., 2007). The function of TrkB.T1 signaling in regulating the
differentiation of NSCs/NPCs is probably an important mechanism of choosing between
neural and glial fate. The pathways involved are partially known, however identification
of  the  components  of  the  signaling  pathway that  promotes  the  glial  fate  in  NSCs/NPCs,
may provide the actual connection between BDNF/TrkB signaling and FMRP (Cheng et
al., 2007).
Reduced amount of FMRP, impaired BDNF/TrkB signaling and reduced RGS4
expression are implicated in schizophrenia. This may also provide new applications for
treatment of FXS, since schizophrenia is under intense investigation. Furthermore, the
relationship between FMRP and BDNF/TrkB signaling should be further investigated,
since BDNF/TrkB signaling is such an important survival factor for neurons of the
developing and mature brain. To summarize, the early developmental aspects of any given
nervous system disorder should be evaluated to design more specific and efficient drugs to
be used for treating adult patients.
87
12. Conclusions
This thesis aimed to elucidate the role of NSCs in fragile X syndrome and to investigate
the effects of impaired BDNF/TrkB signaling on NSC survival, proliferation and
differentiation. Based on the findings presented in this thesis, following conclusions can
be drawn:
1. Mouse and human NSCs lacking FMRP generate more neurons with short neurites and
small soma size and less astrocytes than control NSCs.
2. NSCs lacking FMRP give rise to more cells responsive to mGluR activation. The
responses to mGluR in differentiating cells correlate with oscillatory intracellular Ca2+
responses to neurotransmitters. The oscillatory response to mGluR activation was
sensitive to mGluR5 antagonist suggesting alterations in cellular plasticity of a distinct
cell population responding to mGluR activation in fragile X syndrome.
3. An increased number of cells expressing Tbr2 accumulates in the embryonic SVZ of
Fmr1-KO mice suggesting alterations in glutamatergic neurogenesis. The aberrant cells
contribute to alterations in the formation of the deeper neocortical layers in the early
postnatal brain of Fmr1-KO mice.
4. RGS4 mRNA expression is decreased in the hippocampus and neocortex of the early
postnatal brain of Fmr1-KO mice suggesting a role for FMRP in G-protein signaling.
5. Overexpression of the tyrosine kinase activity deficient TrkB.T1 receptor increases the
proliferation of cultured NPCs and simultaneously decreases the survival of the
neurosphere-forming cells. Exogenous BDNF abolishes the defects in the survival of
neurosphere-forming cells, which suggests that TrkB.T1 may inhibit BDNF/TrkB
signaling in NPCs by sequestering the endogenous BDNF. TrkB.T1 overexpression
increases neuronal differentiation of NPCs. Neuronal apoptosis is paralleled by increase in
neuronal differentiation suggesting a homeostatic feedback loop between the survival of
neurons and proliferation rate of NPCs.
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